ME02819B - Formulacije sa visokom koncentracijom antitijela - Google Patents
Formulacije sa visokom koncentracijom antitijelaInfo
- Publication number
- ME02819B ME02819B MEP-2017-147A MEP14717A ME02819B ME 02819 B ME02819 B ME 02819B ME P14717 A MEP14717 A ME P14717A ME 02819 B ME02819 B ME 02819B
- Authority
- ME
- Montenegro
- Prior art keywords
- ser
- thr
- val
- leu
- pro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
<br>SEQUENCE LISTING <br>5 <br>[0129] <br><110> Timothy Osslund <br>10 <120> High Concentration Antibody Formulations <br><130> 31173/45219A <br><140> US-61/334,986 <br>15 <141> 2010-05-14 <br>20 <br>25 <br>30 <br><160> 248 <br><170> Patentln version 3.5 <br><210> 1 <br><211> 13 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-A & Ab-1 LCDR1 <br><400> 1 <br>Gln Ser Ser Gln Ser Val Tyr Asp As n Asn Trp Leu Ala <br>l 5 10 <br>35 <210> 2 <br><211> 7 <br><212> PRT <br><213> Artificial Sequence <br>40 <220> <br><223> Ab-A and Ab-1 LCDR2 <br><400> 2 <br>45 <br><210> 3 <br>50 <211> 10 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>55 <223> Ab-A and Ab-1 LCDR3 <br><400> 3 <br>Asp Ala Ser Asp Leu Ala Ser <br>l 5 <br>20 EP 2 569 010 81 <br>Gln Gly Ala Tyr Asn Asp Va l Il e Tyr Al a <br>l 5 10 <br>5 <br>10 <br>15 <br><210> 4 <br><211> 5 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-A and Ab-1 HCDR1 <br><400> 4 <br>20 <210> 5 <br><211> 16 <br><212> PRT <br><213> Artificial Sequence <br>25 <220> <br><223> Ab-1 and Ab-2 HCDR2 <br><400> 5 <br>30 <br>Ser Tyr Trp Met Asn <br>l 5 <br>Thr Ile Asp Ser Gly Gly Arg Thr Asp Tyr Ala Ser Trp Al a Lys Gly <br>l 5 10 15 <br>35 <210> 6 <br><211 > 4 <br><212> PRT <br><213> Artificial Sequence <br>40 <220> <br><223> Ab-A and Ab-1 HCDR3 <br><400> 6 <br>45 <br><210> 7 <br>50 <211> 654 <br><212> DNA <br><21 3> Artificial Sequence <br><220> <br>55 <223> Rabbit-Mouse Chimera <br><220> <br><221 > misc_feature <br>Asn Trp Asn Leu <br>l <br>21 i <br>EP 2 569 010 81 <br><223> Ab-A light chain (no signal) <br><400> 7 <br>5 <br>gcgcaagtgc tgacccagac tccagcctcc gtgtctgcag ctgtgggagg cacagtcacc 60 <br>atcaattgcc agtccagtca gagtgtttat gataacaact ggttagcctg gtttcagcag 120 <br>10 <br>aaaccagggc agcctcccaa gctcctgatt tatgatgcat ccgatctggc atctggggtc 180 <br>ccatcgcggt tcagtggcag tggatctggg acacagttca ctctcaccat cagcggcgtg 240 <br>15 <br>cagtgtgccg atgctgccac ttactactgt caaggcgctt ataatgatgt tatttatgct 300 <br>ttcggcggag ggaccgaggt ggtggtcaaa cgtacggatg ctgcaccaac tgtatccatc 360 <br>ttcccaccat ccagtgagca gttaacatct ggaggtgcct cagtcgtgtg cttcttgaac 420 <br>20 <br>aacttctacc ccaaagacat caatgtcaag tggaagattg atggcagtga acgacaaaat 480 <br>ggcgtcctga acagttggac tgatcaggac agcaaagaca gcacctacag catgagcagc 540 <br>25 <br>accctcacgt tgaccaagga cgagtatgaa cgacataaca gctatacctg tgaggccact 600 <br>cacaagacat caacttcacc cattgtcaag agcttcaaca ggaatgagtg t tag 654 <br><210> 8 <br>30 <br><211>217 <br><2 12> PRT <br><213> Artificial Sequence <br><220> <br>35 <br><223> Rabbit-Mouse Chimera <br><220> <br><221> MISC FEATURE <br>-<br><223> Ab-A light chain (no signal) <br>40 <br><400> 8 <br>45 <br>50 <br>55 <br>22 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>Ala Gln Val Leu Thr Gln Thr Pro Ala Ser Va l Ser Ala Ala Va l Gly <br>l 5 10 15 <br>Gly Thr Val Thr Ile Asn Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn <br>20 25 30 <br>Asn Trp Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu <br>35 40 45 <br>Leu Ile Tyr Asp Ala Ser Asp Leu Ala Ser Gly Val Pro Ser Arg Phe <br>50 55 60 <br>Ser Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Gly Val <br>65 70 75 80 <br>Gln Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Ala Tyr Asn Asp <br>85 90 95 <br>Val Ile Tyr Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys Arg Thr <br>100 105 110 <br>Asp Ala Ala Pro Thr Val Ser Il e Phe Pro Pro Ser Ser Glu Gln Leu <br>115 120 125 <br>Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro <br>130 135 140 <br>Lys Asp Ile Asn Val Lys Trp Ly s Ile Asp Gly Ser Glu Arg Gln Asn <br>145 150 155 160 <br>Gly Val Leu Asn Se r Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr <br>165 170 175 <br>Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg Hi s <br>180 185 190 <br>Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile <br>195 200 205 <br>Val Lys Ser Phe Asn Arg Asn Glu Cys <br>210 215 <br>23 • <br>EP 2 569 010 B1 <br><210> 9 <br><211> 1302 <br><212> DNA <br><213> Artificial Sequence <br>5 <br><220> <br><223> Humanized Antibody <br><220> <br>10 <br><221 > misc_feature <br><223> Ab-A heavy chain (no signal) <br><400> 9 <br>15 <br>60 cagtcgctgg aggagtccgg gggtcgcctg gtcacgcctg ggacacccct gacactcacc <br>tgcacagcct ctggattctc cctcagtagt tattggatga actgggtccg ccaggctcca 120 <br>20 <br>ggggaggggc tggaatggat cggaaccatt gattctggtg gtaggacgga ctacgcgagc 180 <br>tgggcaaaag gccgattcac catctccaga acctcgacta cgatggatct gaaaatgacc 240 <br>agtctgacga ccggggacac ggcccgttat ttctgtgcca gaaattggaa cttgtggggc 300 <br>25 <br>caaggcaccc tcgtcaccgt ctcgagcgct tctacaaagg gcccatctgt ctatccactg 360 <br>gcccctggat ctgctgccca aactaactcc atggtgaccc tgggatgcct ggtcaagggc 420 <br>30 <br>tatttccctg agccagtgac agtgacctgg aactctggat ccctgtccag cggtgtgcac 480 <br>accttcccag ctgtcctgca gtctgacctc tacactctga gcagctcagt gactgtcccc 540 <br>tccagcacct ggcccagcga gaccgtcacc tgcaacgttg cccacccggc cagcagcacc 600 <br>35 <br>40 <br>45 <br>50 <br>55 <br>24 ~ <br>EP 2 569 010 81 <br>aaggtggaca agaaaattgt gcccagggat tgt ggttgta agccttgcat atgtacagtc 660 <br>ccagaagtat catctgtctt catcttcccc ccaaagccca aggatgtgct caccattact 720 <br>5 <br>ctgactccta aggt cacgtg tgt tgtggta gacatcagca aggatgatcc cgaggtccag 780 <br>ttcagctggt ttgtagatga tgtggaggtg cacacagctc agacgcaacc ccgggaggag 840 <br>10 <br>cagttcaaca gcactttccg ctcagtcagt gaacttccca tcatgcacca ggactggctc 900 <br>aatggcaagg agt t caaatg cagggtcaac agtgcagctt tccctgcccc catcgagaaa 960 <br>accatctcca aaaccaaagg cagaccgaag gctccacagg tgtacaccat tccacctccc 1020 <br>15 <br>aaggagcaga tggccaagga taaagtcagt c t gacctgca tgataacaga cttcttccct 1080 <br>gaagacatta ctgt ggagtg gcagtggaat gggcagccag cggagaacta caagaacact 1140 <br>20 <br>cagcccatca tggacacaga tggctcttac ttcgtctaca gcaagctcaa t gtgcagaag 1200 <br>agcaactggg aggcaggaaa tactttcacc tgctctgtgt tacatgaggg cctgcacaac 1260 <br>caccatactg agaagagcct ctcccactct cctggtaaat ga 1302 <br>25 <br><210> 10 <br><211> 433 <br><2 12> PRT <br><213> Artificial Sequence <br>30 <br><220> <br><223> Humanized antibody <br><220> <br>35 <221> MISC FEATURE <br>-<br><223> Ab-A heavy chain (no signal) <br><400> 10 <br>40 <br>45 <br>50 <br>55 <br>25 EP 2 569 010 8 1 <br>Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro <br>l 5 10 15 <br>5 <br>Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Ser Tyr Tr p <br>20 25 30 <br>10 <br>Met Asn Trp Val Arg Gln Ala Pro Gly Glu Gly Leu Glu Trp Ile Gly <br>35 40 45 <br>Thr Ile Asp Ser Gly Gly Arg Thr Asp Tyr Ala Ser Trp Ala Lys Gly <br>15 <br>50 55 60 <br>Arg Phe Thr Ile Ser Arg Thr Ser Thr Thr Met Asp Leu Lys Met Thr <br>65 70 75 80 <br>20 <br>Ser Leu Thr Thr Gly Asp Thr Ala Arg Tyr Phe Cys Ala Arg Asn Trp <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>26 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>85 90 95 <br>Asn Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr <br>100 105 110 <br>Lys Gly Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr <br>115 120 125 <br>Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu <br>130 135 140 <br>Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His <br>145 150 155 160 <br>Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser <br>165 170 175 <br>Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn <br>180 185 190 <br>Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro <br>195 200 205 <br>Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser <br>210 215 220 <br>Ser Va l Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr <br>225 230 235 240 <br>Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp <br>245 250 255 <br>Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr <br>260 265 270 <br>Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser <br>275 280 285 <br>Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Gl u <br>290 295 300 <br>Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys <br>305 310 315 320 <br>Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr <br>27 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>EP 2 569 010 81 <br>325 330 335 <br>Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr <br>340 345 350 <br>Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln <br>355 360 365 <br>Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met <br>370 375 380 <br>Asn Thr As n Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys <br>385 390 395 400 <br>Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu <br>405 410 415 <br>Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly <br>420 425 430 <br>Lys <br><210> 11 <br><211> 390 <br><212> DNA <br><213> Artificial Sequence <br><220> <br><223> Humanized antibody <br><220> <br>40 <221 > mise_ feature <br><223> Ab-1 light variab le (with signal) <br>45 <br>50 <br>55 <br>28 <400 > ll <br>atggacacga <br>5 <br>acatttgctc <br>gtgactatta <br>cagcaaaaac <br>10 <br>ggtgtgccaa <br>tctctccagc <br>15 <br>tatgccttcg <br><210 > 12 <br>20 <211> 133 <br><212> PRT <br>gggcccccac <br>aagttctgac <br>cctgtcaatc <br>cgggcaaagc <br>gccgtttcag <br>cggaagattt <br>gtcagggcac <br><213> Artificial Sequence <br><220> <br>25 <223> Humanized antibody <br><220> <br><221> MISC_FEATURE <br>EP 2 569 010 81 <br>tcagctgctg gggctcctgc <br>ccagagtcca agcagtctct <br>tagtcagagc gtgtatgata <br>cccgaagctg ctcatctatg <br>tggcagtggc agcggtactg <br>cgccacttac tattgtcaag <br>taaagtagaa <br><223> Ab-1 light variable {with signal) <br>30 <br><400> 12 <br>35 <br>40 <br>45 <br>50 <br>55 <br>29 <br>tgctctggct cccaggtgcc 60 <br>ccgccagcgt aggcgatcgt 120 <br>acaattggct ggcgtggtac 180 <br>acgcgtccga tctggctagc 2 40 <br>actttaccct cacaatttcg 3 00 <br>gtgcttacaa cgatgtgatt 360 <br>390 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>EP 2 569 010 81 <br>Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gl y Leu Leu Leu Leu Trp <br>l 5 10 15 <br>Leu Pro Gl y Ala Thr Phe Ala Gln Val Leu Thr Gln Ser Pro Ser Ser <br>20 25 30 <br>Leu Ser Ala Ser Val Gl y Asp Arg Val Thr Ile Thr Cys Gln Ser Ser <br>35 40 45 <br>Gln Ser Val Tyr Asp Asn Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro <br>50 55 60 <br>Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asp Leu Ala Ser <br>65 70 75 80 <br>Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr <br>85 90 95 <br>Leu Thr I l e Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys <br>100 105 110 <br>Gln Gly Al a Tyr Asn Asp Val Ile Tyr Ala Phe Gly Gln Gly Thr Lys <br>115 120 125 <br>Val Glu Ile Lys Arg <br>130 <br><21 0> 13 <br><2 11> 393 <br><212> DNA <br>40 <213> Artificial Sequence <br><220> <br><223> Humanized antibody <br>45 <220> <br><221 > misc_feature <br><223> Ab-1 heavy variable (with signal) <br><400> 13 <br>50 <br>55 <br>30 y <br>EP 2 569 010 81 <br>atggagactg ggctgcgctg gcttctcctg gtcgctgtgc tcaaaggtgt ccactgtgag 60 <br>gtgcagctgt tggagtctgg aggcgggctt gtccagcctg gagggagcct gcgtctctct 120 <br>5 <br>tgtgcagcaa gcggcttcag ctt a t cctct tactggatga attgggtgcg gcaggcacct 180 <br>gggaagggcc tggagtgggt gggcaccatt gattccggag gccgtacaga ctacgcgtct 2 40 <br>10 <br>tgggcaaagg gccgtttcac catt t cccgc gaca act cca aaaataccat gtacctccag 300 <br>atgaactctc tccgcgcaga ggacacagca cgttattact gtgcacgcaa ctggaatctg 360 <br>tggggt caag gtactcttg t aacagt ctcg age 393 <br>15 <br><210> 14 <br><211> 131 <br><212> PRT <br><213> Artificial Sequence <br>20 <br><220> <br><223> Humanized antibody <br><400> 14 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>31 EP 2 569 010 B1 <br>Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly <br>l 5 10 15 <br>5 <br>Val His Cys Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln <br>20 25 30 <br>10 <br>Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gl y Phe Ser Leu <br>35 40 45 <br>Ser Ser Tyr Trp Met Asn Trp Val Arg Gln Al a Pro Gly Lys Gly Leu <br>15 <br>50 55 60 <br>Glu Trp Val Gly Thr Ile Asp Ser Gly Gly Arg Thr Asp Tyr Ala Ser <br>65 70 75 80 <br>20 <br>Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr <br>85 90 95 <br>25 <br>Met Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Arg Tyr <br>100 105 110 <br>30 Tyr Cys Ala Arg Asn Trp Asn Leu Trp Gly Gln Gly Thr Leu Val Thr <br>115 120 125 <br>Val Ser Ser <br>35 <br>130 <br>40 <210> 15 <br><211> 10 <br><212> PRT <br><213> Artificial Sequence <br>45 <220> <br><223> Ab-B LCDR1 <br><400> 15 <br>50 <br>Ser Ala Ser Ser Ser Val Ser Phe Val Asp <br>l 5 10 <br><210> 16 <br>55 <211>7 <br><212> PRT <br><213> Artificial Sequence <br>32 <220> <br><223> Ab-B LCDR2 <br><400> 16 <br>5 <br>10 <210> 17 <br><211> 9 <br><212> PRT <br><213> Artificial Sequence <br>15 <220> <br><223> LCDR3 <br><400> 17 <br>20 <br><210> 18 <br>25 <211> 7 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>30 <223> Ab-B HCDR1 <br>35 <br><400> 18 <br><210> 19 <br><211> 16 <br>40 <212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-B HCDR2 <br>45 <br><400> 19 <br>EP 2 569 010 81 <br>Arg Thr Ser Asn Leu Gly Phe <br>l 5 <br>Gln Gl n Arg Ser Thr Tyr Pro Pro Thr <br>l 5 <br>Thr Ser Gly Met Gly Val Gly <br>l 5 <br>His Ile Trp Trp Asp Asp Val Lys Arg Tyr Asn Pro Val Leu Lys Ser <br>50 <br>l 5 10 15 <br><210> 20 <br><211 > 14 <br><212> PRT <br>55 <21 3> Artificial Sequence <br><220> <br><223> Ab-B HCDR3 <br>33 5 <br><400> 20 <br><210> 21 <br><211> 642 <br><212> DNA <br>EP 2 569 010 B1 <br>Glu Asp Phe Asp Tyr Asp Glu Glu Tyr Tyr Ala Met Asp Tyr <br>l 5 10 <br>10 <213> Mus musculus <br><220> <br><221 > misc_feature <br><223> Ab-B light chain (no signal) <br>15 <br><400> 21 <br>caaattgttc tcacccagtc tccaacaatc gtgtctgcat ctccagggga gaaggtcacc <br>20 <br>ctaatctgca gtgccagttc aagtgtaagt ttcgtggact ggttccagca gaagccaggc <br>acttctccca aacgctggat ttacagaaca tccaacctgg gttttggagt ccctgctcgc <br>25 <br>ttcagtggcg gtggatctgg gacctctcac tctctcacaa tcagccgaat ggaggctgaa <br>gatgctgcca cttattactg ccagcaaagg agtacttacc cacccacgtt cggtgctggg <br>accaagctgg aactgaaacg ggctgatgct gcaccaactg tatccatctt cccaccatcc <br>30 <br>agtgagcagt taacatctgg aggtgcctca gtcgtgtgct tcttgaacaa cttctacccc <br>aaagacatca atgtcaagtg gaagattgat ggcagtgaac gacaaaatgg cgtcctgaac <br>35 <br>agttggactg atcaggacag caaagacagc acctacagca tgagcagcac cctcacgttg <br>accaaggacg agtatgaacg acat aacagc tatacctgtg aggccactca caagacatca <br>acttcaccca ttgtcaagag cttcaacagg aatgagtgtt ag <br>40 <br><21 0> 22 <br><2 11 > 213 <br><212> PRT <br><213> Mus musculus <br>45 <br><220> <br><221> MISC FEATURE <br>-<br><223> Ab-B light chain (no signal) <br>50 <br><400> 22 <br>55 <br>34 <br>60 <br>120 <br>180 <br>240 <br>300 <br>360 <br>420 <br>480 <br>540 <br>600 <br>642 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>Gln Ile Val Leu Thr Gln Ser Pro Thr Ile Val Ser Ala Ser Pro Gly <br>l 5 10 15 <br>Glu Lys Val Thr Leu Ile Cys Ser Ala Ser Ser Ser Val Ser Phe Val <br>20 25 30 <br>Asp Trp Phe Gln Gln Lys Pro Gly Thr Ser Pro Lys Arg Trp Ile Tyr <br>35 40 45 <br>Arg Thr Ser Asn Leu Gly Phe Gl y Val Pro Ala Arg Phe Ser Gly Gly <br>50 55 60 <br>Gly Ser Gly Thr Ser His Ser Leu Thr Ile Ser Arg Met Glu Ala Glu <br>65 70 75 BO <br>Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Thr Tyr Pro Pro Thr <br>85 90 95 <br>Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala Pro <br>100 105 110 <br>Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly <br>115 120 125 <br>Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn <br>130 135 140 <br>Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn <br>145 150 155 160 <br>Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser <br>165 170 175 <br>Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr <br>180 185 190 <br>Cys Glu Al a Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe <br>195 <br>Asn Arg Asn Glu Cys <br>210 <br>35 <br>200 205 • <br>EP 2 569 010 8 1 <br><210> 23 <br><211> 1350 <br><212> DNA <br><213> Mus musculus <br>5 <br><220> <br><221> misc_feature <br><223> Ab-B heavy chain (no signal) <br>10 <br><400> 23 <br>caggttactc tgaaagagtc tggccctggg atattgcagc cctcccagac cctcagtctg 60 <br>acttgttctt tctctgggtt ttcactgagc acttctggta tgggtgtagg ctggattcgt 120 <br>15 <br>cacccatcag ggaagaatct ggagtggctg gcacacattt ggtgggatga tgtcaagcgc 180 <br>tataacccag tcctgaagag ccgactgact atctccaagg atacctccaa cagccaggta 240 <br>20 <br>ttcctcaaga tcgccaatgt ggacactgca gatactgcca catactactg tgctcgaata 300 <br>gaggactttg attacgacga ggagtattat gctatggact actggggtca aggaacctca 360 <br>25 <br>gtcatcgtct cctcagccaa aacgacaccc ccatctgtct atccactggc ccctggatct 420 <br>gctgcccaaa ctaactccat ggt gaccctg ggatgcctgg tcaagggcta tttccctgag 480 <br>ccagtgacag tgacctggaa ctctggatcc ctgtccagcg gtgtgcacac cttcccagct 540 <br>30 <br>gtcctgcagt ctgacctcta cactctgagc agctcagtga ctgtcccctc cagcacctgg 600 <br>cccagcgaga ccgtcacctg caacgttgcc cacccggcca gcagcaccaa ggtggacaag 660 <br>35 <br>aaaattgtgc ccagggattg tggt tgtaag ccttgcatat gtacagtccc agaagtatca 720 <br>tctgtcttca tcttcccccc aaagcccaag gatgt gctca ccattactct gactcctaag 780 <br>gtcacgtgtg ttgtggtaga cat cagcaag gatgatcccg aggtccagtt cagctggttt 840 <br>40 <br>gtagatgatg tggaggtgca cacagctcag acgcaacccc gggaggagca gttcaacagc 900 <br>actttccgct cagtcagtga acttcccatc atgcaccagg actggctcaa tggcaaggag 960 <br>45 <br>ttcaaatgca gggtcaacag tgcagctttc cctgccccca tcgagaaaac catctccaaa 1020 <br>accaaaggca gaccgaaggc tccacaggtg t acaccattc cacctcccaa ggagcagatg 1080 <br>gccaaggata aagtcagtct gacctgcatg ataacagact tcttccctga agacattact 1140 <br>50 <br>gtggagtggc agtggaatgg gcagccagcg gagaactaca agaacactca gcccatcatg 1200 <br>gacacagatg gctcttactt cgtctacagc aagctcaatg tgcagaagag caactgggag 1260 <br>55 gcaggaaata ctttcacctg ctct gtgtta catgagggcc tgcacaacca ccatactgag 1320 <br>36 EP 2 569 010 81 <br>aagagcctct cccact ctcc tggt aaatga <br>5 <210> 24 <br><211> 449 <br><212> PRT <br><213> Mus musculus <br>10 <220> <br><221> MISC_FEATURE <br><223> Ab-B heavy chain (no signal) <br><400> 24 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>37 <br>1350 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln <br>l 5 10 15 <br>Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser <br>20 25 30 <br>Gly Met Gly Val Gly Trp Ile Arg His Pro Ser Gly Lys Asn Leu Glu <br>35 40 45 <br>Trp Leu Ala His Ile Trp Trp Asp Asp Val Lys Arg Tyr Asn Pro Val <br>50 55 60 <br>Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Asn Ser Gln Val <br>65 70 75 80 <br>Phe Leu Lys Ile Ala Asn Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr <br>85 90 95 <br>Cys Ala Arg Ile Glu Asp Phe Asp Tyr Asp Glu Glu Tyr Tyr Ala Met <br>100 105 110 <br>Asp Tyr Trp Gly Gln Gly Thr Ser Val Ile Val Ser Ser Ala Lys Thr <br>115 120 125 <br>Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr <br>130 135 140 <br>Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu <br>145 150 155 160 <br>Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His <br>165 170 175 <br>Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser <br>38 ) <br>5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>180 185 190 <br>Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn <br>195 200 205 <br>Val Ala His Pro Ala Ser Ser Thr Lys Va l Asp Lys Lys Ile Val Pro <br>210 215 220 <br>Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Va l Pro Glu Va l Ser <br>225 230 235 240 <br>Ser Va l Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr <br>245 250 255 <br>Leu Thr Pro Lys Va l Thr Cys Va l Val Va l Asp Il e Ser Lys Asp As p <br>260 265 270 <br>Pro Glu Va l Gln Phe Ser Trp Phe Val Asp Asp Va l Glu Va l His Thr <br>275 280 285 <br>Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser <br>290 295 300 <br>Val Ser Glu Leu Pro Il e Met His Gln Asp Trp Leu Asn Gly Lys Glu <br>305 310 315 320 <br>Phe Lys Cys Arg Val As n Ser Ala Ala Phe Pro Ala Pro Il e Glu Lys <br>325 330 335 <br>Thr Ile Ser Lys Thr Lys Gl y Arg Pro Lys Ala Pro Gln Va l Tyr Thr <br>340 345 350 <br>Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Va l Ser Leu Thr <br>355 360 365 <br>Cys Met Il e Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln <br>370 375 380 <br>Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys As n Thr Gln Pro Ile Met <br>385 390 395 400 <br>Asp Thr Asp Gl y Ser Tyr Phe Va l Tyr Ser Lys Leu Asn Va l Gln Lys <br>405 410 415 <br>Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu <br>39 EP 2 569 010 81 <br>420 425 430 <br>5 <br>Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly <br>435 440 445 <br>10 <br>15 <br>20 <br>Lys <br><210> 25 <br><211> 15 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-C LCDR1 <br><400> 25 <br>Lys Ala Ser Gln Ser Val Asp Tyr Asp Gl y Asp Ser Tyr Met Asn <br>l 5 10 15 <br>25 <210> 26 <br><211> 7 <br><212> PRT <br><213> Artificial Sequence <br>30 <220> <br><223> Ab-C LCDR2 <br><400> 26 <br>35 <br><210> 27 <br>40 <211> 9 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>45 <223> Ab-C LCDR3 <br>50 <br><400> 27 <br><210> 28 <br><211> 5 <br>55 <212> PRT <br><213> Artificial Sequence <br><220> <br>Al a Ala Ser Asn Leu Glu Ser <br>l 5 <br>Gln Gln Ser Asn Gl u Asp Pro Trp Thr <br>l 5 <br>40 <223> Ab-C HCDR1 <br><400> 28 <br>5 <br><210> 29 <br>10 <211> 17 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>15 <223> Ab-C HCDR2 <br><400> 29 <br>EP 2 569 010 81 <br>Asp Cys Tyr Met Asn <br>l 5 <br>20 <br>Asp Ile Asn Pro Phe Asn Gly Gl y Thr Thr Tyr Asn Gl n Lys Phe Lys <br>l 5 10 15 <br>25 <br>30 <br>35 <br>Gly <br><210> 30 <br><211>16 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-C HCDR3 <br><400> 30 <br>Ser His Tyr Tyr Phe Asp Gly Ar g Val Pro Trp Asp Al a Met Asp Tyr <br>l 5 10 15 <br>40 <210> 31 <br><211> 657 <br><212> DNA <br><213> Mus musculus <br>45 <220> <br><221 > misc_feature <br><223> Ab-C light chain (no signal) <br><400> 31 <br>50 <br>55 <br>41 • <br>EP 2 569 010 81 # <br>gacattgtgc tgacccaatc tccagcttct ttgactgtgt ctctaggcct gagggccacc 60 <br>atctcctgca aggccagcca aagtgttgat tatgatggtg atagttatat gaactggtac 120 <br>5 <br>cagcagaaac caggacagcc acccaaactc ctcatctatg ctgcatccaa tctagaatct 180 <br>gggatcccag ccaggtttag tggcaatggg tctgggacag acttcaccct caacatccat 240 <br>10 <br>cctgtggagg aggaggatgc tgt aacctat t actgtcaac aaagtaatga ggatccgtgg 300 <br>acgttcggtg gaggcaccaa gct ggaaatc aaacgggctg atgctgcacc aactgtatcc 360 <br>15 <br>atcttcccac catccagtga gcagttaaca tctggaggtg cctcagtcgt gtgcttcttg 420 <br>aacaacttct accccaaaga catcaatgtc aagtggaaga ttgatggcag tgaacgacaa 480 <br>aatggcgtcc tgaacagttg gactgatcag gacagcaaag acagcaccta cagcatgagc 540 <br>20 <br>agcaccctca cgtt gaccaa ggacgagtat gaacgacata acagctatac ctgtgaggcc 600 <br>actcacaaga catcaacttc acccattgtc aagagcttca acaggaatga gtgttag 657 <br>25 <br><210> 32 <br><211> 218 <br><21 2> PRT <br><213> Mus musculus <br>30 <br><220> <br><221> MISC FEATURE <br><223> Ab-C light chain (no signal) <br><400> 32 <br>35 <br>40 <br>45 <br>50 <br>55 <br>42 EP 2 569 010 B1 <br>Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Thr Val Ser Leu Gly <br>l 5 10 15 <br>5 <br>Leu Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp <br>20 25 30 <br>10 <br>Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro <br>35 40 45 <br>Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala <br>15 <br>50 55 60 <br>Arg Phe Ser Gly Asn Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His <br>65 70 75 80 <br>20 <br>Pro Val Glu Glu Glu Asp Ala Val Thr Tyr Tyr Cys Gln Gln Ser Asn <br>85 90 95 <br>25 <br>Gl u Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg <br>100 105 110 <br>30 <br>Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln <br>115 120 125 <br>Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr <br>35 130 135 140 <br>Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln <br>40 <br>145 150 155 160 <br>Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr <br>45 <br>165 170 175 <br>Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg <br>180 185 190 <br>50 <br>His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro <br>195 200 205 <br>55 <br>Ile Val Lys Ser Phe Asn Arg Asn Glu Cys <br>210 215 <br>43 EP 2 569 010 81 <br><2 10> 33 <br><2 11 > 1350 <br><212> DNA <br><2 13> Mus muscu lus <br>5 <br><220> <br><221> misc_feature <br><223> Ab-C heavy chain (no signal) <br>10 <br><400> 33 <br>gaggtccagc tgcaacaatc tggacctgag ctggtgaagc ctgggacttc agtgaagatg 60 <br>tcctgtaagg cttctggata cacattcact gactgctaca tgaactgggt gaagcagagc 120 <br>15 <br>catgggaaga gccttgaatg gattggagat attaatcctt tcaacggtgg tactacctac 180 <br>aaccagaagt tcaagggcaa ggccacattg actgtagaca aatcctccag cacagcctac 240 <br>20 <br>atgcagctca acagcctgac atctgacgac tctgcagtct attactgtgc aagatcccat 300 <br>tattacttcg atggtagagt cccttgggat gctatggact actggggtca aggaacctca 360 <br>25 <br>gtcaccgtct cctcagccaa aacgacaccc ccatctgtct atccactggc ccctggatct 420 <br>gctgcccaaa ctaactccat ggtgaccctg ggatgcctgg tcaagggcta tttccctgag 480 <br>ccagtgacag tgacctggaa ctctggatcc ctgtccagcg gtgtgcacac cttcccagct 540 <br>30 <br>gtcctgcagt ctgacctcta cactctgagc agctcagtga ctgtcccctc cagcacctgg 600 <br>cccagcgaga ccgtcacctg caacgttgcc cacccggcca gcagcaccaa ggtggacaag 660 <br>35 <br>aaaattgtgc ccagggattg tggttgtaag ccttgcatat gtacagtccc agaagtatca 720 <br>tctgtcttca tcttcccccc aaagcccaag gatgtgctca ccattactct gactcctaag 780 <br>gtcacgtgtg ttgtggtaga catcagcaag gatgatcccg aggtccagtt cagctggttt 840 <br>40 <br>gtagatgatg tggaggtgca cacagctcag acgcaacccc gggaggagca gttcaacagc 900 <br>actttccgct cagtcagtga acttcccatc atgcaccagg actggctcaa tggcaaggag 960 <br>45 <br>ttcaaatgca gggtcaacag tgcagctttc cctgccccca tcgagaaaac catctccaaa 1020 <br>accaaaggca gaccgaaggc tccacaggtg tacaccattc cacctcccaa ggagcagatg 1080 <br>50 <br>gccaaggata aagtcagtct gacctgcatg ataacagact tcttccctga agacattact 1140 <br>gtggagtggc agtggaatgg gcagccagcg gagaactaca agaacactca gcccatcatg 1200 <br>gacacagatg gctcttactt catctacagc aagctcaatg tgcagaagag caactgggag 1260 <br>55 <br>gcaggaaata ctttcacctg ctctgtgtta catgagggcc tgcacaacca ccatactgag 1320 <br>aagagcctct cccactctcc tggtaaatga 1350 <br>44 5 <br><210> 34 . <br><211> 449 <br><212> PRT <br><213> Mus musculus <br><220> <br><221> MISC_FEATURE <br><223> Ab-C heavy chain (no signal) <br>EP 2 569 010 81 <br>10 <400> 34 <br>Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Thr <br>l 5 10 15 <br>15 <br>Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Cys <br>20 25 30 <br>20 <br>Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile <br>35 40 45 <br>25 <br>Gly Asp Ile Asn Pro Phe Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe <br>50 55 60 <br>Lys Gly Ly s Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr <br>30 <br>65 70 75 80 <br>Met Gln Leu Asn Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys <br>85 90 95 <br>35 <br>Ala Arg Ser Hi s Tyr Tyr Phe Asp Gly Arg Val Pro Trp Asp Ala Met <br>100 10 5 110 <br>40 <br>Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr <br>115 120 125 <br>45 Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr <br>50 <br>55 <br>45 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>130 135 140 <br>Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Gl u <br>145 150 155 160 <br>Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His <br>165 170 175 <br>Thr Phe Pro Al a Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser <br>180 185 190 <br>Val Thr Val Pro Ser Ser Thr Trp Pro Ser Gl u Thr Val Thr Cys Asn <br>195 200 205 <br>Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro <br>210 215 220 <br>Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser <br>225 230 235 240 <br>Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr <br>245 250 255 <br>Leu Thr Pro Lys Val Thr Cys Va l Val Va l Asp Ile Ser Lys Asp Asp <br>260 265 270 <br>Pro Gl u Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr <br>275 280 285 <br>Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser <br>290 295 300 <br>Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu <br>305 310 315 320 <br>Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys <br>325 330 335 <br>Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr <br>340 345 350 <br>Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr <br>355 360 365 <br>Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln <br>46 5 <br>10 <br>15 <br>20 <br>EP 2 569 010 81 <br>370 375 380 <br>Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met <br>385 390 395 400 <br>Asp Thr Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Val Gln Lys <br>405 410 415 <br>Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu <br>420 425 430 <br>Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly <br>Lys <br><210> 35 <br><211> 11 <br>435 440 445 <br>25 <212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-D LCDR1 <br>30 <br><400> 35 <br>Gln Ala Ser Gln Gly Thr Ser Ile Asn Leu Asn <br>35 <br>l 5 10 <br><21 0> 36 <br><211> 7 <br><212> PRT <br>40 <213> Artificial Sequence <br><220> <br><223> Ab-D LCDR2 <br>45 <400> 36 <br>50 <br>55 <br><21 0> 37 <br><211> 9 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-D LCDR3 <br>Gly Ser Ser Asn Leu Glu Asp <br>l 5 <br>47 5 <br><400> 37 <br><210> 38 <br><211> 5 <br><212> PRT <br>10 <213> Artificial Sequence <br><220> <br><223> Ab-D HCDR1 <br>15 <400> 38 <br>20 <br>25 <br>30 <br><210> 39 <br><211>17 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-D HCDR2 <br><400> 39 <br>EP 2 569 010 B1 <br>Leu Gln His Ser Tyr Leu Pro Tyr Thr <br>l 5 <br>Asp His Tyr Met Ser <br>l 5 <br>Asp Ile As n Pro Tyr Ser Gly Glu Thr Thr Tyr Asn Gln Lys Phe Lys <br>l 5 10 15 <br>35 <br>Gly <br><210> 40 <br><211> 10 <br>40 <212> PRT <br>45 <br>50 <br><213> Artificial Sequence <br><220> <br><223> Ab-D HCDR3 <br><400> 40 <br><210> 41 <br><211> 645 <br><212> DNA <br>55 <213> Mus musculus <br><400> 41 <br>Asp Asp Tyr Asp Ala Ser Pro Phe Ala Tyr <br>l 5 10 <br>48 . <br>EP 2 569 010 B1 ) <br>gatgtccaga tgattcagtc tccatcctcc ctgtctgcat ctttgggaga catagtcacc 60 <br>atgact tgcc aggcaagtca gggcactagc attaatttaa actggtttca gcaaaaacca 120 <br>5 <br>gggaaggctc ctaagctcct gatctatggt tcaagcaact tggaagatgg ggtcccatca 180 <br>aggttcagtg gcagtagata tgggacagat ttcactctca ccatcagcag cctggaggat 240 <br>10 <br>gaagatctgg caacttattt ctgtctacaa catagttatc tcccgtacac gttcggaggg 300 <br>gggaccaagc tggaaataaa acgggctgat gctgcaccaa ctgtatccat cttcccacca 360 <br>15 <br>tccagtgagc agttaacatc tggaggtgcc tcagtcgtgt gcttcttgaa caacttctac 420 <br>cccaaagaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa tggcgtcctg 480 <br>aacagttgga ctgatcagga cagcaaagac agcacctaca gcatgagcag caccctcacg 540 <br>20 <br>ttgaccaagg acgagtatga acgacataac agctatacct gtgaggccac tcacaagaca 600 <br>tcaacttcac ccattgtcaa gagcttcaac aggaatgagt gttag 645 <br>25 <br><210> 42 <br><211>214 <br><212> PRT <br><213> Mus musculus <br>30 <400> 42 <br>35 <br>40 <br>45 <br>50 <br>55 <br>49 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>Asp Val Gln Met Ile Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly <br>l 5 10 15 <br>Asp Ile Val Thr Met Thr Cys Gln Ala Ser Gln Gly Thr Ser Ile Asn <br>20 25 30 <br>Leu Asn Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile <br>35 40 45 <br>Tyr Gly Ser Ser Asn Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly <br>50 55 60 <br>Ser Arg Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Asp <br>65 70 75 80 <br>Glu Asp Leu Ala Thr Tyr Phe Cys Leu Gln His Ser Tyr Leu Pro Tyr <br>85 90 95 <br>Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala <br>100 105 110 <br>Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly <br>115 120 125 <br>Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile <br>130 135 140 <br>Asn Val Lys Trp Lys Ile Asp Gl y Ser Glu Arg Gln Asn Gly Val Leu <br>145 150 155 160 <br>Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser <br>165 170 175 <br>Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr <br>180 185 190 <br>Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser <br>195 200 205 <br>Phe Asn Arg Asn Glu Cys <br>210 <br>50 EP 2 569 010 81 <br><210> 43 <br><211 > 1332 <br><212> DNA <br><21 3> Mus musculus <br>5 <br><400> 43 <br>gaggtccagc tgcaacagtc tggacctgaa ctggtgacgc ctggggcttc agtgaagata 60 <br>10 <br>tcttgtaagg cttctggata cacattcact gaccactaca tgagctgggt gaagcagagt 120 <br>catggaaaaa gccttgagtg gattggagat attaatccct attctggtga aactacctac 180 <br>15 <br>aaccagaagt tcaagggcac ggccacattg actgtagaca agtcttccag tatagcctac 2 40 <br>atggagatcc gcggcctgac atct gaggac tctgcagtct attactgtgc aagagatgat 300 <br>tacgacgcct ctccgtttgc ttactggggc caagggactc tggtcactgt ctctgcagcc 360 <br>20 <br>aaaacgacac ccccatctgt ctatccactg gcccctggat ctgctgccca aactaactcc 420 <br>atggtgaccc tgggatgcct ggtcaagggc tatttccctg agccagtgac agtgacctgg 480 <br>25 <br>aactctggat ccctgtccag cggt gtgcac accttcccag ctgtcctgca gtctgacctc 540 <br>tacactctga gcagctcagt gact gtcccc tccagcacct ggcccagcga gaccgtcacc 600 <br>tgcaacgttg cccacccggc cagcagcacc aaggtggaca agaaaattgt gcccagggat 660 <br>30 <br>tgtggttgta agccttgcat atgtacagtc ccagaagtat catctgtctt catcttcccc 720 <br>ccaaagccca aggatgtgct caccattact ctgactccta aggtcacgtg tgttgtggta 780 <br>35 <br>gaca t cagea aggatgatcc cgaggtccag ttcagctggt ttgtagatga tgtggaggtg 840 <br>cacacagctc agacgcaacc ccgggaggag cagttcaaca gcact ttc c g c t cagtcagt 90 0 <br>gaacttccca tcatgcacca ggactggctc aatggcaagg agttcaaatg cagggtcaac 960 <br>40 <br>agtccagctt tccctgcccc catcgagaaa accatctcca aaaccaaagg cagaccgaag 10 2 0 <br>gctccacagg tgtacaccat tccacctccc aaggagcaga tggccaagga taaagtcagt 1080 <br>45 <br>ctgacctgca tgataacaga cttcttccct gaagacatta ctgtggagtg gcagtggaat 1140 <br>gggcagccag cggagaacta caagaacact cagcccatca tggacacaga tggctcttac 1200 <br>50 <br>ttcatctaca gcaagctcaa tgtgcagaag agcaactggg aggcaggaaa tactttcacc 1260 <br>tgctctgtgt tacatgaggg cctgcacaac caccatactg agaagagcct ctcccactct 1320 <br>cctggtaaat ga 1332 <br>55 <br><210> 44 <br><211> 443 <br><212> PRT <br>51 EP 2 569 010 81 <br><213> Mus musculus <br><400> 44 <br>5 <br>Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Thr Pro Gly Ala <br>l 5 10 15 <br>10 <br>Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His <br>20 25 30 <br>Tyr Met Ser Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile <br>15 <br>35 40 45 <br>Gly Asp Ile Asn Pro Tyr Ser Gly Glu Thr Thr Tyr Asn Gln Lys Phe <br>50 55 60 <br>20 <br>Lys Gly Thr Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Ile Ala Tyr <br>65 70 75 80 <br>25 <br>Met Glu Ile Arg Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys <br>85 90 95 <br>30 <br>Ala Arg Asp Asp Tyr Asp Ala Ser Pro Phe Ala Tyr Trp Gly Gln Gly <br>100 105 110 <br>Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro Pro Ser Val Tyr <br>35 <br>115 120 125 <br>Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu <br>130 135 140 <br>40 <br>Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp <br>45 <br>50 <br>55 <br>52 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>145 150 155 160 <br>Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu <br>165 170 175 <br>Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser <br>180 185 190 <br>Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser <br>195 200 205 <br>Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys Lys <br>210 215 220 <br>Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe Pro <br>225 230 235 240 <br>Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr <br>245 250 255 <br>Cys Va l Val Val Asp Ile Ser Lys Asp Asp Pro Glu Va l Gln Phe Ser <br>260 265 270 <br>Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro Arg <br>275 280 285 <br>Glu Gl u Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile <br>290 295 300 <br>Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn <br>305 310 315 320 <br>Ser Pro Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys <br>325 330 335 <br>Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu <br>340 345 350 <br>Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe <br>355 360 365 <br>Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala <br>370 375 380 <br>Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr <br>53 EP 2 569 010 81 <br>385 390 395 400 <br>5 <br>Phe Ile Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly <br>405 410 415 <br>Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn His His <br>10 <br>420 425 430 <br>Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys <br>15 <br><210> 45 <br><211> 11 <br><212> PRT <br>435 440 <br><213> Artificial Sequence <br>20 <br><220> <br><223> Ab-2 LCDR1 <br><400> 45 <br>25 <br>30 <210> 46 <br><211> 7 <br><212> PRT <br>Arg Ala Ser Ser Ser Val Tyr Tyr Tyr Met Hi s <br>l 5 10 <br><213> Artificial Sequence <br>35 <220> <br><223> Ab-2 LCDR2 <br><400> 46 <br>40 <br><210> 47 <br>45 <211> 9 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>50 <223> Ab-3 LCDR3 <br><400> 47 <br>55 <br><210> 48 <br>Ala Thr Ser Asn Leu Ala Ser <br>l 5 <br>Gln Gln Trp Ser Ser Asp Pro Leu Thr <br>l 5 <br>54 <21 1>5 <br><212> PRT <br><213> Artificial Sequence <br>5 <220> <br><223> Ab-2 HCDR1 <br><400> 48 <br>10 <br><210> 49 <br>15 <211>17 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>20 <223> Ab-2 HCDR2 <br><400> 49 <br>EP 2 569 010 81 <br>Asp Iyr Phe Ile His <br>l 5 <br>25 <br>Arg Leu Asp Pro Glu Asp Gly Glu Ser Asp Iyr Ala Pro Lys Phe Gl n <br>l 5 10 15 <br>30 <br>35 <br>40 <br>A sp <br><210> 50 <br><211>12 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-2 HCDR3 <br><400> 50 <br>Glu Asp Iyr Asp Gly Ihr Iyr Ihr Phe Phe Pro Iyr <br>45 <210> 51 <br><211> 642 <br><212> DNA <br><213> Mus musculus <br>50 <220> <br><221 > misc_feature <br>l 5 10 <br><223> Ab-2 light chain (no signal) <br><400> 51 <br>55 <br>55 EP 2 569 010 B1 <br>caaattgttc tctcccagtc tccagcaatc ctgtctacat ctccagggga gaaggtcaca 60 <br>atgacttgca gggccagctc aagt gtatat tacatgcact ggtaccagca gaagccagga 120 <br>5 <br>tcctccccca aaccctggat t tatgccaca tccaacctgg ct t ctggagt ccctgttcgc 180 <br>ttcagt ggca gt gggtctgg gacctcttac tctctcacaa tcaccagagt ggaggctgaa 240 <br>10 <br>gatgctgcca cttattactg ccagcagtgg agtagtgacc cactcacgtt cggtgctggg 300 <br>accaagctgg agctgaaacg ggctgatgct gcaccaactg tatccatctt cccaccatcc 360 <br>15 <br>agtgagcagt taacat ctgg aggtgcctca gtcgtgtgct tcttgaacaa cttctacccc 420 <br>aaagacatca a t gtcaagtg gaag attgat g gcagt gaac gacaaaatgg cgtcctgaac 480 <br>agttggactg atcaggacag caaagacagc acctacagca tgagcagcac cctcacgttg 540 <br>20 <br>accaaggacg agtat gaacg acataacagc tatacctgtg aggccactca caagacatca 600 <br>acttcaccca ttgtcaagag ct t caacagg aatgagtgtt ag 642 <br>25 <br><210> 52 <br><211>213 <br><212> PRT <br><213> Mus musculus <br>30 <220> <br><221> MISC FEATURE <br>-<br><223> Ab-2 light chain (no signal) <br><400> 52 <br>35 <br>40 <br>45 <br>50 <br>55 <br>56 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Thr Ser Pro Gly <br>l 5 10 15 <br>Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Tyr Tyr Met <br>20 25 30 <br>His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr <br>35 40 45 <br>Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser <br>50 55 60 <br>Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Thr Arg Val Glu Ala Glu <br>65 70 75 80 <br>Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asp Pro Leu Thr <br>85 90 95 <br>Phe Gly Ala Gly Thr Lys Leu Gl u Leu Lys Arg Ala Asp Ala Ala Pro <br>100 105 110 <br>Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly <br>115 120 125 <br>Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn <br>130 135 140 <br>Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn <br>145 150 155 160 <br>Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser <br>165 170 175 <br>Thr Leu Thr Leu Thr Lys Asp Gl u Tyr Glu Arg His Asn Ser Tyr Thr <br>180 185 190 <br>Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe <br>195 200 205 <br>Asn Arg Asn Glu Cys <br>210 <br>57 EP 2 569 010 B1 <br><210> 53 <br><211 > 1338 <br><212> DNA <br><213> Mus musculus <br>5 <br><220> <br><221 > mise_ feature <br><223> Ab-2 heavy chain (no signal) <br>10 <br><400> 53 <br>gaggttcagg tgcagcagtc tgggccagaa cttgtgaagc caggggcctc agtcaagttg 60 <br>tcctgcacag cttctggctt caacattaaa gactact tta tacactgggt gaagcagagg 120 <br>15 <br>cctgaacagg gcctggagtg gattggaagg cttgatcctg aggatggtga aagtgattat 180 <br>gccccgaagt tccaggacaa ggccattatg acagcagaca catcatccaa cacagcctat 240 <br>20 <br>cttcagctca gaagcctgac atctgaggac actgccatct attattgtga gagagaggac 300 <br>tacgatggta cctacacctt ttttccttac tggggccaag ggactctggt cactgtctct 360 <br>25 <br>gcagccaaaa cgacaccccc atctgtctat ccactggcc c ctggatctgc tgcccaaact 420 <br>aactccatgg tgaccctggg atgcctggtc aagggctatt tccctgagcc agtgacagtg 480 <br>acctggaact ctggatccct gtccagcggt gtgcacacct tcccagctgt cctgcagtct 540 <br>30 <br>gacctctaca ctctgagcag ctcagtgact gtcccctcca gcacctggcc cagcgagacc 600 <br>gtcacctgca acgttgccca cccggccagc agcaccaagg tggacaagaa aattgtgccc 660 <br>35 <br>agggattgtg gttgtaagcc ttgcatatgt acagtcccag aagtatcatc tgtcttcatc 720 <br>ttccccccaa agcccaagga tgtgctcacc attactctga ctcctaaggt cacgtgtgtt 780 <br>gtggtagaca tcagcaagga tgatcccgag gtccagttca gctggtttgt agatgatgtg 840 <br>40 <br>gaggtgcaca cagctcagac gcaaccccgg gaggagcagt tcaacagcac tttccgctca 900 <br>gtcagtgaac ttcccatcat gcaccaggac tggctcaatg gcaaggagtt caaatgcagg 960 <br>45 <br>gtcaacagtg cagctttccc tgcccccatc gagaaaacca tctccaaaac caaaggcaga 1020 <br>ccgaaggctc cacaggtgta caccattcca cctcccaagg agcagatggc caaggataaa 1080 <br>50 <br>gtcagtctga cctgcatgat aacagacttc ttccctgaag acattactgt ggagtggcag 1140 <br>tggaatgggc agccagcgga gaactacaag aacactcagc ccatcatgga cacagatggc 1 2 00 <br>tcttacttca tctacagcaa gctcaatgtg cagaagagca actgggaggc aggaaatact 1 260 <br>55 <br>ttcacctgct ctgtgttaca tgagggcctg cacaaccacc atactgagaa gagcctctcc 13 20 <br>cactctcctg gtaaatga 1338 <br>58 5 <br><210> 54 <br><211> 445 <br><212> PRT <br><213> Mus musculus <br><220> <br><221 > MISC_FEATURE <br><223> Ab-2 heavy chain (no signal) <br>EP 2 569 010 B1 <br>10 <400> 54 <br>Glu Val Gln Val Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala <br>l 5 10 15 <br>15 <br>Ser Va l Lys Leu Ser Cys Thr Ala Ser Gl y Phe Asn Ile Lys Asp Tyr <br>20 25 30 <br>20 <br>Phe Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile <br>35 40 45 <br>25 <br>Gl y Arg Leu Asp Pro Glu Asp Gly Glu Ser Asp Tyr Al a Pro Lys Phe <br>50 55 60 <br>Gln Asp Lys Ala Ile M et Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr <br>30 <br>65 70 75 80 <br>Leu Gln Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Ile Tyr Tyr Cys <br>85 90 95 <br>35 <br>Glu Arg Glu Asp Ty r Asp Gl y Thr Tyr Thr Phe Phe Pro Tyr Trp Gl y <br>100 105 110 <br>40 <br>Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro Pro Ser <br>45 <br>50 <br>55 <br>59 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 8 1 <br>115 120 125 <br>Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val <br>130 135 140 <br>Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val <br>145 150 155 160 <br>Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala <br>165 170 175 <br>Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro <br>180 185 190 <br>Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro <br>195 200 205 <br>Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly <br>210 215 220 <br>Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe I l e <br>225 230 235 240 <br>Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys <br>245 250 255 <br>Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln <br>260 265 270 <br>Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln <br>275 280 285 <br>Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu <br>290 295 300 <br>Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg <br>305 310 315 320 <br>Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys <br>325 330 335 <br>Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro <br>340 345 350 <br>Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr <br>60 5 <br>10 <br>15 <br>20 <br>EP 2 569 010 B1 <br>355 360 365 <br>Asp Phe Phe Pr o Gl u Asp I le Thr Val Gl u Trp Gln Trp Asn Gly Gln <br>370 375 380 <br>Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly <br>385 390 395 400 <br>Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Va l Gl n Lys Ser Asn Trp Glu <br>405 410 415 <br>Ala Gly Asn Thr Phe Thr Cys Ser Val Leu Hi s Glu Gly Le u His Asn <br>420 425 430 <br>His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys <br>435 440 445 <br><210> 55 <br>25 <211> 12 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>30 <223> Ab-3 and Ab-15 LCDR 1 <br><400> 55 <br>35 <br>Ser Val Ser Ser Thr I l e Ser Ser Asn His Leu His <br>l 5 10 <br><210> 56 <br><211> 7 <br>40 <212> PRT <br>45 <br>50 <br><213> Artificial Sequence <br><220> <br><223> Ab-3 and Ab-15 LCDR2 <br><400> 56 <br><210> 57 <br><211> 9 <br><212> PRT <br>55 <213> Artificial Sequence <br><220> <br><223> Ab-3 and Ab-15 LCDR3 <br>Gl y Thr Ser Asn Leu Al a Ser <br>l 5 <br>61 5 <br><400> 57 <br><210> 58 <br><211> 5 <br><212> PRT <br>EP 2 569 010 81 <br>Gln Gln Trp Ser Ser Tyr Pro Leu Thr <br>l 5 <br>10 <213> Artificial Sequence <br><220> <br><223> Ab-3 and Ab-15 HCDR1 <br>15 <400> 58 <br>20 <br>25 <br>30 <br>35 <br><210> 59 <br><211 > 17 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-3 and Ab-15 HCDR2 <br><400> 59 <br>Asp Ph e Tyr Leu His <br>l 5 <br>Arg Ile Asp Pro Glu Asn Gly Asp Thr Leu Tyr Asp Pro Lys Phe Gln <br>l 5 10 15 <br>As p <br><210> 60 <br><211> 16 <br>40 <212> PRT <br>45 <br>50 <br><213> Artificial Sequence <br><220> <br><223> Ab-3 and Ab-15 HCDR3 <br><400> 60 <br>Gl u Ala Asp Tyr Phe His Asp Gl y Thr Ser Tyr Trp Tyr Phe Asp Va l <br>l 5 10 15 <br><210> 61 <br><211> 648 <br><212> DNA <br>55 <213> Mus musculus <br><220> <br><221 > mise_ feature <br>62 EP 2 569 010 81 <br><223> Ab-3 light chain <br><400> 61 <br>5 <br>60 gaaat t gtgc tcacccagtc tccagcactc atggctgcat c t ccggggga gaaggtcacc <br>atcacctgca gtgtcagttc aactataagt tccaaccact tgcactggtt ccagcagaag 120 <br>10 <br>tcagacacct cccccaaacc ctggatttat ggcacatcca acctggcttc tggagtccct 180 <br>gttcgcttca gtggcagtgg atctgggacc tet tat tete tcacaatcag cagcatggag 240 <br>gctgaggat g ctgccactta t t actgtcaa cagtggagta gttacccact cacgttcggc 300 <br>15 <br>gctgggacca agctggagct gagacgggct gatgctgcac caactgtatc catct tccca 360 <br>ccatccagt g agcagttaac atctggaggt gcctcagtcg tgtgcttctt gaacaacttc 420 <br>20 <br>taccccaaag acatcaatgt caagtggaag attgatggca g t gaacgaca aaat ggcgtc 480 <br>ctgaacagtt ggactgatca ggacagcaaa gacagcacct acagcatgag cagcaccctc 540 <br>acgttgacca aggacgagta tgaacgacat aacagctata cctgtgaggc cact cacaag 600 <br>25 <br>acatcaactt cacccattgt caagagcttc aacaggaatg agtgttag 648 <br><210> 62 <br><211>215 <br>30 <212> PRT <br><213> Mus musculus <br><220> <br><221> MISC FEATURE <br>-<br>35 <223> Ab-3 light chain (no signal) <br><400> 62 <br>40 <br>45 <br>50 <br>55 <br>63 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>Glu Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ala Ala Ser Pro Gly <br>l 5 10 15 <br>Gl u Lys Va l Thr Ile Thr Cys Ser Val Ser Ser Thr Ile Ser Ser Asn <br>20 25 30 <br>His Leu His Trp Phe Gln Gln Lys Ser Asp Thr Ser Pro Lys Pro Trp <br>35 40 45 <br>Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser <br>50 55 60 <br>Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu <br>65 70 75 80 <br>Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro <br>85 90 95 <br>Leu Thr Phe Gl y Ala Gly Thr Lys Leu Glu Leu Arg Arg Ala Asp Ala <br>100 105 110 <br>Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser <br>115 120 125 <br>Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp <br>130 135 140 <br>Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val <br>145 150 155 160 <br>Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met <br>165 170 175 <br>Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser <br>180 185 190 <br>Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys <br>195 200 205 <br>Ser Phe Asn Arg Asn Glu Cys <br>210 215 <br>64 EP 2 569 010 B1 <br><210> 63 <br><211> 1350 <br><212> DNA <br><213> Mus musculus <br>5 <br><220> <br><221 > mise_ feature <br><223> Ab-3 heavy chain <br>10 <br><400> 63 <br>gaggttcagc tgcagcagtc tggggctgaa cttgtgaggc caggggcctt agtcaagttg 60 <br>15 <br>tcctgcacag ct t ctgactt caacattaaa gacttctatc t acactggat gaggcagcgg 120 <br>cctgaacagg gcctggactg gattggaagg attgatcctg agaatggtga t act ttatat 180 <br>gacccgaagt tccaggacaa ggccactctt acaacagaca catcctccaa cacagcctac 240 <br>20 <br>ctgcagctca gcggcctgac a t c t gagacc act gccgtct attactgttc tagagaggcg 300 <br>gattatttcc acgatggtac c t cctactgg tacttcgatg t ctggggcgc agggaccac a 360 <br>25 <br>atcaccgtct cct cagccaa aacgacaccc ccat ctgtct a t ccactggc ccctggatct 420 <br>gctgcccaaa ctaactccat ggt gaccctg g gatgcctgg tcaagggcta tttccctgag 480 <br>ccagt gacag tga cctggaa c t c t ggat cc c t gtccagcg g t gtgcacac cttcccagct 540 <br>30 <br>gtcctgcagt ctgacctcta cact ctgagc agctcagtga c t gtcccctc cagcacctgg 600 <br>cccagcgaga ccgt cacctg caacgttgcc cacccggcca gcagcaccaa ggtggacaag 660 <br>35 <br>aaaat t gtgc ccagggattg tggttgtaag cct tgcatat g t acagtccc agaagtatca 720 <br>tctgtcttca tctt cccccc aaagcccaag gat gtgctca ccattactct gact cctaag 780 <br>40 <br>gtcacgtgtg ttgt ggtaga cat cagcaag gat gatcccg aggtccagtt cagctggtt t 840 <br>gtagat gatg tggaggtgca cacagct cag acgcaacccc gggaggagca gttcaacagc 900 <br>actttccgct cagt cagtga act tcccatc a t gcaccagg actggctcaa t ggcaaggag 960 <br>45 <br>ttcaaatgca gggtcaacag tgcagctttc cctgccccca tcgagaaaac catctccaaa 1020 <br>accaaaggca gaccgaaggc tccacaggtg t acaccattc cacctcccaa ggagcagatg 1080 <br>50 <br>gccaaggata aagtcagtct gacctgcatg a t aacagact t cttccctga agacattact 1140 <br>gtggagtggc agt ggaatgg gcagccagcg gagaactaca agaacactca gcccatcatg 1200 <br>gacacagatg gctcttactt ca t ctacagc aagctcaatg tgcagaagag caactgggag 126 0 <br>55 <br>gcaggaaata ctt t cacctg ctct gtgtta catgagggcc tgcacaacca ccatactgag 132 0 <br>aagagcctct cccactctcc tggtaaatga 1350 <br>65 5 <br><210> 64 <br><211> 449 <br><212> PRT <br><213> Mus musculus <br><220> <br><221> MISC_FEATURE <br><223> Ab-3 heavy chain (no signal) <br>EP 2 569 010 B1 <br>10 <400> 64 <br>Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala <br>l 5 10 15 <br>15 <br>Leu Val Lys Leu Ser Cys Thr Ala Ser Asp Phe Asn I l e Lys Asp Phe <br>20 25 30 <br>20 <br>Tyr Leu His Trp Met Arg Gln Arg Pro Glu Gln Gly Leu Asp Trp Ile <br>35 40 45 <br>25 <br>Gly Arg Ile Asp Pro Glu Asn Gly Asp Thr Leu Tyr Asp Pro Lys Phe <br>50 55 60 <br>Gln Asp Lys Ala Thr Leu Thr Thr Asp Thr Ser Ser Asn Thr Ala Tyr <br>30 <br>65 70 75 80 <br>Leu Gln Leu Ser Gly Leu Thr Ser Glu Thr Thr Ala Val Tyr Tyr Cys <br>35 <br>40 <br>45 <br>50 <br>55 <br>66 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>85 90 95 <br>Ser Arg Glu Ala Asp Tyr Phe His Asp Gly Thr Ser Tyr Trp Tyr Phe <br>100 105 110 <br>Asp Val Trp Gly Ala Gly Thr Thr Ile Thr Val Ser Ser Ala Lys Thr <br>115 120 125 <br>Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr <br>130 135 140 <br>Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu <br>145 150 155 160 <br>Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His <br>165 170 175 <br>Thr Phe Pro Ala Va l Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser <br>180 185 190 <br>Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys As n <br>195 200 205 <br>Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro <br>210 215 220 <br>Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser <br>225 230 235 240 <br>Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr <br>245 250 255 <br>Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp <br>260 265 270 <br>Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr <br>275 280 285 <br>Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser <br>290 295 300 <br>Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu <br>305 310 315 320 <br>Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys <br>67 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>EP 2 569 010 B1 <br>325 330 335 <br>Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Al a Pro Gln Val Tyr Thr <br>340 345 350 <br>Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr <br>355 360 365 <br>Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln <br>370 375 380 <br>Trp Asn Gl y Gln Pro Al a Glu Asn Tyr Lys As n Thr Gl n Pro Ile M e t <br>385 390 395 400 <br>Asp Thr Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Val Gln Lys <br>405 410 415 <br>Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu <br>420 425 430 <br>Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gl y <br>435 440 445 <br>Lys <br>35 <210> 65 <br><211> 324 <br><212> DNA <br><213> Mus musculus <br>40 <220> <br>45 <br>50 <br>55 <br><221 > mise_ feature <br><223> Ab-15 light variable <br><400> 65 <br>gacatccaga tgacccagtc <br>ataacatgca gcgtatcatc <br>cccggcaaag cacctaaatc <br>tcaagatttt caggctctgg <br>cccgaagact tcgcaaccta <br>ggcggcacaa aagtagaaat <br>tccatcctcc ctctcagcat ccgt aggcga tagagttaca <br>aactatatca tcaaatcatc tt cattggtt ccaacagaaa <br>acttatatac ggcacatcaa atctcgcatc aggcgttcct <br>ctcaggcacc gactttactc ttacaatatc ctccctccaa <br>ttactgtcaa caatggtcct cat atccact cacatttggc <br>ta aa <br>68 <br>60 <br>120 <br>180 <br>240 <br>300 <br>324 5 <br><210> 66 <br><211> 108 <br><212> PRT <br><213> Mus musculus <br><220> <br><221> MISC_FEATURE <br><223> Ab-15 light variable <br>EP 2 569 010 B1 <br>10 <400> 66 <br>Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly <br>l 5 10 15 <br>15 <br>Asp Arg Va l Thr Ile Thr Cys Ser Val Ser Ser Thr Il e Ser Ser Asn <br>20 25 30 <br>20 <br>His Leu His Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu <br>35 40 45 <br>25 <br>Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser <br>50 55 60 <br>Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln <br>30 <br>65 70 75 80 <br>Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro <br>85 90 95 <br>35 <br>Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys <br>100 105 <br>40 <210> 67 <br><211>375 <br><212> DNA <br><213> Mus musculus <br>45 <220> <br><221 > mise_ featu re <br><223> Ab-15 heavy variable <br><400> 67 <br>50 <br>55 <br>69 EP 2 569 010 B1 <br>gaggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60 <br>tcctgcaagg cttctgactt caacattaaa gacttctatc tacactgggt gcgacaggcc 120 <br>5 <br>cctggacaag ggcttgagtg gattggaagg attgatcctg agaatggtga tactttatat 180 <br>gacccgaagt tccaggacaa ggtcaccatg accacagaca cgtccaccag cacagcctac 240 <br>10 <br>atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagaggcg 300 <br>gattatttcc acgatggtac ctcctactgg tact tcgatg tctggggccg tggcaccctg 360 <br>15 <br>gtcaccgt ct ctagt 375 <br><210> 68 <br>20 <br><211> 125 <br><212> PRT <br><213> Mus musculus <br><220> <br>25 <br><221> MISC FEATURE <br>-<br><223> Ab-15 heavy variable <br><400> 68 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>70 - , <br>5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>EP 2 569 010 8 1 <br>Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala <br>l 5 10 15 <br>Ser Val Lys Val Ser Cys Lys Ala Ser Asp Phe Asn Ile Lys Asp Phe <br>20 25 30 <br>Tyr Leu Hi s Trp Va l Arg Gln Al a Pro Gly Gln Gly Leu Glu Trp I l e <br>35 40 45 <br>Gly Arg I l e Asp Pro Glu Asn Gl y Asp Thr Leu Tyr Asp Pro Lys Phe <br>50 55 60 <br>Gln Asp Lys Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr <br>65 70 75 80 <br>Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys <br>85 90 95 <br>Ala Arg Gl u Ala Asp Tyr Phe Hi s Asp Gly Thr Ser Tyr Trp Tyr Phe <br>100 105 11 0 <br>Asp Val Trp Gly Arg Gly Thr Leu Val Thr Va l Ser Ser <br><210> 69 <br><211 > 645 <br>115 120 125 <br>35 <212> DNA <br>40 <br><213> Artificial Sequence <br><220> <br><223> Humanized antibody <br><220> <br><221 > mise_ feature <br><223> Ab-15 light chain <br>45 <400> 69 <br>50 <br>55 <br>71 EP 2 569 010 81 <br>gacatccaga tgacccagtc tccatcctcc ct ct cagea t ccgtaggcga t agagttaca 60 <br>ataacatgca gcgtatcatc aactatatca tcaaatcatc t t cattggtt ccaacagaaa 120 <br>5 <br>cccggcaaag cacct aaatc act t atatac ggcacatcaa a t ctcgcatc aggcgttcct 180 <br>tcaagatttt caggctctgg ctcaggcacc gactttactc t t acaatatc ctccctccaa 240 <br>10 <br>cccgaagact tcgcaaccta ttactgtcaa caatggtcct catatccact cacatttggc 300 <br>ggcggcacaa aagtagaaat ta aacgtacg gtggctgcac catctgtctt catcttcccg 360 <br>ccatctgatg agcagttgaa atct ggaact gcctctgttg tgtgcctgct gaataacttc 420 <br>15 <br>tatcc c agag aggc caaagt acagt ggaag gtggataacg ccctccaatc gggtaactcc 480 <br>caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 540 <br>20 <br>acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag 600 <br>ggcctgagct cgcccgtcac aaagagcttc aacaggggag agt gt 645 <br><210> 70 <br>25 <br><211>215 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>30 <br><223> Humanized antibody sequence <br><220> <br><221> MISC FEATURE <br>-<br><223> Ab-15 light chain <br>35 <br><400> 70 <br>40 <br>45 <br>50 <br>55 <br>72 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly <br>l 5 10 15 <br>Asp Arg Val Thr Ile Thr Cys Ser Val Ser Ser Thr Il e Ser Ser Asn <br>20 25 30 <br>His Leu His Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu <br>35 40 45 <br>Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser <br>50 55 60 <br>Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln <br>65 70 75 80 <br>Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Tyr Pro <br>85 90 95 <br>Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Va l Ala <br>100 105 110 <br>Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser <br>115 120 125 <br>Gly Thr Al a Ser Val Va l Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu <br>130 135 140 <br>Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser <br>145 150 155 160 <br>Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu <br>165 170 175 <br>Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Va l <br>180 185 190 <br>Tyr Ala Cys Glu Val Thr His Gl n Gly Leu Ser Ser Pro Val Thr Lys <br>195 200 205 <br>Ser Phe Asn Arg Gly Glu Cys <br>210 215 <br>73 5 <br><210>71 <br><211 > 1353 <br><212> DNA <br><213> Artificial Sequence <br><220> <br><223> Humanized antibody <br><220> <br>10 <221 > misc_feature <br><223> Ab-15 heavy chain <br><400> 71 <br>15 <br>gaggtgcagc tggtgcagtc <br>tcctgc aagg cttctgactt <br>20 <br>cctggacaag ggctt gagtg <br>gacccgaagt tccaggacaa <br>atggagctga ggagcctgag <br>25 <br>gattat t tcc acgatggtac <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60 <br>caacattaaa gacttctatc tacactgggt gcgacaggcc 12 0 <br>gattggaagg attgatcctg agaatggtga tactttatat 180 <br>ggtcaccatg accacagaca cgtccaccag cacagcctac 2 40 <br>atctgacgac acggccgtgt attactgtgc gagagaggcg 300 <br>ctcctactgg tacttcgatg tct ggggccg tggcaccctg 360 <br>74 " <br>EP 2 569 010 81 <br>gtcaccgtct ctagtgcctc caccaagggc ccatcggtct tccccctggc gccctgctcc 42 0 <br>aggagcacct ccgagagcac agcggccctg ggctgcctgg tcaaggacta cttccccgaa 480 <br>5 <br>540 ccggtgacgg tgtcgtggaa ctcaggcgct ctgaccagcg gcgtgcacac cttcccagct <br>gtcctacagt cctcaggact ctactccctc agcagcgtgg t gaccgtgcc ctccagcaac 600 <br>10 <br>ttcggcaccc agacctacac ctgcaacgta gat cacaagc ccagcaacac caaggtggac 660 <br>aagacagttg agcgcaaatg ttgt gtcgag tgcccaccgt gcccagcacc acctgtggca 720 <br>ggaccgtcag tct tcctctt ccccccaaaa cccaaggaca ccctcatgat ctcccggacc 780 <br>15 <br>cctgaggtca cgt gcgtggt ggt ggacgtg agccacgaag a ccccgaggt ccagttcaac 840 <br>tggtacgt gg acggcgtgga ggtgcataat gccaagacaa agccacggga ggagcagttc 900 <br>20 <br>aacagcacgt tccgtgtggt cagcgtcctc accgttgtgc accaggactg gctgaacggc 960 <br>aaggagtaca agtgcaaggt ctccaacaaa ggcctcccag cccccatcga gaaaaccatc 10 2 0 <br>tccaaaacca aagggcagcc ccgagaacca caggtgtaca ccctgccccc atcccgggag 1080 <br>25 <br>gagatgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta ccccagcgac 1140 <br>atcgccgtgg agtgggagag caat gggcag ccggagaaca actacaagac cacacctccc 1200 <br>30 <br>atgctggact ccgacggctc ct t cttcctc tacagcaagc tcaccgtgga caagagcagg 1260 <br>tggcagcagg ggaacgtctt ctcat gctcc g t gatgcatg aggctctgca caaccactac 1320 <br>acgcagaaga gcctctccct gtct ccgggt a aa 1353 <br>35 <br><210> 72 <br><211>451 <br><212> PRT <br><213> Artificial Sequence <br>40 <br><220> <br><223> Humanized antibody sequence <br><220> <br>45 <br><221> MISC FEATURE <br>-<br><223> Ab-15 heavy chain <br><400> 72 <br>50 <br>55 <br>75 EP 2 569 010 8 1 <br>Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala <br>l 5 10 15 <br>5 <br>Ser Val Lys Val Ser Cys Lys Al a Ser Asp Phe Asn Ile Lys Asp Phe <br>20 25 30 <br>10 <br>Tyr Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>76 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>35 40 45 <br>Gly Arg Ile Asp Pro Glu Asn Gl y Asp Thr Leu Tyr Asp Pro Lys Phe <br>50 55 60 <br>Gln Asp Lys Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr <br>65 70 75 80 <br>Met Gl u Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Va l Tyr Tyr Cys <br>85 90 95 <br>Ala Arg Glu Ala Asp Tyr Phe His Asp Gly Thr Ser Tyr Trp Tyr Phe <br>100 105 110 <br>Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr <br>115 120 125 <br>Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser <br>130 135 140 <br>Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu <br>145 150 155 160 <br>Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His <br>165 170 175 <br>Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser <br>180 185 190 <br>Val Va l Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys <br>195 200 205 <br>Asn Va l Asp His Lys Pro Ser Asn Thr Lys Va l Asp Lys Thr Val Gl u <br>210 215 220 <br>Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala <br>225 230 235 240 <br>Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met <br>245 250 255 <br>Ile Ser Arg Thr Pro Gl u Val Thr Cys Val Val Val Asp Val Ser His <br>260 265 270 <br>Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gl y Val Glu Va l <br>77 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>EP 2 569 010 B1 <br>275 280 285 <br>His Asn Al a Lys Thr Lys Pro Arg Glu Glu Gl n Phe Asn Ser Thr Phe <br>290 295 300 <br>Arg Val Val Ser Va l Leu Thr Val Val His Gl n Asp Trp Leu Asn Gly <br>305 310 315 320 <br>Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gl y Leu Pro Ala Pro Ile <br>32 5 330 335 <br>Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val <br>340 345 350 <br>Tyr Thr Leu Pro Pro Ser Arg Gl u Glu Met Thr Lys Asn Gln Va l Ser <br>355 360 365 <br>Leu Thr Cys Leu Val Lys Gl y Phe Tyr Pro Ser Asp I l e Ala Va l Glu <br>370 375 380 <br>Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro <br>385 390 395 400 <br>Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val <br>405 410 415 <br>Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met <br>420 425 430 <br>His Glu Al a Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser <br>435 440 445 <br>Pro Gly Lys <br>450 <br><210> 73 <br><211> 11 <br>50 <212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-4 and Ab-5 LCDR1 <br>55 <br><400> 73 <br>78 EP 2 569 010 81 <br>Ar g Ala Ser Gl n Asp Il e Ser As n I yr Leu Asn <br>l 5 10 <br>5 <210> 74 <br><211> 7 <br><212> PRT <br><213> Artificial Sequence <br>10 <220> <br><223> Ab-4 and Ab-5 LCDR2 <br><400> 74 <br>15 <br><210> 75 <br>20 <211>9 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>25 <223> Ab-4 and Ab-5 LCDR3 <br>30 <br><400> 75 <br><210> 76 <br><211>5 <br>35 <212> PRT <br>40 <br>45 <br><213> Artificial Sequence <br><220> <br><223> Ab-4 and Ab-5 HCD R 1 <br><400> 76 <br><210> 77 <br><211> 17 <br><212> PRT <br>50 <213> Artificial Sequence <br><220> <br><223> Ab-4 and Ab-5 HCDR2 <br>55 <400> 77 <br>I y r Ihr Ser Arg Leu Leu Ser <br>l 5 <br>Gln Gln Gly Asp Ihr Leu Pr o Tyr Ihr <br>l 5 <br>Asp Iyr Asn Met Hi s <br>l 5 <br>79 5 <br>EP 2 569 010 81 <br>Glu Ile Asn Pro Asn Ser Gly Gly Ala Gl y Tyr Asn Gln Lys Phe Lys <br>l 5 10 15 <br>Gly <br><210> 78 <br><211>14 <br>10 <212> PRT <br><213> Artificial Sequence <br><220> <br><223> HCDR3 <br>15 <br><400> 78 <br>Leu Gly Tyr Asp Asp Ile Tyr Asp Asp Trp Tyr Phe Asp Val <br>20 <br>l 5 10 <br><210> 79 <br><211> 645 <br><212> DNA <br>25 <213> Mus musculus <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br><220> <br><221 > misc_feature <br><223> Ab-4 light chain <br><400> 79 <br>gatatccaga tgacacagat <br>atcagt tgca gggcaagtca <br>gatggaactt t t aaactcct <br>aggttcagtg gcagtgggtc <br>gaagattttg ccact tactt <br>gggaccaagc tggaaataaa <br>tccagtgagc agttaacatc <br>cccaaagaca tcaat gtcaa <br>aacagttgga ctgat cagga <br>ttgaccaagg acgagtatga <br>tcaacttcac ccattgtcaa <br><210> 80 <br><211>214 <br><212> PRT <br>tacatcctcc ctgtctgcct ctctgggaga <br>agacattagc aattatttaa actggtatca <br>tat cttctac acatcaagat tactctcagg <br>tggaacagat tattctctca ccatttacaa <br>ttgccaacag ggagatacgc ttccgtacac <br>acgggctgat gctgcaccaa ctgtatccat <br>tggaggtgcc tcagtcgtgt gcttcttgaa <br>gtggaagatt gatggcagtg aacgacaaaa <br>cagea a ag ac agcacctaca gcatgagcag <br>acgacataac agct atacct gtgaggccac <br>gagcttcaac aggaatgagt gttag <br>80 <br>cagggtctcc <br>gcagaaacca <br>agtcccatca <br>cctggagcaa <br>t ttcggaggg <br>cttcccacca <br>caacttctac <br>tggcgtcctg <br>caccctcacg <br>tcacaagaca <br>60 <br>120 <br>180 <br>240 <br>300 <br>360 <br>420 <br>480 <br>540 <br>600 <br>645 EP 2 569 010 81 <br><213> Mus musculus <br><220> <br><221> MISC_FEATURE <br>5 <223> Ab-4 light chain <br><400> 80 <br>10 Asp Ile Gln Met Thr Gln Ile Thr Ser Ser Leu Ser Ala Ser Leu Gl y <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>81 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>l 5 lO 15 <br>Asp Arg Val Ser Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr <br>20 25 30 <br>Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Phe Lys Leu Leu Ile <br>35 40 45 <br>Phe Tyr Thr Ser Arg Leu Leu Ser Gly Va l Pro Ser Arg Phe Ser Gly <br>50 55 60 <br>Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Tyr Asn Leu Glu Gln <br>65 70 75 80 <br>Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Asp Thr Leu Pro Tyr <br>85 90 95 <br>Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala <br>100 105 110 <br>Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly <br>115 120 125 <br>Gly Ala Ser Val Va l Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile <br>130 135 140 <br>Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Va l Leu <br>145 150 155 160 <br>Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser <br>165 170 175 <br>Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr <br>180 185 190 <br>Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser <br>195 200 205 <br>Phe Asn Arg Asn Glu Cys <br>210 <br><21 0> 81 <br><211> 1344 <br><212> DNA <br>82 EP 2 569 010 B1 <br><213> Mus musculus <br><220> <br><221> misc_feature <br>5 <br><223> Ab-4 heavy chain <br><400> 81 <br>gaggtccaac tgcaacagtc tggacctgaa ctaatgaagc ctggggcttc agtgaagatg 60 <br>10 <br>tcctgcaagg cttct ggata tacat tcact gactacaaca t gcactgggt gaagcagaac 120 <br>caaggaaaga ccctagagtg gataggagaa attaatccta acagtggtgg tgctggctac 180 <br>15 <br>aaccagaagt tcaagggcaa ggccacattg actgtagaca agt cctccac cacagcctac 240 <br>atggagctcc gcagcctgac atctgaggac tctgcagtct attactgtgc aagattgggc 300 <br>tacgatgata tctacgacga ctggtacttc gatgtctggg gcgcagggac cacggtcacc 360 <br>20 <br>gtctcctcag ccaaaacgac acccccatct gtctatccac tggcccctgg atctgctgcc 420 <br>caaactaact ccatggtgac cctgggatgc ctggtcaagg gctatttccc tgagccagtg 480 <br>25 <br>acagtgacct ggaactctgg atccctgtcc agcggtgtgc acaccttccc agct gtcctg 540 <br>cagtctgacc tcta cactct gagcagctca gtgactgtcc cct ccagcac ctggcccagc 600 <br>30 <br>gagaccgtca cctgcaacgt tgcccacccg gccagcagca ccaaggtgga caagaaaatt 660 <br>gtgcccaggg attgt ggttg taagccttgc atatgtacag tcccagaagt atcatctgtc 720 <br>ttcatcttcc ccccaaagcc caaggatgtg ctcaccatta ctctgactcc taaggtcacg 780 <br>35 <br>tgtgttgtgg tagacatcag caaggatgat cccgaggtcc agttcagctg gtt tgtagat 840 <br>gatgtggagg tgca cacagc tcagacgcaa ccccgggagg agcagttcaa cagcactttc 900 <br>40 <br>cgctcagtca gtgaacttcc catcatgcac caggactggc tcaatggcaa ggagttcaaa 960 <br>tgcagggtca acagtgcagc tttccctgcc cccatcgaga aaaccatctc caaaaccaaa 1020 <br>ggcagaccga aggctccaca ggtgtacacc attccacctc ccaaggagca gatggccaag 1080 <br>45 <br>gataaagtca gtctgacctg cat gataaca gacttcttcc c t gaagacat tactgtggag 1140 <br>tggcagtgga atgggcagcc agcggagaac tacaagaaca ctcagcccat catggacaca 1200 <br>50 gatggctctt acttcatcta cagcaagctc aatgtgcaga agagcaactg ggaggcagga 1260 <br>aatact ttca cctgctctgt gttacatgag ggcctgcaca accaccatac tgagaagagc 1320 <br>ctctcccact ctcctggtaa at ga 1344 <br>55 <br><210> 82 <br><211> 447 <br><212> PRT <br>83 EP 2 569 010 81 <br><213> Mus musculus <br><220> <br><221> MISC_FEATURE <br>5 <223> Ab-4 heavy chain <br><400> 82 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>84 > <br>5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Met Lys Pro Gly Ala <br>l 5 10 15 <br>Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr <br>20 25 30 <br>Asn Met His Trp Val Lys Gln Asn Gln Gly Lys Thr Leu Glu Trp Ile <br>35 40 45 <br>Gly Glu Ile Asn Pro Asn Ser Gly Gly Ala Gly Tyr Asn Gln Lys Phe <br>50 55 60 <br>Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr <br>65 70 75 80 <br>Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys <br>85 90 95 <br>Ala Arg Leu Gly Tyr Asp Asp Ile Tyr Asp Asp Trp Tyr Phe Asp Val <br>100 105 110 <br>Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Pro <br>115 120 125 <br>Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser <br>130 135 140 <br>Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val <br>145 150 155 160 <br>Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe <br>165 170 175 <br>Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr <br>180 185 190 <br>Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala <br>195 200 205 <br>His Pro Ala Ser Ser Thr Lys Va l Asp Lys Lys Ile Val Pro Arg Asp <br>210 215 220 <br>Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val <br>85 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>225 230 235 240 <br>Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr <br>245 250 255 <br>Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu <br>260 265 270 <br>Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln <br>275 280 285 <br>Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser <br>290 29 5 300 <br>Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu .Phe Lys <br>305 310 315 320 <br>Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile <br>325 330 335 <br>Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro <br>340 345 350 <br>Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met <br>355 360 365 <br>Ile Thr Asp Phe Phe Pro Glu Asp Il e Thr Val Glu Trp Gln Trp Asn <br>370 375 380 <br>Gly Gln Pro Ala Gl u Asn Tyr Lys Asn Thr Gln Pro I l e Met Asp Thr <br>385 390 395 400 <br>Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn <br>405 410 415 <br>Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu <br>420 425 430 <br>His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys <br><2 10> 83 <br><2 11 >321 <br><212> DNA <br>435 440 445 <br>86 EP 2 569 010 81 <br><213> Mus musculus <br><220> <br><221 > mise_ feature <br>5 <223> Ab-5 light variable <br><400> 83 <br>10 <br>gacatccaga tgacccagtc tccatcctcc ctctccgcat <br>ataacatgta gagc atctca agat atttcc aactatttga <br>ggcaaagcac ctaaactcct catt tactat acatcaagac <br>15 <br>cgattctcag gctccggctc cggcacagat t t cacactca <br>gaagattttg caacctatta ctgt caacaa ggcgatacac <br>20 <br>ggcacaaaag ttgaaattaa a <br><210> 84 <br><211> 107 <br><212> PRT <br>25 <213> Mus musculus <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br><220> <br><221> MISC_FEATURE <br><223> Ab-5 light variable <br><400> 84 <br>87 <br>ccgtaggcga ccgcgtaacc 60 <br>attggtacca acaaaaaccc 120 <br>tcctctccgg cgttccatca 180 <br>ctatt t cctc cct ccaacca 240 <br>tcccatacac attcggcggc 300 <br>321 EP 2 569 010 B1 <br>Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly <br>l 5 10 15 <br>5 <br>Asp Arg Va l Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr <br>20 25 30 <br>10 <br>Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile <br>35 40 45 <br>Tyr Tyr Thr Ser Arg Leu Leu Ser Gly Val Pro Ser Arg Phe Ser Gly <br>15 <br>50 55 60 <br>Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro <br>65 70 75 80 <br>20 <br>Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asp Thr Leu Pro Tyr <br>85 90 95 <br>25 <br>Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys <br>100 105 <br><210> 85 <br>30 <211> 369 <br><212> DNA <br><213> Mus musculus <br><220> <br>35 <221 > mise_ feature <br><223> Ab-5 heavy variable <br><400> 85 <br>40 <br>gaggtgcagc tggtgcagag cggcgccgag gtaaaaaaac caggagcaag cgttaaagtt <br>tcttgtaaag caagcggata tacatttaca gattacaaca tgcattgggt aagacaagcg <br>45 <br>ccaggacaag gattggaatg gatgggcgaa attaacccta atagtggagg agcaggctac <br>aatcaaaaat tcaaagggag agttacaatg acaacagaca caagcacttc aacagcatat <br>atggaactgc gatcacttag aagcgacgat acagctgtat actattgcgc acgacttggg <br>50 <br>tatgatgata tatatgatga ctggtatttc gatgtttggg gccagggaac aacagttacc <br>gtctctagt <br>55 <br><210> 86 <br><211> 123 <br><212> PRT <br><213> Mus musculus <br>88 <br>60 <br>120 <br>180 <br>240 <br>300 <br>360 <br>369 <220> <br><221> MISC FEATURE <br><223> Ab-5 heavy variable <br>EP 2 569 010 81 <br>5 <400> 86 <br>Glu Val Gln Leu Va l Gln Ser Gl y Ala Gl u Va l Lys Lys Pro Gl y Al a <br>l 5 10 15 <br>10 <br>Ser Val Lys Val Ser Cys Lys Al a Ser Gl y Tyr Thr Phe Thr Asp Tyr <br>20 25 30 <br>15 <br>As n Met His Trp Val Arg Gln Al a Pr o Gl y Gl n Gly Leu Glu Trp Met <br>35 40 45 <br>20 <br>Gly Glu Il e Asn Pro Asn Ser Gl y Gly Ala Gly Tyr Asn Gln Lys Phe <br>50 55 60 <br>Lys Gly Ar g Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr <br>25 <br>65 70 75 80 <br>Met Glu Le u Ar g Ser Le u Ar g Ser Asp Asp Thr Ala Va l Tyr Tyr Cys <br>85 90 95 <br>30 <br>Ala Arg Le u Gl y Tyr Asp Asp I l e Tyr Asp Asp Trp Tyr Ph e Asp Val <br>100 105 110 <br>35 <br>100 105 110 <br>40 <br>Trp Gl y Gln Gly Thr Thr Va l Thr Val Ser Ser <br>115 120 <br><210> 87 <br>45 <211> 642 <br><212> DNA <br><213> Artificial Sequence <br><220> <br>50 <223> Humanized antibody <br>55 <br><220> <br><221 > misc_feature <br><223> Ab-5 light chain <br><400> 87 <br>89 EP 2 569 010 B1 <br>gacatccaga tgacccagtc tccatcctcc ctctccgcat ccgtaggcga ccgcgtaacc 60 <br>ataacatgta gagcatctca agatatttcc aactatttga attggtacca acaaaaaccc 120 <br>5 <br>ggcaaagcac ctaaactcct catttactat acatcaagac tcctctccgg cgttccatca 180 <br>cgattctcag gctccggctc cggcacagat ttcacactca ctatttcctc cctccaacca 240 <br>10 <br>gaagattttg caacctatta ctgtcaacaa ggcgatacac tcccatacac attcggcggc 300 <br>ggcacaaaag ttgaaattaa acgtacggtg gctgcaccat ctgtcttcat cttcccgcca 360 <br>tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 420 <br>15 <br>cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 480 <br>gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 540 <br>20 <br>ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc 600 <br>ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt g t 642 <br><210> 88 <br>25 <br><211> 214 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>30 <br><223> Humanized anti body <br><220> <br><221> MISC FEATURE <br>-<br><223> Ab-5 light chain <br>35 <br><400> 88 <br>Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly <br>40 <br>45 <br>50 <br>55 <br>90 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>l 5 lO 15 <br>Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr <br>20 25 30 <br>Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile <br>35 40 45 <br>Tyr Tyr Thr Ser Arg Leu Leu Ser Gly Va l Pro Ser Arg Phe Ser Gly <br>50 55 60 <br>Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro <br>65 70 75 80 <br>Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asp Thr Leu Pro Tyr <br>85 90 95 <br>Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala <br>100 105 110 <br>Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly <br>115 120 125 <br>Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala <br>130 135 140 <br>Lys Val Gl n Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln <br>145 150 155 160 <br>Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser <br>165 170 175 <br>Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr <br>180 185 190 <br>Ala Cys Glu Val Thr Hi s Gln Gly Leu Ser Ser Pro Val Thr Lys Ser <br>195 200 205 <br>Phe Asn Arg Gly Glu Cys <br>210 <br><210> 89 <br><211> 1347 <br><212> DNA <br>91 .. <br>EP 2 569 010 B1 <br><213> Artificial Sequence <br><220> <br><223> Humanized antibody <br>5 <br><220> <br><221 > misc_feature <br><223> Ab-5 heavy chain <br>10 <br><400> 89 <br>gaggtgcagc tggtgcagag cggcgccgag gtaaaaaaac caggagcaag cgttaaagtt 60 <br>tcttgtaaag caagcggata tacatttaca gattacaaca tgcattgggt aagacaagcg 120 <br>15 <br>ccaggacaag gattggaatg gatgggcgaa attaacccta atagtggagg agcaggctac 180 <br>aatcaaaaat tcaaagggag agttacaatg acaacagaca caagcacttc aacagcatat 240 <br>20 <br>atggaactgc gatcacttag aagcgacgat acagctgtat actattgcgc acgacttggg 300 <br>tatgatgata tatatgatga ctggtatttc gatgtttggg gccagggaac aacagttacc 360 <br>gtctctagtg cctccaccaa gggcccatcg gtcttccccc tggcgccctg ctccaggagc 420 <br>25 <br>acctccgaga gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg 480 <br>acggtgtcgt ggaactcagg cgctctgacc agcggcgtgc acaccttccc agctgtccta 540 <br>30 <br>cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag caacttcggc 600 <br>acccagacct acacctgcaa cgtagatcac aagcccagca acaccaaggt ggacaagaca 660 <br>35 <br>gttgagcgca aatgttgtgt cgagtgccca ccgtgcccag caccacctgt ggcaggaccg 720 <br>tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag 780 <br>gtcacgtgcg tggtggtgga cgtgagccac gaagaccccg aggtccagtt caactggtac 840 <br>40 <br>gtggacggcg tggaggtgca taatgccaag acaaagccac gggaggagca gttcaacagc 900 <br>acgttccgtg tggtcagcgt cctcaccgtt gtgcaccagg actggctgaa cggcaaggag 960 <br>45 <br>tacaagtgca aggtctccaa caaaggcctc ccagccccca tcgagaaaac catctccaaa 1020 <br>accaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggaggagatg 1080 <br>accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctaccccag cgacatcgcc 1140 <br>50 <br>gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacacc tcccatgctg 1200 <br>gactccgacg gctccttctt cctctacagc aagctcaccg tggacaagag caggtggcag 1260 <br>55 caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag 1320 <br>aagagcctct ccctgtctcc gggtaaa 1347 <br>92 5 <br><210> 90 <br><211> 449 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Humanized antibody <br><220> <br>10 <221> MISC_FEATURE <br><223> Ab-5 heavy chain <br><400> 90 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>93 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala <br>l 5 10 15 <br>Ser Val Lys Val Ser Cys Lys Al a Ser Gly Tyr Thr Phe Thr Asp Tyr <br>20 25 30 <br>Asn Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met <br>35 40 45 <br>Gly Glu Ile Asn Pro Asn Ser Gly Gly Ala Gly Tyr Asn Gln Lys Phe <br>50 55 60 <br>Lys Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr <br>65 70 75 80 <br>Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys <br>85 90 95 <br>Ala Arg Leu Gly Tyr Asp Asp Ile Tyr Asp Asp Trp Tyr Phe Asp Va l <br>100 105 110 <br>Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly <br>115 120 125 <br>Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser <br>130 135 140 <br>Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val <br>145 150 155 160 <br>Thr Val Ser Trp Asn Ser Gly Ala Le u Thr Ser Gly Val His Thr Phe <br>165 170 175 <br>Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val <br>180 185 190 <br>Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cy s Asn Val <br>195 200 205 <br>Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys <br>94 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>210 215 220 <br>Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro <br>225 230 235 240 <br>Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser <br>245 250 255 <br>Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp <br>260 265 270 <br>Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn <br>275 280 285 <br>Ala Lys Thr Lys Pro Arg Glu Gl u Gln Phe Asn Ser Thr Phe Arg Va l <br>290 295 300 <br>Val Ser Va l Leu Thr Val Val Hi s Gln Asp Trp Leu Asn Gly Lys Glu <br>305 310 315 320 <br>Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys <br>325 330 335 <br>Thr Ile Ser Lys Thr Lys Gly Gl n Pro Arg Glu Pro Gln Val Tyr Thr <br>340 345 350 <br>Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr <br>355 360 365 <br>Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Gl u <br>370 375 380 <br>Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu <br>385 390 395 400 <br>Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys <br>405 410 415 <br>Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu <br>420 425 430 <br>Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly <br>435 440 445 <br>Lys <br>95 5 <br>10 <br><210> 91 <br><211> 11 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-6 LCDR1 <br><400> 91 <br>EP 2 569 010 81 <br>Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn <br>l 5 10 <br>15 <210> 92 <br><211> 7 <br><212> PRT <br><213> Artificial Sequence <br>20 <220> <br><223> Ab-6 LCDR2 <br><400> 92 <br>25 <br><21 0> 93 <br>30 <211> 9 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>35 <223> Ab-6 LCDR3 <br>40 <br><400> 93 <br><210> 94 <br><211>5 <br>45 <212> PRT <br>50 <br>55 <br><213> Artificial Sequence <br><220> <br><223> Ab-6 HCDR1 <br><400> 94 <br><210> 95 <br><211>17 <br>Tyr Thr Ser Arg Leu His Ser <br>l 5 <br>Gln Gln Gly Asp Thr Leu Pro Tyr Thr <br>l 5 <br>Asp Tyr Asn Met His <br>l 5 <br>96 EP 2 569 010 81 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>5 <223> Ab-6 HCDR2 <br><400> 95 <br>10 <br>Glu Ile Asn Pro Asn Ser Gly Gl y Ser Gly Tyr Asn Gln Lys Phe Lys <br>l 5 10 15 <br>15 <br>20 <br>25 <br>Gly <br><210> 96 <br><211>14 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-6 HCDR3 <br><400> 96 <br>Leu Va l Tyr Asp Gl y Ser Tyr Glu Asp Trp Tyr Phe Asp Val <br>l 5 10 <br>30 <210> 97 <br><211> 645 <br><212> DNA <br><213> Mus musculus <br>35 <220> <br>40 <br>45 <br>50 <br>55 <br><221 > misc_feature <br><223> Ab-6 light chain <br><400> 97 <br>97 EP 2 569 010 81 <br>gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga <br>atcagttgca gggcaagtca ggacattagc aattatttaa actggtttca <br>5 <br>gatggaactc ttaaactcct gatcttctac acatcaagat tacactcagg <br>aggttcagtg gcagtgggtc tggaacagat tattctctca ccattagcaa <br>10 <br>gaagatattg ccacttactt ttgccaacag ggtgatacgc t t ccgtacac <br>gggaccaagc tggaaataag acgggctgat gctgcaccaa ctgtatccat <br>tccagt gagc agttaacatc tggaggtgcc tcagtcgtgt gct tcttgaa <br>15 <br>cccaaagaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa <br>aacagttgga ctgatcagga cagcaaagac agcacctaca gcatgagcag <br>20 <br>ttgaccaagg acgagtatga acgacataac agctatacct gtgaggccac <br>tcaacttcac ccattgtcaa gagct tcaac aggaatgagt gttag <br>25 <br>30 <br><210> 98 <br><211>214 <br><212> PRT <br><213> Mus musculus <br><220> <br><221 > MISC_FEATURE <br><223> Ab-6 light chain <br>35 <400> 98 <br>40 <br>45 <br>50 <br>55 <br>98 <br>... <br>cagagtcacc 60 <br>gcagaaacca 120 <br>agttccatca 180 <br>cctggagcaa 240 <br>gttcgggggg 300 <br>c t tcccacca 360 <br>caacttctac 420 <br>t ggcgtcct g 480 <br>c accctcacg 540 <br>tcacaagaca 600 <br>645 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly <br>l 5 10 15 <br>Asp Arg Val Thr Ile Ser Cys Arg Al a Ser Gln Asp Il e Ser As n Tyr <br>20 25 30 <br>Leu Asn Trp Phe Gln Gln Lys Pr o Asp Gly Thr Leu Lys Leu Leu Ile <br>35 40 45 <br>Phe Tyr Thr Ser Arg Leu His Ser Gl y Va l Pro Ser Arg Phe Ser Gly <br>50 55 60 <br>Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln <br>65 70 75 80 <br>Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asp Thr Leu Pro Tyr <br>85 90 95 <br>Thr Phe Gly Gl y Gly Thr Lys Leu Glu Ile Arg Arg Ala Asp Ala Ala <br>100 105 110 <br>Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Le u Thr Ser Gly <br>115 120 125 <br>Gly Ala Ser Val Va l Cys Phe Leu Asn Asn Phe Tyr Pr o Lys Asp Ile <br>130 135 140 <br>Asn Val Lys Trp Lys Il e Asp Gly Ser Glu Arg Gln Asn Gly Va l Leu <br>145 150 155 160 <br>Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser <br>165 170 175 <br>Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr <br>180 185 190 <br>Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser <br>195 200 205 <br>Phe Asn Arg Asn Glu Cys <br>210 <br>99 EP 2 569 010 81 <br><210> 99 <br><211> 1344 <br><212> DNA <br><213> Mus musculus <br>5 <br><220> <br><221> misc_feature <br><223> Ab-6 heavy chain <br>10 <br><400> 99 <br>gaggtccagc tgcaacagtc tggacctgaa ctaatgaagc ctggggcttc agtgaagatg 60 <br>15 <br>tcctgcaagg cttctggata cacattcact gactacaaca tgcactgggt gaaacagaac 120 <br>caaggaaaga gcctagagtg gataggagaa attaatccta acagtggtgg tagtggctac 180 <br>aaccaaaagt tcaaaggcaa ggccacattg actgtagaca agtcttccag cacagcctac 240 <br>20 <br>atggagctcc gcagcctgac atctgaggac tctgcagtct att actgtgc aagattggtc 300 <br>tacgatggca gctacgagga ctggtacttc gatgtctggg gcgcagggac cacggtcacc 360 <br>25 <br>gtctcctcag ccaaaacgac acccccatct gtctatccac tggcccctgg atctgctgcc 420 <br>caaactaact ccatggtgac cct gggatgc ctggtcaagg g ctatttccc tgagccagtg 480 <br>acagtgacct ggaactctgg at ccctgtcc agcggtgtgc acaccttccc agctgtcctg 540 <br>30 <br>cagtctgacc tctacactct gagcagctca gtgactgtcc cctccagcac ctggcccagc 600 <br>gagaccgtca cctgcaacgt tgcccacccg gccagcagca ccaaggtgga caagaaaatt 660 <br>35 <br>gtgcccaggg attgtggttg taagccttgc atatgtacag tcccagaagt atcatctgtc 720 <br>ttcat cttcc ccccaaagcc caaggatgtg ctcaccatta ctctgactcc t aaggtcacg 780 <br>tgtgttgtgg tagacatcag caaggatgat cccgaggtcc agttcagctg g t ttgtagat 840 <br>40 <br>gatgtggagg tgcacacagc tcagacgcaa ccccgggagg agcagttcaa cagcactttc 900 <br>cgctcagtca gtgaacttcc catcatgcac caggactggc tcaatggcaa ggagttcaaa 960 <br>45 tgcagggtca acagtgcagc tttccctgcc cccatcgaga aaaccatctc caaaaccaaa 1020 <br>ggcagaccga aggctccaca ggt gtacacc at t ccacctc ccaaggagca gatggccaag 1080 <br>gataaagtca gtctgacctg catgataaca gacttcttcc ctgaagacat tactgtggag 1140 <br>50 <br>tggcagtgga atgggcagcc agcggagaac tacaagaaca ctcagcccat catggacaca 1200 <br>gatggctctt acttcatcta cagcaagctc aatgtgcaga agagcaactg ggaggcagga 1260 <br>55 <br>aatactttca cctgctctgt gttacatgag ggcctgcaca accaccatac tgagaagagc 1320 <br>ctctcccact ctcct ggtaa atga 1344 <br>100 5 <br><210> 100 <br><211> 447 <br><212> PRT <br><213> Mus musculus <br><220> <br><221> MISC_FEATURE <br><223> Ab-6 heavy chain <br>EP 2 569 010 B1 <br>10 <400> 100 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>Glu Val Gln Leu Gln Gln Ser Gl y Pro Gl u Leu Met Lys Pro Gly Ala <br>l 5 10 15 <br>Ser Val Lys Met Ser Cys Lys Al a Ser Gly Tyr Thr Phe Thr Asp Tyr <br>20 25 30 <br>Asn Met His Trp Va l Lys Gln Asn Gln Gly Lys Ser Leu Glu Trp Ile <br>35 40 45 <br>Gly Glu Ile Asn Pro Asn Ser Gly Gly Ser Gly Tyr Asn Gln Lys Phe <br>50 55 60 <br>Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr <br>65 70 75 80 <br>Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys <br>85 90 95 <br>Al a Arg Leu Val Tyr Asp Gly Ser Tyr Gl u Asp Trp Tyr Phe Asp Va l <br>100 105 110 <br>Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Pro <br>115 120 125 <br>Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser <br>130 135 140 <br>Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Va l <br>145 150 155 160 <br>Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe <br>101 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>165 170 175 <br>Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr <br>180 185 190 <br>Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala <br>195 200 205 <br>His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp <br>210 215 220 <br>Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val <br>225 230 235 240 <br>Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr <br>245 250 255 <br>Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu <br>260 265 270 <br>Val Gln Phe Ser Trp Phe Val Asp Asp Val Gl u Val His Thr Ala Gl n <br>275 280 285 <br>Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser <br>290 295 300 <br>Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys <br>305 310 315 320 <br>Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile <br>325 330 335 <br>Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro <br>340 345 350 <br>Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met <br>355 360 365 <br>Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn <br>370 375 380 <br>Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr <br>385 390 395 400 <br>Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn <br>102 EP 2 569 010 B1 <br>405 410 415 <br>5 <br>Trp Glu Al a Gly Asn Thr Phe Th r Cys Ser Val Leu His Glu Gly Leu <br>420 425 430 <br>His Asn His His Thr Gl u Lys Ser Leu Ser Hi s Ser Pro Gly Lys <br>10 <br>435 440 445 <br><210> 101 <br><211> 11 <br><212> PRT <br>15 <213> Artificial Sequence <br><220> <br><223> Ab-7 LCDR1 <br>20 <400> 101 <br>Arg Ala Ser Gln Val I le Thr Asn Tyr Leu Tyr <br>l 5 10 <br>25 <br>30 <br>35 <br><210> 102 <br><211> 7 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-7 LCDR2 <br><400> 102 <br>40 <210> 103 <br><211> 9 <br><212> PRT <br><213> Artificial Sequence <br>45 <220> <br><223> Ab-7 LCDR3 <br><400> 103 <br>50 <br><210> 104 <br>55 <211>5 <br><212> PRT <br><213> Artificial Sequence <br>Tyr Thr Ser Arg Leu Hi s Ser <br>l 5 <br>Gln Gl n Gly Asp Thr Leu Pro Tyr Thr <br>l 5 <br>103 <220> <br><223> Ab-7 HCDR1 <br><400> 104 <br>5 <br>10 <210> 105 <br><211>17 <br><212> PRT <br><213> Artificial Sequence <br>15 <220> <br><223> Ab-7 HCDR2 <br><400> 105 <br>20 <br>EP 2 569 010 B1 <br>Asp Tyr Asn Met His <br>l 5 <br>Glu Ile Asn Pro Asn Ser Gly Gl y Ala Gly Tyr Asn Gln Gln Ph e Lys <br>l 5 10 15 <br>25 <br>Gl y <br><210> 106 <br><211>14 <br><212> PRT <br>30 <213> Artificial Sequence <br><220> <br><223> Ab-7 HCDR3 <br>35 <400> 106 <br>Leu Gl y Tyr Val Gl y Asn Tyr Glu Asp Trp Tyr Phe Asp Val <br>l 5 1 0 <br>40 <br>45 <br><210> 107 <br><211> 642 <br><212> DNA <br><213> Mus musculus <br><220> <br><221 > misc_feature <br><223> Ab-7 light chain <br>50 <400> 107 <br>55 <br>104 EP 2 569 010 B1 <br>gatat ccaga tgacacagac tacat cctcc ctgtctgcct ctctgggaga cagagtcacc 60 <br>atctgttgca gggcaagtca ggtcattacc aattatttat actggtatca gcagaaacca 120 <br>5 <br>gatggaactt ttaaactcct gatctactac acatcaagat t acactcagg agtcccatca 180 <br>aggttcagtg gcagtgggtc tggaacagat t attctctca ccattagcaa cctggaacag 240 <br>10 <br>gaagatattg ccactt actt t t gccaacag ggtgatacgc ttccgtacac gttcggaggg 300 <br>gggaccaagc tggaaataaa acgggctgat gctgcaccaa ctgtatccat cttcccacca 360 <br>15 <br>tccagtgagc agttaacatc tggaggtgcc tcagtcgtgt gcttcttgaa caacttctac 420 <br>cccaaagaca tcaatgtcaa gtggaagatt gat ggcagtg aacgacaaaa tggcgtcctg 480 <br>aacagttgga ctgatcagga cagcaaagac agcacctaca gcatgagcag caccctcacg 540 <br>20 <br>ttgaccaagg acgagtatga acgacataac agctatacct gtgaggccac tcacaagaca 600 <br>tcaacttcac ccattgtcaa gagcttcaac aggaatgagt g t 642 <br>25 <br><210> 108 <br><211>21 4 <br><212> PRT <br><213> Mus musculus <br>30 <br><220> <br><221> MISC FEATURE <br>-<br><223> Ab-7 light chain <br><400> 108 <br>35 <br>40 <br>45 <br>50 <br>55 <br>105 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly <br>l 5 10 15 <br>Asp Arg Val Thr Ile Cys Cys Arg Ala Ser Gln Val Ile Thr Asn Tyr <br>20 25 30 <br>Leu Tyr Trp Tyr Gln Gln Lys Pro Asp Gly Thr Phe Lys Leu Leu Ile <br>35 40 45 <br>Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly <br>50 55 60 <br>Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln <br>65 70 75 80 <br>Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asp Thr Leu Pro Tyr <br>85 90 95 <br>Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala <br>100 105 110 <br>Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly <br>115 120 125 <br>Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile <br>130 135 140 <br>Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu <br>145 150 155 160 <br>Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser <br>165 170 175 <br>Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr <br>180 185 190 <br>Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser <br>195 200 205 <br>Phe Asn Arg Asn Glu Cys <br>210 <br>106 EP 2 569 010 81 <br><210> 109 <br><211> 1341 <br><212> DNA <br><213> Mus musculus <br>5 <br><220> <br><221 > mise_ feature <br><223> Ab-7 heavy chain <br>10 <br><400> 109 <br>gaggtccagc tgcaacagtc tggacctgaa ctaatgaagc ctggggcttc agtgaagatg 60 <br>tcctgcaagg cttct ggata cacattcact gactacaaca tgcactggat gaagcagaac 120 <br>15 <br>caaggaaaga gcctagaatg gataggagaa attaatccta acagtggtgg tgctggctac 180 <br>aaccagcagt tcaaaggcaa ggccacattg actgtagaca agtcctccag gacagcctac 240 <br>20 <br>atggagctcc gcagcctgac atctgaggac tctgcagtct attactgtgc aagattgggc 300 <br>tacgttggta attacgagga ctggtacttc gatgtctggg gcgcagggac cacggtcacc 360 <br>25 <br>gtctcctcag ccaaaacgac acccccatct gtctatccac tggcccctgg atctgctgcc 420 <br>caaact aact ccatggtgac cctgggatgc ctggtcaagg gctatttccc tgagccagtg 48 0 <br>acagtgacct ggaactctgg atccctgtcc agcggtgtgc acaccttccc agctgtcctg 540 <br>30 <br>cagtctgacc tctacactct gagcagctca gtgactgtcc cctccagcac ctggcccagc 600 <br>gagaccgtca cctgcaacgt tgcccacccg gccagcagca ccaaggtgga caagaaaatt 660 <br>35 <br>gtgcccaggg attgtggttg taagccttgc atatgtacag tcccagaagt atcatctgtc 720 <br>ttcatcttcc ccccaaagcc caaggatgtg ctcaccatta ctctgactcc taaggtcacg 780 <br>tgtgttgtgg tagacatcag caaggatgat cccgaggtcc agttcagctg gtttgtagat 840 <br>40 <br>gatgtggagg tgcacacagc tcagacgcaa ccccgggagg agcagttcaa cagcactttc 900 <br>cgctcagtca gtgaacttcc catcatgcac caggactggc tcaatggcaa ggagttcaaa 960 <br>45 <br>tgcagggtca acagtgcagc tttccctgcc cccatcgaga aaaccatctc caaaaccaaa 1020 <br>ggcagaccga aggctccaca ggtgtacacc attccacctc ccaaggagca gatggccaag 1080 <br>50 <br>gataaagtca gtctgacctg catgataaca gacttcttcc ctgaagacat tactgtggag 1140 <br>tggcagtgga atgggcagcc agcggagaac tacaagaaca ctcagcccat catggacaca 1 200 <br>gatggctctt act tea teta cagcaagctc aatgtgcaga agagcaactg ggaggcagga 1 260 <br>55 <br>aatactttca cctgctctgt gttacatgag ggcctgcaca accaccatac tgagaagagc 1320 <br>ctctcccact ctcct ggtaa a 134 1 <br>107 5 <br><210> 110 <br><211>447 <br><212> PRT <br><213> Mus musculus <br><220> <br><221> MISC_FEATURE <br><223> Ab-7 heavy chain <br>EP 2 569 010 81 <br>10 <400> 110 <br>Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Met Lys Pro Gly Ala <br>l 5 10 15 <br>15 <br>Ser Val Lys Met Ser Cys Lys Al a Ser Gl y Tyr Thr Ph e Thr Asp Tyr <br>20 25 30 <br>20 <br>Asn Met His Trp Met Lys Gln Asn Gln Gly Lys Ser Leu Glu Trp Ile <br>35 40 45 <br>25 <br>Gly Glu Ile Asn Pro Asn Ser Gly Gly Ala Gly Tyr Asn Gln Gln Phe <br>50 55 60 <br>Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Arg Thr Ala Tyr <br>30 <br>65 70 75 80 <br>Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys <br>85 90 95 <br>35 <br>Ala Arg Leu Gly Tyr Va l Gly Asn Tyr Gl u Asp Trp Tyr Phe Asp Val <br>100 105 110 <br>40 <br>Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Pro <br>115 120 125 <br>45 Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser <br>50 <br>55 <br>108 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>130 135 140 <br>Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val <br>145 150 155 160 <br>Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe <br>165 170 175 <br>Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr <br>180 185 190 <br>Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala <br>195 200 205 <br>His Pro Al a Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp <br>210 215 220 <br>Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Va l <br>225 230 235 240 <br>Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr <br>245 250 255 <br>Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu <br>260 265 270 <br>Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gl n <br>275 280 285 <br>Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser <br>290 295 300 <br>Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys <br>305 310 315 320 <br>Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile <br>325 330 335 <br>Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro <br>340 345 350 <br>Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met <br>355 360 365 <br>Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn <br>109 EP 2 569 010 B1 <br>370 375 380 <br>5 <br>Gl y Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr <br>385 390 395 400 <br>Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn <br>10 <br>405 410 415 <br>Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu <br>420 425 430 <br>15 <br>His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys <br>20 <210> 111 <br><211> 11 <br><212> PRT <br>435 440 445 <br><213> Artificial Sequence <br>25 <220> <br><223> Ab-8 LCDR1 <br><400> 111 <br>30 <br><210> 112 <br>35 <211> 7 <br><212> PRT <br>Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn <br>l 5 10 <br><213> Artificial Sequence <br><220> <br>40 <223> Ab-8 LCDR2 <br>45 <br><400> 112 <br><210> 113 <br><211> g <br>50 <212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-8 LCDR3 <br>55 <br><400> 113 <br>Tyr Thr Ser Arg Leu Leu Ser <br>l 5 <br>110 5 <210> 114 <br><211> 5 <br><212> PRT <br><213> Artificial Sequence <br>10 <220> <br><223> Ab-8 HCDR1 <br><400> 114 <br>15 <br><210> 115 <br>20 <211>17 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>25 <223> Ab-8 HCDR2 <br><400> 115 <br>EP 2 569 010 81 <br>Gln Gln Gly Asp Thr Leu Pr o Tyr Thr <br>l 5 <br>Asp Tyr Asn Met Hi s <br>l 5 <br>30 <br>Glu Ile Asn Pro Asn Ser Gly Gl y Ala Gly Tyr Asn Gl n Lys Phe Lys <br>l 5 10 15 <br>35 <br>40 <br>45 <br>Gly <br><210> 116 <br><211>14 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-8 HCDR3 <br><400> 116 <br>Leu Gl y Tyr Asp Asp Ile Tyr Asp Asp Trp Tyr Ph e Asp Va l <br>l 5 10 <br>50 <210> 117 <br><211> 645 <br><212> DNA <br><213> Mus musculus <br>55 <220> <br><221 > misc_feature <br><223> Ab-8 light chain <br>111 EP 2 569 010 81 <br><400> 117 <br>gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagggtctcc 60 <br>5 <br>atcagttgca gggcaagtca agacattagc aattatttaa actggtatca gcagaaacca 120 <br>gatggaactt ttaaactcct tatcttctac acatcaagat tactctcagg agtcccatca 180 <br>10 <br>aggttcagtg gcagtgggtc tggaacagat tattctctca ccatttacaa cctggagcaa 240 <br>gaagattttg ccacttactt ttgccaacag ggagatacgc ttccgtacac tttcggaggg 300 <br>15 <br>gggaccaaac tggaaataaa acgggctgat gctgcaccaa ctgtatccat cttcccacca 360 <br>tccagtgagc agttaacatc tggaggtgcc tcagtcgtgt gcttcttgaa caacttctac 420 <br>cccaaagaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa tggcgtcctg 480 <br>20 <br>aacagttgga ctgatcagga cagcaaagac agcacctaca gcatgagcag caccctcacg 540 <br>ttgaccaagg acgagtatga acgacataac agctatacct gtgaggccac tcacaagaca 600 <br>25 <br>tcaacttcac ccattgtcaa gagcttcaac aggaatgagt gttag 645 <br><210> 118 <br><211 > 214 <br><212> PRT <br>30 <br><213> Mus musculus <br><220> <br><221 > MISC FEATURE <br>-<br><223> Ab-8 light chain <br>35 <br><400> 118 <br>40 <br>45 <br>50 <br>55 <br>112 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>Asp Ile Gl n Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly <br>l 5 10 15 <br>Asp Arg Val Ser Ile Ser Cys Arg Ala Ser Gln Asp I l e Ser Asn Tyr <br>20 25 30 <br>Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Phe Lys Leu Leu Ile <br>35 40 45 <br>Phe Tyr Thr Ser Arg Leu Leu Ser Gly Va l Pro Ser Arg Phe Ser Gly <br>50 55 60 <br>Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Tyr Asn Leu Glu Gln <br>65 70 75 80 <br>Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Asp Thr Leu Pro Tyr <br>85 90 95 <br>Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala <br>100 105 110 <br>Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly <br>115 120 125 <br>Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile <br>130 135 14 0 <br>Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Va l Leu <br>145 150 155 160 <br>Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Me t Ser <br>165 170 175 <br>Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr <br>180 185 190 <br>Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser <br>195 200 205 <br>Phe Asn Arg Asn Glu Cys <br>210 <br><21 0> 11 9 <br><211 > 1344 <br>113 EP 2 569 010 81 <br><212> DNA <br><2 13> Mus musculus <br><220> <br>5 <221 > mise_ feature <br><223> Ab-8 heavy chain <br><400> 119 <br>10 <br>60 gaggtccaac tgcaacagtc tggacctgaa ctaatgaagc ctggggcttc agtgaagatg <br>tcctgcaagg cttctggata tacattcact gactacaaca tgcactgggt gaagcagaac 120 <br>15 <br>caaggaaaga ccctagactg gataggagaa attaatccta acagtggtgg tgctggctac 180 <br>aaccagaagt tcaagggcaa ggccacattg actgtagaca agt cctccac cacagcctac 240 <br>atggagctcc gcagcctgac atctgaggac tctgcagtct attactgtgc aagattgggc 300 <br>20 <br>tacgatgata tctacgacga ctggtacttc gatgtctggg gcgcagggac cacggtcacc 360 <br>gtctcctcag ccaaaacgac acccccatct gtctatccac tggcccctgg atctgctgcc 420 <br>25 <br>caaactaact ccatggtgac cctgggatgc ctggtcaagg gctatttccc tgagccagtg 480 <br>acagtgacct ggaactctgg atccctgtcc agcggtgtgc acaccttccc agctgtcctg 540 <br>cagtctgacc tctacactct gagcagctca gtgactgtcc cctccagcac ctggcccagc 600 <br>30 <br>gagaccgtca cctgcaacgt tgcccacccg gccagcagca ccaaggtgga caagaaaatt 660 <br>gtgcccaggg attgtggttg taagccttgc atatgtacag tcccagaagt atcatctgtc 720 <br>35 <br>ttcatcttcc ccccaaagcc caaggatgtg ctcaccatta ctctgactcc taaggtcacg 780 <br>tgtgttgtgg tagacatcag caaggatgat cccgaggtcc agttcagctg gtttgtagat 840 <br>40 <br>gatgtggagg tgcacacagc tcagacgcaa ccccgggagg agcagttcaa cagcactttc 900 <br>cgctcagtca gtgaacttcc catcatgcac caggactggc tcaatggcaa ggagttcaaa 960 <br>tgcagggtca acagtgcagc tttccctgcc cccatcgaga aaaccatctc caaaaccaaa 10 2 0 <br>45 <br>ggcagaccga aggctccaca ggtgtacacc attccacctc ccaaggagca gatggccaag 1080 <br>gataaagtca gtctgacctg catgataaca gacttcttcc ctgaagacat tactgtggag 1140 <br>50 <br>tggcagtgga atgggcagcc agcggagaac tacaagaaca ctcagcccat catggacaca 1200 <br>gatggctctt act tea teta cagea a get e aatgtgcaga agagcaactg ggaggcagga 1260 <br>aatactttca cctgctctgt gttacatgag ggcctgcaca accaccatac tgagaagagc 1320 <br>55 <br>ctctcccact ctcctggtaa at ga 1344 <br><210> 120 <br>114 <211>447 <br><212> PRT <br><213> Mus musculus <br>EP 2 569 010 81 <br>5 <220> <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br><221> MISC_FEATURE <br><223> Ab-8 heavy chain <br><400> 120 <br>Glu Val Gln Leu Gln Gln Ser Gl y Pro Glu Leu Met Lys Pro Gly Ala <br>l 5 10 15 <br>Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr <br>20 25 30 <br>Asn Met Hi s Trp Val Lys Gln Asn Gl n Gly Lys Thr Le u Asp Trp I l e <br>35 40 45 <br>Gly Glu Ile Asn Pro Asn Ser Gly Gl y Ala Gly Tyr Asn Gln Lys Phe <br>50 55 60 <br>Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr <br>65 70 75 80 <br>Met Glu Le u Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys <br>85 90 95 <br>Ala Arg Leu Gl y Tyr Asp Asp Ile Tyr Asp Asp Trp Tyr Phe Asp Val <br>115 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>100 105 110 <br>Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Pro <br>115 120 125 <br>Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser <br>130 135 140 <br>Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val <br>145 150 155 160 <br>Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe <br>165 170 175 <br>Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr <br>180 185 190 <br>Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala <br>195 200 205 <br>His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp <br>210 215 220 <br>Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val <br>225 230 235 240 <br>Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr <br>245 250 255 <br>Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu <br>260 265 270 <br>Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln <br>275 280 285 <br>Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser <br>290 295 300 <br>Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys <br>305 310 315 320 <br>Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile <br>325 330 335 <br>Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro <br>116 .. <br>' <br>5 <br>10 <br>15 <br>20 <br>25 <br>EP 2 569 010 81 <br>340 345 350 <br>Pro Pr o Lys Gl u Gln Met Al a Lys Asp Lys Val Ser Leu Thr Cys Met <br>355 360 365 <br>Ile Thr Asp Phe Ph e Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn <br>370 375 380 <br>Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro I l e Met Asp Thr <br>385 390 395 400 <br>Asp Gly Ser Tyr Phe I le Tyr Ser Lys Leu Asn Val Gl n Lys Ser Asn <br>405 410 415 <br>Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu Hi s Gl u Gly Leu <br>420 425 430 <br>His Asn Hi s His Thr Gl u Lys Ser Leu Ser His Ser Pr o Gly Lys <br><210> 121 <br><211> 11 <br>435 440 445 <br>30 <212> PRT <br><213> Artificial Sequence <br>35 <br>40 <br><220> <br><223> Ab-9 LCDR1 <br><400> 121 <br><210> 122 <br><211> 7 <br><212> PRT <br>Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn <br>l 5 10 <br>45 <213> Artificial Sequence <br><220> <br><223> Ab-9 LCDR2 <br>50 <400> 122 <br>55 <br><210> 123 <br><211> 9 <br><212> PRT <br>Tyr Thr Ser Arg Leu Ph e Ser <br>l 5 <br>117 5 <br>10 <br><213> Artificial Sequence <br><220> <br><223> Ab-9 LCDR3 <br><400> 123 <br><210> 124 <br><211> 5 <br><212> PRT <br>EP 2 569 010 B1 <br>Gln Gln Gly Asp Thr Leu Pro Tyr Thr <br>l 5 <br>15 <213> Artificial Sequence <br><220> <br><223> Ab-9 HCDR1 <br>20 <400> 124 <br>25 <br>30 <br>35 <br>40 <br><210> 125 <br><211>17 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-9 HCDR2 <br><400> 125 <br>Asp Tyr Asn Met His <br>l 5 <br>Gl u Ile As n Pro Asn Ser Gly Gly Ala Gly Tyr Asn Gl n Lys Phe Lys <br>l 5 10 15 <br>Gly <br><210> 126 <br><211>14 <br>45 <212> PRT <br>50 <br>55 <br><213> Artificial Sequence <br><220> <br><223> Ab-9 HCDR3 <br><400> 126 <br>Leu Gly Tyr Asp Asp Ile Tyr Asp Asp Trp Tyr Phe Asp Va l <br><210> 127 <br><211> 642 <br>l 5 10 <br>118 <br>' <br>" ""' <br>EP 2 569 010 B1 <br><212> DNA <br><2 13> Mus musculus <br><400> 127 <br>5 <br>gatatccaga tgacacagat tacatcctcc ctgtctgcct ctctgggaga cagggtctcc 60 <br>atcagttgca gggcaagtca agacattagc aattatttaa attggtatca gcagaaacca 120 <br>10 <br>gatggaactt ttaaactcct tatcttctac acatcaagat tattttcagg agtcccatca 180 <br>aggttcagtg gcagtgggtc tggaacagat tattctctca ccatttacaa cctggagcaa 240 <br>15 <br>gaagattttg ccact t actt ttgccaacag ggagatacgc ttccgtacac tttcggaggg 300 <br>gggaccaagg tggaaataaa acgggctgat gctgcaccaa ctgtatccat cttcccacca 360 <br>tccagtgagc agttaacatc tggaggtgcc tcagtcgtgt gcttcttgaa caacttctac 420 <br>20 <br>cccaaagaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa tggcgtcctg 480 <br>aacagttgga ctgatcagga cagcaaagac agcacctaca gcatgagcag caccctcacg 540 <br>25 <br>ttgaccaagg acgagtatga acgacataac agctatacct gtgaggccac tcacaagaca 600 <br>tcaacttcac ccattgtcaa gagcttcaac aggaatgagt g t 642 <br><210> 128 <br>30 <2 11 > 214 <br><212> PRT <br><213> Mus musculus <br><400> 128 <br>35 <br>40 <br>45 <br>50 <br>55 <br>119 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>Asp Ile Gln Met Thr Gln Ile Thr Ser Ser Leu Ser Ala Ser Leu Gly <br>l 5 10 15 <br>Asp Arg Val Ser Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr <br>20 25 30 <br>Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Phe Lys Leu Leu Ile <br>35 40 45 <br>Phe Tyr Thr Ser Arg Leu Phe Ser Gly Val Pro Ser Arg Phe Ser Gly <br>50 55 60 <br>Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Tyr Asn Leu Glu Gln <br>65 70 75 80 <br>Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Asp Thr Leu Pro Tyr <br>85 90 95 <br>Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Ala Asp Ala Ala <br>100 105 110 <br>Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly <br>115 120 125 <br>Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile <br>130 135 140 <br>Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu <br>145 150 155 160 <br>Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser <br>165 170 175 <br>Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr <br>180 185 190 <br>Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser <br>195 200 205 <br>Phe Asn Arg Asn Glu Cys <br>210 <br><210> 129 <br><211> 1350 <br>120 EP 2 569 010 81 <br><212> DNA <br><213> Mus musculus <br><400> 129 <br>5 <br>gaggtccaac tgcaacagtc tggacctgaa ctaatgaagc c t gggacttc agtgaagatg 60 <br>tcctgcaagg ctt c t ggata tacattcact gactacaaca tgcactgggt gaagcagacc 120 <br>10 <br>caaggaaaga ccctagagtg gataggagaa attaatccta acagtggtgg tgctggct ac 180 <br>aaccagaagt tcaagggcaa ggccacattg act gtagaca agt cctccac cacagcctac 240 <br>15 <br>atggagct cc gcagcctgac atctgaggac tctgcagtct attactgtgc aaaattgggc 300 <br>tacgatgata tctacgacga c t ggt a t ttc gatgt ctggg g cgcagggac cacggtcacc 360 <br>gtctcctcag ccaaaacaac agccccatcg gtctatccac t ggcccctgt gtgtggagat 420 <br>20 <br>acaactggct cctcggtgac tctaggatgc ctggtcaagg gt t atttccc tgagccagtg 480 <br>accttgacct ggaactctgg atccctgtcc agtgatgtgc acaccttccc agctctcctg 540 <br>25 <br>cagtctggcc tctacaccct cagcagctca gtgactgtaa c cacctggcc cagccagacc 600 <br>atca cctgca atgtggccca cccggcaagc agcaccaaag t g gacaagaa aattgagccc 660 <br>agagggtccc caacacataa accctgtcct ccatgcccag c t cctaacct c t tgggtgga 720 <br>30 <br>ccatccgtct tcatcttccc tccaaagatc aaggatgtac tcat gatctc cctgagcccc 780 <br>atggtcacgt gtgt ggtggt ggatgt gagc gaggatgacc cagatgtcca tgtcagctgg 840 <br>35 ttcgt gaaca acgtggaagt acacacagct cagacacaaa ceca tag aga ggattacaac 900 <br>agtactatcc gggtggtcag tgccct cccc a t ccagcacc aggactggat gagtggcaag 960 <br>40 <br>gagttcaaat gcaaggtcaa caacaaagcc ctcccagcgc ccatcgagag aaccatctca 1020 <br>aaacccaaag ggccagtaag agctccacag gtatatgtct tgcctccacc agaagaagag 1080 <br>atgactaaga aacaggtcac tctgacctgc atgatcacag acttcatgcc tgaagacatt 1140 <br>45 <br>tacgtggagt ggaccaacaa cgggcaaaca gagctaaact acaagaacac tgaaccagtc 1200 <br>ctggactctg atggt tctta cttcatgtac agcaagctga gagtggaaaa gaagaactgg 1260 <br>50 <br>gtggaaagaa atagctactc ctgttcagtg gtccacgagg gtctgcacaa tcaccacacg 1320 <br>actaagagct tctcccggac tccgggtaaa 1350 <br><210> 130 <br>55 <br><211> 450 <br><212> PRT <br><213> Mus musculus <br>121 EP 2 569 010 B1 <br><400> 130 <br>Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Met Lys Pro Gly Thr <br>l 5 10 15 <br>5 <br>Ser Val Lys Met Ser Cys Lys Al a Ser Gly Tyr Thr Phe Thr Asp Tyr <br>20 25 JO <br>10 <br>Asn Met His Trp Val Lys Gln Thr Gln Gly Lys Thr Leu Glu Trp Ile <br>35 40 45 <br>15 <br>Gly Glu Ile Asn Pro Asn Ser Gly Gly Ala Gly Tyr Asn Gln Lys Phe <br>50 55 60 <br>20 <br>Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr <br>65 70 75 80 <br>Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys <br>25 <br>85 90 95 <br>Ala Lys Leu Gly Tyr Asp Asp Ile Tyr Asp Asp Trp Tyr Phe Asp Val <br>100 105 110 <br>30 <br>Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Ala <br>115 120 125 <br>35 <br>Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser <br>130 135 140 <br>40 Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val <br>45 <br>50 <br>55 <br>122 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>145 150 15 5 160 <br>Thr Le u Thr Trp Asn Ser Gl y Ser Leu Ser Ser Asp Val His Thr Phe <br>165 170 175 <br>Pro Ala Le u Leu Gln Ser Gl y Leu Tyr Thr Leu Ser Ser Ser Va l Thr <br>180 185 190 <br>Val Thr Thr Trp Pro Ser Gl n Thr Ile Thr Cys As n Val Al a His Pr o <br>195 200 205 <br>Ala Ser Ser Thr Lys Va l As p Lys Lys I l e Glu Pro Arg Gl y Ser Pro <br>210 215 220 <br>Thr Hi s Lys Pro Cys Pro Pro Cys Pro Ala Pro Asn Leu Leu Gl y Gl y <br>225 230 235 240 <br>Pr o Ser Val Ph e Ile Phe Pro Pro Lys I l e Lys Asp Val Leu Met Il e <br>245 250 255 <br>Ser Le u Ser Pro M et Val Thr Cys Val Va l Val Asp Va l Ser Gl u Asp <br>260 265 270 <br>Asp Pro As p Val His Val Ser Trp Phe Va l Asn Asn Val Gl u Val His <br>275 280 285 <br>Thr Al a Gl n Thr Gln Thr His Ar g Glu Asp Tyr Asn Ser Thr Ile Ar g <br>29 0 295 300 <br>Val Va l Ser Ala Leu Pro I l e Gl n His Gl n Asp Trp Me t Ser Gl y Lys <br>305 310 315 320 <br>Glu Ph e Lys Cys Lys Va l As n Asn Lys Al a Leu Pro Al a Pro Il e Gl u <br>325 330 335 <br>Arg Thr Il e Ser Lys Pro Lys Gl y Pro Val Arg Al a Pro Gln Val Tyr <br>340 345 350 <br>Val Le u Pr o Pro Pro Glu Gl u Gl u Met Thr Lys Lys Gln Va l Thr Le u <br>355 360 365 <br>Thr Cys Me t I l e Thr Asp Phe Met Pro Glu Asp I le Tyr Val Gl u Tr p <br>370 375 380 <br>Thr As n As n Gl y Gl n Thr Gl u Leu Asn Tyr Lys Asn Thr Glu Pro Va l <br>123 EP 2 569 010 81 <br>385 390 395 400 <br>5 <br>Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu <br>405 41 0 415 <br>Lys Lys Asn Trp Va l Gl u Arg Asn Ser Tyr Ser Cys Ser Val Val Hi s <br>10 <br>420 425 430 <br>Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pr o <br>15 <br>Gly Lys <br>450 <br>20 <210> 131 <br><211> 11 <br><212> PRT <br>435 440 445 <br><213> Artificial Sequence <br>25 <220> <br><223> Ab-10 LCDR1 <br><400> 131 <br>30 <br><210> 132 <br>35 <211> 7 <br><212> PRT <br>Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn <br>l 5 10 <br><213> Artificial Sequence <br><220> <br>40 <223> Ab-10 LCDR2 <br>45 <br><400> 132 <br><210> 133 <br><211> 9 <br>50 <212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-10 LCDR3 <br>55 <br><400> 133 <br>Tyr Thr Ser Arg Leu Leu Ser <br>l 5 <br>124 5 <210> 134 <br><211> 5 <br><212> PRT <br><213> Artificial Sequence <br>10 <220> <br><223> Ab-10 HCDR1 <br><400> 134 <br>15 <br><210> 135 <br>20 <211 > 17 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>25 <223> Ab-10 HCDR2 <br><400> 135 <br>EP 2 569 010 B1 <br>Gl n Gln Gly Asp Thr Leu Pro Tyr Thr <br>l 5 <br>Asp Tyr Asn Met His <br>l 5 <br>30 <br>Glu Ile Asn Pro Asn Ser Gly Gly Ala Gly Tyr Asn Gln Lys Phe Lys <br>l 5 10 15 <br>35 <br>40 <br>45 <br>Gly <br><210> 136 <br><211> 14 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-10 HCDR3 <br><400> 136 <br>Leu Gly Tyr Asp Asp Ile Tyr Asp Asp Trp Tyr Phe Asp Va l <br>50 <210> 137 <br><21 1> 645 <br><212> DNA <br>l 5 10 <br><213> Mus musculus <br>55 <400> 137 <br>125 EP 2 569 010 B1 ". <br>gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagggtctcc 60 <br>atcagttgca gggcaagtca agacattagc aattatttaa actggtatca gcagaaacca 120 <br>5 <br>gatggaactt ttaaactcct tatcttctac acatcaagat tactctcagg agtcccat c a 180 <br>aggt t cagtg gcagtgggtc tggaacagat tattctctca ccatttacaa cctggagcaa 240 <br>10 <br>gaagattttg ccacttactt ttgccaacag ggagatacgc ttccgtacac tttcggaggg 3 0 0 <br>gggaccaaac tggaaataaa acgggctgat gctgcaccaa ctgtatccat cttcccacta 360 <br>15 <br>tccagtgagc agttaacatc tggaggtgcc tcagtcgtgt gcttcttgaa caacttctac 420 <br>cccaaagaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa tggcgtcctg 480 <br>aacagttgga ctgatcagga cagcaaagac agcacctaca gcatgagcag caccctcacg 540 <br>20 <br>ttgaccaagg acgagtatga acgacataac agctatacct gtgaggccac tcacaagaca 600 <br>tcaacttcac ccattgtcaa gagcttcaac aggaatgagt gttag 645 <br>25 <br><210> 138 <br><211>214 <br><212> PRT <br><213> Mus musculus <br>30 <br><400> 138 <br>35 <br>40 <br>45 <br>50 <br>55 <br>126 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly <br>l 5 10 15 <br>Asp Arg Val Ser Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr <br>20 25 30 <br>Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Phe Lys Leu Leu Ile <br>35 40 45 <br>Phe Tyr Thr Ser Arg Leu Leu Ser Gly Val Pro Ser Arg Phe Ser Gly <br>50 55 60 <br>Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Tyr Asn Leu Glu Gln <br>65 70 75 80 <br>Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Asp Thr Leu Pro Tyr <br>85 90 95 <br>Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala <br>100 105 110 <br>Pro Thr Val Ser Ile Phe Pro Leu Ser Ser Glu Gln Leu Thr Ser Gly <br>115 120 125 <br>Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile <br>130 135 140 <br>Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gl y Val Leu <br>145 150 155 160 <br>As n Ser Trp Thr Asp Gln Asp Ser Ly s Asp Ser Thr Tyr Ser Met Ser <br>165 170 175 <br>Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr <br>180 185 190 <br>Thr Cys Glu Ala Thr His Ly s Thr Ser Thr Ser Pro Ile Val Lys Ser <br>195 200 205 <br>Phe Asn Arg Asn Glu Cys <br>210 <br>127 EP 2 569 010 B1 <br><210> 139 <br><211> 1344 <br><212> DNA <br><213> Mus musculus <br>5 <br><400> 139 <br>gaggtccaac tgcaacagtc tggacctgaa ctaatgaagc ctggggcttc agtgaagatg 60 <br>10 <br>tcctgcaagg cttctggata tacattcact gactacaaca tgcactgggt gaagcagaac 120 <br>caaggaaaga ccctagaatg gataggagaa attaatccta acagtggtgg tgctggctac 180 <br>aaccagaagt tcaagggcaa ggccacattg actgtagaca agtcctccac cacagcctac 240 <br>15 <br>atggagctcc gcagcctgac atctgaggac tctgcagtct attactgtgc aagattgggc 300 <br>tacgatgata tctacgacga ctggtacttc gatgtctggg gcgcagggac cacggtcacc 360 <br>20 <br>gtctcctcag ccaaaacgac acccccatct gtctatccac tggcccctgg atctgctgcc 420 <br>caaactaact ccatggtgac cctgggatgc ctggtcaagg gctatttccc tgagccagtg 480 <br>25 <br>acagtgacct ggaactctgg atccctgtcc agcggtgtgc acaccttccc agctgtcctg 540 <br>cagtctgacc tctacactct gagcagctca gtgactgtcc cctccagcac ctggcccagc 600 <br>gagaccgtca cctgcaacgt tgcccacccg gccagcagca ccaaggtgga caagaaaatt 660 <br>30 <br>gtgcccaggg attgtggttg taagccttgc atatgtacag tcccagaagt atcatctgtc 720 <br>ttcatcttcc ccccaaagcc caaggatgtg ctcaccatta ctctgactcc taaggtcacg 780 <br>35 <br>tgtgttgtgg tagacatcag caaggatgat cccgaggtcc agttcagctg gtttgtagat 840 <br>gatgtggagg tgcacacagc tcagacgcaa ccccgggagg agcagttcaa cagcactttc 900 <br>cgctcagtca gtgaacttcc catcatgcac caggactggc tcaatggcaa ggagttcaaa 960 <br>40 <br>tgcagggtca acagtgcagc tttccctgcc cccatcgaga aaaccatctc caaaaccaaa 1020 <br>ggcagaccga aggctccaca ggtgtacacc attccacctc ccaaggagca gatggccaag 1080 <br>45 gataaagtca gtctgacctg catgataaca gacttcttcc ctgaagacat tactgtggag 1140 <br>tggcagtgga atgggcagcc agcggagaac tacaagaaca ctcagcccat catggacaca 1200 <br>50 <br>gatggctctt act tea teta cagcaagctc aatgtgcaga agagcaactg ggaggcagga 1260 <br>aatactttca cctgctctgt gttacatgag ggcctgcaca accaccatac tgagaagagc 1320 <br>ctctcccact ctcctggtaa at ga 1344 <br>55 <br><21 0> 140 <br><211> 447 <br><212> PRT <br>128 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br><213> Mus musculus <br><400> 140 <br>Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Met Lys Pro Gly Ala <br>l 5 10 15 <br>Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr <br>20 25 30 <br>Asn Met His Trp Val Lys Gln Asn Gln Gly Lys Thr Leu Glu Trp Ile <br>35 40 45 <br>Gly Glu Ile Asn Pro Asn Ser Gly Gly Ala Gly Tyr Asn Gln Lys Phe <br>50 55 60 <br>Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr <br>65 70 75 80 <br>Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys <br>85 90 95 <br>Ala Arg Leu Gly Tyr Asp Asp Ile Tyr Asp Asp Trp Tyr Phe Asp Val <br>100 105 110 <br>Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Pro <br>115 120 125 <br>Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser <br>130 135 140 <br>Met Va l Thr Leu Gly Cys Leu Val Lys Gl y Tyr Phe Pro Glu Pro Val <br>145 150 155 160 <br>Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe <br>165 170 175 <br>Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr <br>129 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>180 185 190 <br>Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Va l Ala <br>195 200 205 <br>His Pro Ala Ser Ser Thr Lys Va l Asp Lys Lys Ile Val Pro Arg Asp <br>210 215 220 <br>Cys Gly Cys Lys Pro Cys Ile Cys Thr Va l Pro Glu Val Ser Ser Val <br>225 230 235 240 <br>Phe Ile Phe Pro Pro Lys Pro Lys Asp Va l Leu Thr Ile Thr Leu Thr <br>245 250 255 <br>Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu <br>260 265 270 <br>Val Gln Phe Ser Trp Phe Val Asp Asp Va l Glu Val His Thr Ala Gln <br>275 280 285 <br>Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser <br>290 295 300 <br>Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys <br>305 310 315 320 <br>Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile <br>325 330 335 <br>Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro <br>340 345 350 <br>Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met <br>355 360 365 <br>Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp As n <br>370 375 380 <br>Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr <br>385 390 395 400 <br>Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn <br>405 410 415 <br>Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu <br>130 EP 2 569 010 B1 <br>42 0 425 430 <br>5 <br>His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys <br>435 440 44 5 <br><210> 141 <br><211>10 <br>10 <212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-11 and Ab-16 LCDR1 <br>15 <br>20 <br><400> 141 <br><210> 142 <br><211> 7 <br><212> PRT <br>25 <213> Artificial Sequence <br><220> <br>Arg Ala Ser Ser Ser I le Ser Tyr Ile His <br>l 5 10 <br><223> Ab-11 and Ab-16 LCDR2 <br>30 <400> 142 <br>35 <br>40 <br><210> 143 <br><211> g <br><212> PRT <br><213> Artificial Sequence <br><220> <br>Al a Thr Ser Asn Leu Al a Ser <br>l 5 <br><223> Ab-11 and Ab-16 LCDR3 <br><400> 143 <br>45 <br>50 <210> 144 <br><211> 5 <br><212> PRT <br><213> Artificial Sequence <br>55 <220> <br>Gl n Gln Trp Ser Ser Asp Pro Leu Thr <br>l 5 <br><223> Ab-11 and Ab-16 HCDR1 <br><400> 144 <br>131 5 <br><210> 145 <br><211>17 <br><212> PRT <br>10 <213> Artificial Sequence <br><220> <br><223> Ab-11 and Ab-16 HCDR2 <br>15 <400> 145 <br>EP 2 569 010 81 <br>Asp Tyr Tyr Ile Hi s <br>l 5 <br>Arg Val Asp Pro Asp Asn Gly Glu Thr Glu Phe Ala Pro Lys Phe Pro <br>l 5 10 15 <br>20 <br>Gly <br><210> 146 <br>25 <211> 12 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>30 <223> Ab-11 and Ab-16 HCDR3 <br><400> 146 <br>35 <br>Glu Asp Tyr Asp Gly Thr Tyr Thr Tr p Phe Pro Tyr <br><210> 147 <br><211> 642 <br>40 <212> DNA <br><213> Mus musculus <br><400> 147 <br>45 <br>50 <br>55 <br>l 5 10 <br>132 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>caaattgttc tctcccagtc tccagcattc ctgtctgtat ctccagggga <br>atgacttgca gggccagctc aagtataagt tacatacact ggtttcagca <br>tcctccccca gatcctggat ttatgccaca tccaacctgg ctt ctggagt <br>ttcagtggca gtgggtctgg gacctcttac tctctcacaa tcagcagagt <br>gatgctgcca cttattactg ccagcagtgg agtagtgacc cactcacgtt <br>accaagctgg agctgaaacg ggctgatgct gcaccaactg tatccatctt <br>agtgagcagt taacatctgg aggtgcctca gtcgtgtgct tcttgaacaa <br>aaagacatca atgtcaagtg gaagattgat ggcagtgaac gacaaaatgg <br>agttggactg atcaggacag caaagacagc acctacagca tgagcagcac <br>accaaggacg agtatgaacg acataacagc tatacctgtg aggccactca <br>acttcaccca ttgtcaagag cttcaacagg aatgagtgtt ag <br><210> 148 <br><211>213 <br><212> PRT <br><213> Mus musculus <br><400> 148 <br>133 <br>taaggtcaca 60 <br>gaagccagga 120 <br>ccctggtcgc 180 <br>ggaggctgag 240 <br>cggtgctggg 300 <br>cccaccat cc 360 <br>cttctacccc 420 <br>cgtcctgaac 480 <br>cctcacgttg 540 <br>caagacatca 600 <br>642 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>Gln Ile Val Leu Ser Gln Ser Pro Ala Phe Leu Ser Val Ser Pro Gly <br>l 5 10 15 <br>Asp Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Ile Ser Tyr Ile <br>20 25 30 <br>His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Arg Ser Trp Ile Tyr <br>35 40 45 <br>Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Gly Arg Phe Ser Gly Ser <br>50 55 60 <br>Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu <br>65 70 75 80 <br>Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asp Pro Leu Thr <br>85 90 95 <br>Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala Pro <br>100 105 110 <br>Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly <br>115 120 125 <br>Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn <br>130 135 140 <br>Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn <br>145 150 155 160 <br>Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser <br>165 170 175 <br>Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr <br>180 185 190 <br>Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe <br>195 <br>Asn Arg Asn Glu Cys <br>210 <br>134 <br>200 205 EP 2 569 010 81 <br><210> 149 <br><211 > 1338 <br><21 2> DNA <br><213> Mus musculus <br>5 <br><400> 149 <br>gaagttcagc tgcaacagtc tggggcagac cttgtgcagc caggggcctc agtcaaggtg 60 <br>10 <br>tcctgcacag cttctggctt cgacattaag gactactata tacactggat gaaacagagg 120 <br>cctgaccagg gcctggagtg gattggaagg gttgatcctg acaatggtga gactgaattt 180 <br>gccccgaagt tcccgggcaa ggccactttt acaacagaca cat cctccaa cacagcctac 240 <br>15 <br>ctacaactca gaggcctgac atctgaggac actgccatct attactgtgg gagagaagac 300 <br>tacgatggta cctacacctg gttt ccttat tggggccaag ggactctggt cactgtctct 360 <br>20 <br>gcagccaaaa cgacaccccc atct gtctat ccactggccc c t ggatctgc tgcccaaact 420 <br>aactccatgg tgaccctggg atgcctggtc aagggctatt tccctgagcc agt gacagtg 480 <br>25 <br>acctggaact ctggatccct g t ccagcggt gtgcacacct tcccagctgt cctgcagtct 540 <br>gacctctaca ctctgagcag c t cagtgact gtcccctcca gcacctggcc cagcgagacc 600 <br>gtcacct gca acgttgccca cccggccagc agcaccaagg tggacaagaa aattgtgccc 660 <br>30 <br>agggattgtg gttgtaagcc ttgcatatgt acagt cccag aagt atcatc tgtcttcatc 720 <br>ttccccccaa agcccaagga tgtgctcacc attactctga ctcctaaggt cacgtgtgtt 780 <br>35 <br>gtggtagaca tcagcaagga t gatcccgag g t ccagttca gct ggtttgt agatgatgtg 840 <br>gaggtgcaca cagctcagac gcaaccccgg gaggagcagt tcaacagcac t t tccgctca 90 0 <br>gtcagtgaac ttcccatcat gcaccaggac tggctcaatg gcaaggagtt caaatgcagg 960 <br>40 <br>gtcaacagtg cagctttccc tgcccccatc gagaaaacca tctccaaaac caaaggcaga 1020 <br>ccgaaggctc cacaggtgta caccattcca cctcccaagg agcagatggc caaggataaa 1080 <br>45 gtcagtctga cctgca t gat aacagacttc ttccctgaag acattactgt ggagtggcag 1140 <br>tggaatgggc agccagcgga gaactacaag aacactcagc ccatcatgga cacagatggc 1200 <br>tcttacttca tctacagcaa gctcaatgtg cagaagagca actgggaggc aggaaatact 1260 <br>50 <br>ttcacctgct ctgtgt t aca tgagggcctg cacaaccacc atactgagaa gagcctctcc 1320 <br>cact ctcctg gtaaatga 1338 <br>55 <br><210> 150 <br><211> 445 <br><212> PRT <br><213> Mus musculus <br>135 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br><400> 150 <br>Glu Val Gln Leu Gln Gln Ser Gly Ala Asp Leu Val Gln Pro Gly Ala <br>l 5 10 15 <br>Ser Val Lys Val Ser Cys Thr Al a Ser Gly Phe Asp Ile Lys Asp Tyr <br>20 25 30 <br>Tyr Ile His Trp Met Lys Gln Arg Pro Asp Gln Gly Leu Glu Trp Ile <br>35 40 45 <br>Gly Arg Val Asp Pro Asp Asn Gly Glu Thr Glu Phe Ala Pro Lys Phe <br>50 55 60 <br>Pro Gly Lys Ala Thr Phe Thr Thr Asp Thr Ser Ser Asn Thr Ala Tyr <br>65 70 75 80 <br>Leu Gln Leu Arg Gly Leu Thr Ser Glu Asp Thr Ala Ile Tyr Tyr Cys <br>85 90 95 <br>Gly Arg Glu Asp Tyr Asp Gly Thr Tyr Thr Trp Phe Pro Tyr Trp Gly <br>100 105 110 <br>Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro Pro Ser <br>115 120 125 <br>Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val <br>130 135 140 <br>Thr Leu Gly Cys Leu Val Lys Gl y Tyr Phe Pro Glu Pro Val Thr Val <br>145 150 155 160 <br>Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala <br>165 170 175 <br>Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro <br>180 185 190 <br>Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Va l Ala His Pro <br>195 200 205 <br>Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly <br>210 215 220 <br>136 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile <br>225 230 235 240 <br>Phe Pro Pro Lys Pro Lys Asp Val Leu Thr I l e Thr Leu Thr Pro Lys <br>245 250 255 <br>Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln <br>260 265 270 <br>Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln <br>275 280 285 <br>Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu <br>290 295 300 <br>Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg <br>305 310 315 320 <br>Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys <br>325 330 335 <br>Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro <br>340 345 350 <br>Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr <br>355 360 365 <br>Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln <br>370 375 380 <br>Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly <br>385 390 395 400 <br>Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu <br>405 410 415 <br>Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn <br>420 425 430 <br>His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys <br><210> 151 <br><211 > 318 <br>435 440 445 <br>137 EP 2 569 010 8 1 <br><212> DNA <br><213> Mus musculus <br><400> 151 <br>5 <br>gacatccagt tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc <br>atcacttgca gggccagctc aagtataagt tacatacact ggtatcagca aaaaccaggg <br>10 <br>aaagccccta agctcctgat ctatgccaca tccaacctgg cttctggggt cccatcaagg <br>ttcagcggca gtggatctgg gacagaattc actctcacaa tcagcagcct gcagcctgaa <br>15 <br>gattttgcaa cttattactg tcagcagtgg agtagtgacc cactcacgtt cggcggaggg <br>accaaggtgg agatcaaa <br><210> 152 <br>20 <211> 106 <br><212> PRT <br><213> Mus muscu lus <br><400> 152 <br>25 <br>Asp Ile Gln Le u Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly <br>l 5 10 15 <br>30 <br>Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Ile Ser Tyr Ile <br>20 25 30 <br>35 <br>His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu · Leu Ile Tyr <br>35 40 45 <br>Al a Thr Ser Asn Leu Ala Ser Gl y Va l Pro Ser Arg Phe Ser Gly Ser <br>40 <br>50 55 60 <br>Gly Ser Gly Thr Glu Phe Thr Leu Tbr Ile Ser Ser Leu Gln Pro Glu <br>65 70 75 80 <br>45 <br>Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asp Pr o Leu Thr <br>85 90 95 <br>50 <br>Phe Gly Gly Gly Thr Lys Val Glu Ile Lys <br>100 105 <br><210> 153 <br>55 <211> 363 <br><212> DNA <br><213> Mus musculus <br>138 <br>60 <br>120 <br>180 <br>240 <br>300 <br>318 EP 2 569 010 81 <br><400> 153 <br>gaggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60 <br>5 <br>tcctgcaagg cttctggatt cgacattaag gactactata tacactgggt gcgacaggcc 120 <br>cctggacaag ggcttgagtg gatcggaagg gttgatcctg acaatggtga gactgaattt 180 <br>10 <br>gccccgaagt tcccgggcaa ggtcaccatg accacagaca cgtccatcag cacagcctac 240 <br>atggagctga gcaggctgag atctgacgac acggccgtgt attactgtgc gagagaagac 300 <br>15 <br>tacgatggta cctacacctg gtttccttat tggggccaag ggactctggt caccgtctct 360 <br>ag t 363 <br><210> 154 <br>20 <211 > 121 <br><212> PRT <br><213> Mus musculus <br><400> 154 <br>25 <br>Glu Val Gl n Leu Val Gln Ser Gl y Ala Glu Va l Lys Lys Pro Gly Al a <br>l 5 10 15 <br>30 <br>Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asp Ile Lys Asp Tyr <br>20 25 30 <br>35 <br>Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile <br>35 40 45 <br>Gly Arg Val Asp Pro Asp Asn Gly Glu Thr Glu Phe Ala Pro Lys Phe <br>40 <br>so 55 60 <br>Pro Gly Lys Val Thr Met Thr Thr Asp Thr Ser Ile Ser Thr Ala Tyr <br>65 70 75 80 <br>45 <br>Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys <br>85 90 95 <br>50 <br>Ala Arg Glu Asp Tyr Asp Gly Thr Tyr Thr Trp Phe Pro Tyr Trp Gly <br>100 105 110 <br>55 Gln Gly Thr Leu Va l Thr Val Ser Ser <br>115 120 <br><210> 155 <br>139 EP 2 569 010 81 <br><211 > 639 <br><212> DNA <br><21 3> Artificial Sequence <br>5 <220> <br><223> Humanized antibody sequence <br><400> 155 <br>10 <br>gacatccagt tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60 <br>atcacttgca gggccagctc aagt ataagt tacatacact ggtatcagca aaaaccaggg 120 <br>15 <br>aaagccccta agctcctgat ctatgccaca tccaacctgg cttctggggt cccatcaagg 180 <br>ttcagcggca gtggatctgg gacagaattc actctcacaa tcagcagcct gcagcctgaa 240 <br>gattttgcaa cttattactg tcagcagtgg agtagtgacc cactcacgtt cggcggaggg 300 <br>20 <br>accaaggtgg agatcaaacg tacggtggct gcaccatctg tcttcatctt cccgccatct 360 <br>gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc 420 <br>25 <br>agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag 480 <br>agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg 540 <br>agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg 600 <br>30 <br>agctcgcccg tcacaaagag cttcaacagg ggagagtgt 639 <br><210> 156 <br><211 > 213 <br>35 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Humanized antibody sequence <br>40 <br><400> 156 <br>45 <br>50 <br>55 <br>140 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly <br>l 5 10 15 <br>Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Ile Ser Tyr I l e <br>20 25 30 <br>His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr <br>35 40 45 <br>Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser <br>50 55 60 <br>Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu <br>65 70 75 BO <br>Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asp Pro Leu Thr <br>85 90 95 <br>Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro <br>100 105 110 <br>Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr <br>115 120 125 <br>Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys <br>130 135 140 <br>Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu <br>145 150 155 160 <br>Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser <br>165 170 175 <br>Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala <br>180 185 190 <br>Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe <br>195 200 205 <br>Asn Arg Gly Glu Cys <br>210 <br>141 EP 2 569 010 81 <br><210> 157 <br><211> 1341 <br><2 12> DNA <br><213> Artificial Sequence <br>5 <br><220> <br><223> Humanized antibody sequence <br><400> 157 <br>10 <br>gaggtgcagc tggt gcagtc t ggggctgag gtgaagaagc c t ggggcctc agt gaaggtc 60 <br>tcctgcaagg cttctggatt cgacattaag gactactata tacactgggt gcgacaggcc 120 <br>15 <br>cctggacaag ggcttgagtg gatcggaagg gtt gatcctg acaatggtga gactgaattt 180 <br>gccccgaagt tcc cgggcaa ggt caccatg accacagaca cgtccatcag cacagcctac 240 <br>20 <br>atggagctga gcaggctgag atctgacgac acggccgtgt attactgtgc gagagaagac 300 <br>tacgat ggta cctacacctg gtttccttat tggggccaag ggactctggt caccgtctct 360 <br>agtgcctcca ccaagggccc atcggtcttc cccctggcgc cctgctccag gagcacctcc 420 <br>25 <br>gagagcacag cggccctggg ctgcctggtc aaggactact tccccgaacc ggt gacggtg 480 <br>tcgtggaact caggcgctct gaccagcggc gtgcacacct tcccagctgt cctacagtcc 540 <br>30 <br>tcaggactct actccctcag cagcgtggtg accgtgccct ccagcaactt cggcacccag 600 <br>acctacacct gcaacgt aga tcacaagccc agcaacacca aggtggacaa gacagttgag 660 <br>cgcaaatgtt gtgtcgagtg cccaccgtgc ccagcaccac ctgtggcagg accgtcagtc 720 <br>35 <br>ttcctcttcc ccccaaaacc caaggacacc ct catgatct cccggacccc tgaggtcacg 780 <br>tgcgtggtgg tggacgtgag ccacgaagac cccgaggtcc agttcaactg gtacgtggac 840 <br>40 <br>ggcgtggagg tgcataatgc caagacaaag ccacgggagg agcagttcaa cagcacgttc 900 <br>cgtgtggtca gcgt cctcac cgttgtgcac caggactggc tgaacggcaa ggagtacaag 960 <br>45 <br>tgcaaggtct ccaacaaagg cctcccagcc cccatcgaga aaaccatctc caaaaccaaa 1020 <br>gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag 1080 <br>aaccaggtca gcctgacctg cctggtcaaa ggcttctacc ccagcgacat cgccgtggag 1140 <br>50 <br>tgggagagca atgggcagcc ggagaacaac tacaagacca cacctcccat gctggactcc 1200 <br>gacggctcct tct tcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg 1260 <br>55 <br>aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc 1320 <br>ctctccctgt ctccgggtaa a 1341 <br>142 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br><210> 158 <br><211> 447 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Humanized antibody sequence <br><400> 158 <br>Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala <br>l 5 10 15 <br>Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asp I le Lys Asp Tyr <br>20 25 30 <br>Tyr Ile His Trp Val Arg Gln Al a Pro Gl y Gln Gly Leu Glu Trp Ile <br>35 40 45 <br>Gly Arg Val Asp Pro Asp Asn Gly Glu Thr Glu Phe Ala Pro Lys Phe <br>50 55 60 <br>Pro Gly Lys Val Thr Met Thr Thr Asp Thr Ser Ile Ser Thr Ala Tyr <br>65 70 75 80 <br>Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys <br>85 90 95 <br>Ala Arg Glu Asp Tyr Asp Gly Thr Tyr Thr Trp Phe Pro Tyr Trp Gly <br>100 105 110 <br>Gln Gly Thr Leu Va l Thr Val Ser Ser Ala Ser Thr Ly s Gly Pro Ser <br>143 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>115 120 125 <br>Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala <br>130 135 140 <br>Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val <br>145 150 155 160 <br>Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala <br>165 170 175 <br>Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val <br>180 185 190 <br>Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His <br>195 200 205 <br>Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys <br>210 215 220 <br>Val Gl u Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gl y Pro Ser Val <br>225 230 235 240 <br>Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr <br>245 250 255 <br>Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu <br>260 265 270 <br>Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys <br>275 280 285 <br>Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser <br>290 295 300 <br>Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys <br>305 310 315 320 <br>Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile <br>325 330 335 <br>Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro <br>340 345 350 <br>Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu <br>144 5 <br>10 <br>15 <br>20 <br>EP 2 569 010 B1 <br>355 360 365 <br>Va l Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn <br>370 375 380 <br>Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser <br>385 390 395 400 <br>Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg <br>405 410 415 <br>Trp Gln Gln Gl y Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu <br>420 425 430 <br>His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys <br>435 440 445 <br><210> 159 <br>25 <211 > 11 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>30 <223> Ab-12 LCDR1 <br><400> 159 <br>35 <br>Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn <br>l 5 10 <br><21 0> 160 <br><211> 7 <br>40 <212> PRT <br>45 <br>50 <br><213> Artificial Sequence <br><220> <br><223> Ab-12 LCDR2 <br><400> 160 <br><210> 161 <br><211> 9 <br><212> PRT <br>55 <213> Artificial Sequence <br><220> <br><223> Ab-12 LCDR3 <br>Tyr Thr Ser Thr Leu Gln Ser <br>l 5 <br>145 5 <br><400> 161 <br><210> 162 <br><211> 5 <br><212> PRT <br>10 <213> Artificial Sequence <br><220> <br><223> Ab-12 HCDR1 <br>15 <400> 162 <br>20 <br>25 <br>30 <br><210> 163 <br><211>17 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-12 HCDR2 <br><400> 163 <br>EP 2 569 010 B1 <br>Gln Gln Gly Asp Thr Leu Pro Tyr Thr <br>l 5 <br>Asp Tyr Asn Met His <br>l 5 <br>Glu Ile Asn Pro Asn Ser Gly Gly Ser Gly Tyr Asn Gln Lys Phe Lys <br>35 <br>l 5 10 15 <br>Gly <br><210> 164 <br><211>14 <br>40 <212> PRT <br>45 <br>50 <br><213> Artificial Sequence <br><220> <br><223> Ab-12 HCDR3 <br><400> 164 <br><210> 165 <br><211> 645 <br><212> DNA <br>Leu Gly Tyr Tyr Gly Asn Tyr Glu Asp Trp Tyr Phe Asp Val <br>l 5 10 <br>55 <213> Mus musculus <br><400> 165 <br>146 EP 2 569 010 81 <br>gatctccaga tgacacagac tacttcctcc ctgtctgcct ctctgggaga cagagtcacc 60 <br>atcagttgca gggcaagtca ggacattagc aattatttaa actggtatca gcagaaacca 120 <br>5 <br>gatggaactg ttaagctcct gatcttctac acatcaacat tacagtcagg agtcccatcg 180 <br>aggttcagtg gcagtgggtc tggaacaaat tattctctca ccattaccaa cctggagcaa 240 <br>10 <br>gatgatgctg ccacttactt t t gccaacag ggtgatacgc ttccgtacac gttcggaggg 300 <br>gggaccaagc tggaaataaa acgggctgat gctgcaccaa ctgtatccat cttcccacca 360 <br>15 <br>tccagtgagc agttaacatc tggaggtgcc tcagtcgtgt gcttcttgaa caacttctac 420 <br>cccaaagaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa tggcgtcctg 480 <br>aacagttgga ctgatcagga cagcaaagac agcacctaca gcatgagcag caccctcacg 540 <br>20 <br>ttgaccaagg acgagt atga acgacataac agctatacct gtgaggccac tcacaagaca 600 <br>tcaacttcac ccattgtcaa gagcttcaac aggaatgagt gttag 645 <br>25 <br><210> 166 <br><2 11 > 214 <br><212> PRT <br><213> Mus musculus <br>30 <br><400> 166 <br>35 <br>40 <br>45 <br>50 <br>55 <br>147 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>Asp Leu Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly <br>l 5 10 15 <br>Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr <br>20 25 30 <br>Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile <br>35 40 45 <br>Phe Tyr Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly <br>50 55 60 <br>Ser Gly Ser Gly Thr Asn Tyr Ser Leu Thr Ile Thr Asn Leu Glu Gln <br>65 70 75 80 <br>Asp Asp Ala Ala Thr Tyr Phe Cys Gln Gln Gly Asp Thr Leu Pro Tyr <br>85 90 95 <br>Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala <br>100 105 110 <br>Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly <br>115 120 125 <br>Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile <br>130 135 140 <br>Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu <br>145 150 155 160 <br>Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser <br>165 170 175 <br>Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr <br>180 185 190 <br>Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser <br>195 200 205 <br>Phe Asn Arg Asn Glu Cys <br>210 <br>148 EP 2 569 010 81 <br><21 0> 167 <br><211 > 1344 <br><212> DNA <br><213> Mus musculus <br>5 <br><400> 167 <br>gaggtccagt tgcaacagtc tggacctgaa ctaatgaagc ctggggcttc agtgaagatg 60 <br>10 <br>tcctgcaagg cttctggata cacattcact gactacaaca tgcactggat 120 gaagcagaac <br>caaggaaaga gcctagagtg gataggagag attaatccta acagtggtgg ttctggttac 180 <br>aaccagaagt tcaaaggcaa ggccacattg actgtagaca agtcctccag cacagcctac 240 <br>15 <br>atggagctcc gcagcctgac atctgaggac tctgcagtct attactgtgc aagattgggc 300 <br>tactatggta actacgagga ctggtatttc gatgtctggg gcgcagggac cacggtcacc 360 <br>20 <br>gtctcctctg ccaaaacgac acccccatct gtctatccac tggcccctgg atctgctgcc 42 0 <br>caaactaact ccatggtgac cctgggatgc ctggtcaagg gctatttccc tgagccagtg 480 <br>25 <br>acagtgacct ggaactctgg atccctgtcc agcggtgtgc acaccttccc agctgtcctg 540 <br>cagtctgacc tctacactct gagcagctca gtgactgtcc cct ccagcac ctggcccagc 600 <br>gagaccgtca cctgcaacgt tgcccacccg gccagcagca ccaaggtgga caagaaaatt 660 <br>30 <br>gtgcccaggg attgtggttg taagccttgc atatgtacag tcccagaagt atcatctgtc 720 <br>ttcatcttcc ccccaaagcc caaggatgtg ctcaccatta ctctgactcc taaggtcacg 780 <br>35 <br>tgtgttgtgg tagacatcag caaggatgat cccgaggtcc agttcagctg gtttgtagat 840 <br>gatgtggagg tgcacacagc tcagacgcaa ccccgggagg agcagttcaa cagcactttc 900 <br>cgctcagtca gtgaacttcc catcatgcac caggactggc tcaatggcaa ggagttcaaa 960 <br>40 <br>tgcagggtca acagtgcagc tttccctgcc cccatcgaga aaaccatctc caaaaccaaa 10 2 0 <br>ggcagaccga aggctccaca ggtgtacacc attccacctc ccaaggagca gatggccaag 1080 <br>45 <br>gataaagtca gtctgacctg catgataaca gacttcttcc ctgaagacat tactgtggag 1140 <br>tggcagtgga atgggcagcc agcggagaac tacaagaaca ctcagcccat catggacaca 1200 <br>50 <br>gatggctctt act tea teta cagcaagctc aatgtgcaga agagcaactg ggaggcagga 1260 <br>aatactttca cctgctctgt gttacatgag ggcctgcaca accaccatac tgagaagagc 13 2 0 <br>ctctcccact ctcctggtaa at ga 1344 <br>55 <br><210> 168 <br><211>447 <br><2 12> PRT <br>149 EP 2 569 010 81 <br><213> Mus musculus <br><400> 168 <br>5 <br>Glu Val Gln Leu Gln Gln Ser Gl y Pro Glu Leu Met Lys Pro Gly Ala <br>l 5 10 15 <br>10 <br>Ser Val Lys Met Ser Cys Ly s Ala Ser Gly Tyr Thr Phe Thr Asp Tyr <br>20 25 30 <br>Asn Met His Trp Met Lys Gln Asn Gln Gly Lys Ser Leu Glu Trp Ile <br>15 <br>35 40 45 <br>Gly Glu Ile Asn Pro Asn Ser Gly Gly Ser Gly Tyr Asn Gln Lys Phe <br>50 55 60 <br>20 <br>Lys Gly Lys Ala Thr Leu Thr Val Asp Ly s Ser Ser Ser Thr Ala Tyr <br>65 70 75 80 <br>25 <br>Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys <br>85 90 95 <br>30 <br>Ala Arg Leu Gl y Tyr Tyr Gly Asn Tyr Glu Asp Trp Tyr Phe Asp Val <br>100 105 110 <br>Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Pro <br>35 <br>115 120 125 <br>Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser <br>130 135 140 <br>40 <br>Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val <br>45 <br>50 <br>55 <br>150 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>145 150 155 160 <br>Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe <br>165 170 175 <br>Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr <br>180 185 190 <br>Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Va l Thr Cys Asn Val Ala <br>195 200 205 <br>His Pro Al a Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp <br>210 215 220 <br>Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val <br>225 230 235 240 <br>Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr <br>245 250 255 <br>Pro Lys Va l Thr Cys Val Val Val Asp I l e Ser Lys Asp Asp Pro Glu <br>260 265 270 <br>Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln <br>275 280 285 <br>Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser <br>290 295 300 <br>Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys <br>305 310 315 320 <br>Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile <br>325 330 335 <br>Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro <br>340 345 350 <br>Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met <br>355 360 365 <br>Ile Thr Asp Phe Phe Pro Gl u Asp Ile Thr Val Glu Trp Gln Trp Asn <br>370 375 380 <br>Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr <br>151 EP 2 569 010 B1 <br>385 390 395 400 <br>5 <br>Asp Gly Ser Tyr Phe Il e Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn <br>10 <br>15 <br>20 <br>25 <br>405 41 0 415 <br>Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu <br>420 425 430 <br>His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys <br><210> 169 <br><211>12 <br><212> PRT <br>435 440 445 <br><213> Artificial Sequence <br><220> <br><223> Ab-13 and Ab-14 LCDR1 <br><400> 169 <br>Arg Ala Ser Ser Ser Val Thr Ser Ser Tyr Leu Asn <br>l 5 10 <br>30 <210> 170 <br><211> 7 <br><212> PRT <br><213> Artificial Sequence <br>35 <220> <br><223> Ab-13 and Ab-14 LCDR2 <br><400> 170 <br>40 <br><210> 171 <br>45 <211> 9 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>Ser Thr Ser Asn Leu Ala Ser <br>l 5 <br>50 <223> Ab-13 and Ab-14 LCDR3 <br><400> 171 <br>55 <br>Gln Gln Tyr Asp Phe Phe Pro Ser Thr <br>l 5 <br><210> 172 <br>152 <211> 5 <br><212> PRT <br><213> Artificial Sequence <br>5 <220> <br>10 <br><223> Ab-13 and Ab-14 HCDR1 <br><400> 172 <br><210> 173 <br><211> 17 <br>15 <212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-13 and Ab-14 HCDR2 <br>20 <br><400> 173 <br>EP 2 569 010 81 <br>Asp Tyr Tyr Met Asn <br>l 5 <br>Asp I l e As n Pro Tyr Asn Asp Asp Thr Thr Tyr Asn His Lys Phe Lys <br>25 <br>l 5 10 15 <br>Gly <br>30 <210> 174 <br><211> 11 <br><212> PRT <br><213> Artificial Sequence <br>35 <220> <br><223> Ab-13 and Ab-14 HCDR3 <br><400> 174 <br>40 <br><210> 175 <br>45 <211> 645 <br><212> DNA <br><213> Mus musculus <br><400> 175 <br>50 <br>55 <br>Glu Thr Ala Val Ile Thr Thr Asn Ala Met Asp <br>l 5 10 <br>153 EP 2 569 010 B1 <br>cagattgttc tcacccagtc tccagcaatc atgtctgcat ctccagggga gaaggtcacc 60 <br>atgacctgca gggccagctc aagtgtaact tccagttact tgaactggta ccagcagaag 120 <br>5 <br>ccaggatctt cccccaaact ctggatttat agcacatcca acctggcttc aggagtccca 180 <br>gctcgcttca gtggcagtgg gtctgggacc tcttactctc tcacaatcag cagtgtggag 240 <br>10 <br>gctgaggatg ctgccactta ttactgccag cagtatgatt ttttcccatc gacgttcggt 300 <br> ggaggcacca agctggaaat caagcgggct gatgctgcac caactgtatc catcttccca 360 <br>15 <br>ccatccagtg agcagttaac atctggaggt gcctcagtcg tgtgcttctt gaacaacttc 420 <br>taccccaaag acatcaatgt caagtggaag attgatggca gtgaacgaca aaatggcgtc 480 <br>ctgaacagtt ggactgatca ggacagcaaa gacagcacct acagcatgag cagcaccctc 540 <br>20 <br>acgttgacca aggacgagta tgaacgacat aacagctata cctgtgaggc cactcacaag 600 <br>acatcaactt cacccatcgt caagagcttc aacaggaatg agtgt 645 <br>25 <br><210> 176 <br><211>215 <br><212> PRT <br><2 13> Mus musculus <br>30 <400> 176 <br>35 <br>40 <br>45 <br>50 <br>55 <br>154 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly <br>l 5 10 15 <br>Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Thr Ser Ser <br>20 25 30 <br>Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp <br>35 40 45 <br>I l e Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser <br>50 55 60 <br>Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu <br>65 70 75 80 <br>Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Phe Phe Pro <br>85 90 95 <br>Ser Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala <br>100 105 110 <br>Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser <br>115 120 125 <br>Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp <br>130 135 140 <br>Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val <br>145 150 155 160 <br>Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met <br>165 170 175 <br>Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser <br>180 185 190 <br>Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys <br>195 200 205 <br>Ser Phe Asn Arg Asn Glu Cys <br>210 215 <br>155 EP 2 569 010 81 <br><210> 177 <br><211> 1335 <br><212> DNA <br><213> Mus musculus <br>5 <br><400> 177 <br>gaggtccagc tgcaacaatc tggacctgag ctggtgaagc ctggggcttc agtgaagatg 60 <br>10 <br>tcctgtaagg cttctggata cacattcact gactactaca tgaactgggt gaagcagagc 120 <br>catggagaga gccttgagtg gattggagat attaatcctt acaacgatga tactacctac 180 <br>aaccacaagt tcaagggcaa ggccacattg actgtagaca aatcctccaa cacagcctac 240 <br>15 <br>atgcagctca acagcctgac atctgaggac tctgcagtct attactgtgc aagagagacg 300 <br>gccgttatta ctacgaatgc tatggactac tggggtcaag gaacctcagt caccgtctcc 360 <br>20 <br>tcagccaaaa cgacaccccc atctgtctat ccactggccc ctggatctgc tgcccaaact 420 <br>aactccatgg tgaccctggg atgcctggtc aagggctatt tccctgagcc agtgacagtg 480 <br>25 <br>acctggaact ctggatccct gtccagcggt gtgcacacct tcccagctgt cctgcagtct 540 <br>gacctctaca ctctgagcag ctcagtgact gtcccctcca gcacctggcc cagcgagacc 600 <br>gtcacctgca acgttgccca cccggccagc agcaccaagg tggacaagaa aattgtgccc 660 <br>30 <br>agggattgtg gttgtaagcc ttgcatatgt acagtcccag aagtatcatc tgtcttcatc 720 <br>ttccccccaa agcccaagga tgtgctcacc attactctga ctcctaaggt cacgtgtgtt 780 <br>35 <br>gtggtagaca tcagcaagga tgatcccgag gtccagttca gctggtttgt agatgatgtg 840 <br>gaggtgcaca cagctcagac gcaaccccgg gaggagcagt tcaacagcac tttccgctca 900 <br>gtcagtgaac ttcccatcat gcaccaggac tggctcaatg gcaaggagtt caaatgcagg 960 <br>40 <br>gtcaacagtg cagctttccc tgcccccatc gagaaaacca tctccaaaac caaaggcaga 1020 <br>ccgaaggctc cacaggtgta caccattcca cctcccaagg agcagatggc caaggataaa 1080 <br>45 gtcagtctga cctgcatgat aacagacttc ttccctgaag acattactgt ggagtggcag 1140 <br>tggaatgggc agccagcgga gaactacaag aacactcagc ccatcatgga cacagatggc 1200 <br>50 <br>tcttacttca tctacagcaa gctcaatgtg cagaagagca actgggaggc aggaaatact 1260 <br>ttcacctgct ctgtgttaca tgagggcctg cacaaccacc atactgagaa gagcctctcc 1320 <br>cactctcctg gtaaa 1335 <br>55 <br><210> 178 <br><211> 445 <br><212> PRT <br>156 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br><213> Mus musculus <br><400> 178 <br>Glu Val Gln Leu Gln Gl n Ser Gly Pro Glu Leu Va l Lys Pro Gl y Al a <br>l 5 10 15 <br>Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr <br>20 25 30 <br>Tyr Met As n Trp Va l Lys Gl n Ser His Gly Glu Ser Le u Glu Trp Ile <br>35 40 45 <br>Gl y Asp Ile Asn Pro Tyr Asn Asp Asp Thr Thr Tyr Asn His Lys Ph e <br>50 55 60 <br>Lys Gly Lys Ala Thr Leu Thr Va l Asp Lys Ser Ser Asn Thr Al a Tyr <br>65 70 75 80 <br>Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Va l Tyr Tyr Cys <br>85 90 95 <br>Ala Arg Glu Thr Ala Val Ile Thr Thr Asn Ala Met Asp Tyr Trp Gl y <br>100 105 110 <br>Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser <br>115 120 125 <br>Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gl n Thr Asn Ser Met Val <br>130 135 140 <br>Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pr o Glu Pro Val Thr Val <br>145 150 155 160 <br>Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala <br>165 170 175 <br>Val Leu Gl n Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro <br>157 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>180 185 190 <br>Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro <br>195 200 205 <br>Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly <br>210 215 220 <br>Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile <br>225 230 235 240 <br>Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys <br>245 250 255 <br>Val Thr Cys Val Val Val Asp I l e Ser Lys Asp Asp Pro Glu Val Gln <br>260 265 270 <br>Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln <br>275 280 285 <br>Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu <br>290 295 300 <br>Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg <br>305 310 315 320 <br>Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys <br>325 330 335 <br>Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro <br>340 345 350 <br>Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr <br>355 360 365 <br>Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln <br>370 375 380 <br>Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly <br>385 390 395 400 <br>Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu <br>405 410 415 <br>Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn <br>158 .. <br>EP 2 569 010 81 <br>420 425 430 <br>5 <br>His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys <br>435 440 445 <br><210> 179 <br><211>324 <br>10 <212> DNA <br><213> Mus musculus <br>15 <br>20 <br>25 <br><400> 179 <br>gacatccagc <br>atcacatgcc <br>ccaggaaaag <br>tctcgatttt <br>ccagaagact <br>ggaggtacaa <br><210> 180 <br><211> 108 <br>30 <212> PRT <br>tgacccagag <br>gcgcctcatc <br>cacctaaact <br>caggatctgg <br>tcgccactta <br>aagtagaaat <br><213> Mus musculus <br><400> 180 <br>35 <br>40 <br>45 <br>50 <br>55 <br>ccccagcttc ctttccgcat ccgt tggtga ccgagtaaca <br>ttcagttaca tet tet tate ttaattggta tcaacaaaaa <br>tcttatatac tctacatcta atct cgcatc aggagttccc <br>atcaggcaca gaatttacac ttactatatc atcactccaa <br>ttactgccaa caatacgatt tttttccaag cacattcgga <br>ea ag <br>159 <br>60 <br>120 <br>180 <br>240 <br>300 <br>324 EP 2 569 010 B1 <br>Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly <br>l 5 10 15 <br>5 <br>Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Val Thr Ser Ser <br>20 25 30 <br>10 <br>Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu <br>35 40 45 <br>Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Va l Pro Ser Arg Phe Ser <br>15 <br>50 55 60 <br>Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln <br>65 70 75 80 <br>20 <br>Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Phe Phe Pro <br>85 90 95 <br>25 <br>Ser Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys <br>100 105 <br><210> 181 <br>30 <211> 363 <br><212> DNA <br>35 <br>40 <br>45 <br>50 <br>55 <br><213> Mus musculus <br><400> 181 <br>gaggtgcagc <br>agttgcaaag <br>cctggacaaa <br>aatcataaat <br>atggaacttt <br>gccgttatta <br>ag t <br><210> 182 <br><211 > 121 <br><212> PRT <br>tggtgcagag <br>catctggata <br>gacttgaatg <br>ttaaaggaag <br>cctcattgag <br>ctactaacgc <br><213> Mus musculus <br><400> 182 <br>cggcgccgag gtcaagaaac ctggagcaag cgtaaaggtt <br>cacatttacc gactactaca tgaattgggt acgacaagcc <br>gatgggagac attaaccctt ataacgacga cactacatac <br>agttacaatt acaagagata catccgcatc aaccgcctat <br>atct gaagac act gctgttt attactgtgc aagagaaact <br>tatggattac tggggtcaag gaaccactgt taccgtctct <br>160 <br>60 <br>120 <br>180 <br>240 <br>300 <br>360 <br>363 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>EP 2 569 010 B1 <br>Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala <br>l 5 10 15 <br>Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr <br>20 25 30 <br>Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met <br>35 40 45 <br>Gly Asp Ile Asn Pro Tyr Asn Asp Asp Thr Thr Tyr Asn His Lys Phe <br>50 55 60 <br>Lys Gly Arg Val Thr Il e Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr <br>65 70 75 80 <br>Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys <br>85 90 95 <br>Al a Arg Glu Thr Ala Val Ile Thr Thr Asn Ala Met Asp Tyr Trp Gly <br>100 105 110 <br>Gln Gly Thr Thr Val Thr Val Ser Ser <br><21 0> 183 <br><211> 363 <br>115 120 <br>35 <212> DNA <br><2 13> Artificial Sequence <br><220> <br><223> Humanized antibody sequence <br>40 <br><400> 183 <br>gaggtgcagc tggtgcagag cggcgccgag gtcaagaaac ctggagcaag cgtaaaggtt <br>45 <br>agttgcaaag catctggata cacatttacc gactactaca tgaattgggt acgacaagcc <br>cctggacaaa gacttgaatg gat gggagac attaaccctt ataacgacga cactacatac <br>50 <br>aatcataaat ttaaaggaag agttacaatt acaagagata catccgcatc aaccgcctat <br>atggaacttt cctcattgag atctgaagac actgctgttt attactgtgc aagagaaact <br>gccgttatta ctactaacgc tatggattac tggggtcaag gaaccactgt taccgtctct <br>55 <br>ag t <br><2 10> 184 <br>161 <br>60 <br>120 <br>180 <br>240 <br>300 <br>360 <br>363 <211>215 <br><212> PRT <br><213> Artificial Sequence <br>EP 2 569 010 B1 <br>5 <220> <br><223> Humanized antibody sequence <br><400> 184 <br>10 <br>Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly <br>l 5 10 15 <br>15 <br>Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Val Thr Ser Ser <br>20 25 30 <br>Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu <br>20 <br>35 40 45 <br>Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser <br>50 55 60 <br>25 <br>Gly Ser Gly Ser Gly Thr Glu Ph e Thr Leu Thr Ile Ser Ser Leu Gln <br>65 70 75 80 <br>30 <br>Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Phe Phe Pro <br>85 90 95 <br>35 <br>Ser Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala <br>100 105 110 <br>Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser <br>40 <br>45 <br>50 <br>55 <br>162 5 <br>10 <br>15 <br>20 <br>25 <br>EP 2 569 010 81 <br>115 120 125 <br>Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu <br>130 135 140 <br>Ala Lys Va l Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser <br>145 150 155 160 <br>Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu <br>165 170 175 <br>Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val <br>180 185 190 <br>Tyr Ala Cys Glu Va l Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys <br>195 200 205 <br>Ser Phe Asn Arg Gly Glu Cys <br><210> 185 <br><211> 1341 <br>210 215 <br>30 <212> DNA <br><213> Artificial Sequence <br><220> <br><223> Humanized antibody sequence <br>35 <br><400> 185 <br>40 <br>45 <br>50 <br>55 <br>163 EP 2 569 010 81 <br>gaggtgcagc tggtgcagag cggcgccgag gtcaagaaac ctggagcaag cgtaaaggtt 60 <br>agttgcaaag catctggata cacatttacc gactactaca tgaattgggt acgacaagcc 120 <br>5 <br>cctggacaaa gacttgaatg gatgggagac attaaccctt ataacgacga cactacatac 180 <br>aatcataaat ttaaaggaag agttacaatt acaagagata catccgcatc aaccgcctat 240 <br>10 <br>atggaacttt cctcattgag atctgaagac actgctgttt attactgtgc aagagaaact 300 <br>gccgttatta ctactaacgc tatggattac tggggtcaag gaaccactgt taccgtctct 360 <br>agtgcctcca ccaagggccc atcggtcttc cccctggcgc cctgctccag gagcacctcc 420 <br>15 <br>gagagcacag cggccctggg ctgcctggtc aaggactact tccccgaacc ggtgacggtg 480 <br>tcgtggaact caggcgctct gaccagcggc gtgcacacct tcccagctgt cctacagtcc 540 <br>20 <br>tcaggactct actccctcag cagcgtggtg accgtgccct ccagcaactt cggcacccag 600 <br>acctacacct gcaacgtaga tcacaagccc agcaacacca aggtggacaa gacagttgag 660 <br>cgcaaatgtt gtgtcgagtg cccaccgtgc ccagcaccac ctgtggcagg accgtcagtc 720 <br>25 <br>ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcacg 780 <br>tgcgtggtgg tggacgtgag ccacgaagac cccgaggtcc agttcaactg gtacgtggac 840 <br>30 <br>ggcgtggagg tgcataatgc caagacaaag ccacgggagg agcagttcaa cagcacgttc 900 <br>cgtgtggtca gcgtcctcac cgttgtgcac caggactggc tgaacggcaa ggagtacaag 960 <br>35 <br>tgcaaggtct ccaacaaagg cctcccagcc cccatcgaga aaaccatctc caaaaccaaa 1020 <br>gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag 1080 <br>aaccaggtca gcctgacctg cctggtcaaa ggcttctacc ccagcgacat cgccgtggag 1140 <br>40 <br>tgggagagca atgggcagcc ggagaacaac tacaagacca cacctcccat gctggactcc 1200 <br>gacggctcct tcttcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg 1260 <br>45 <br>aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc 1320 <br>ctctccctgt ctccgggtaa a 1341 <br><210> 186 <br>50 <br><211> 447 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>55 <br><223> Humanized antibody sequence <br><400> 186 <br>164 EP 2 569 010 81 <br>Glu Val Gl n Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala <br>l 5 10 15 <br>5 <br>Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr <br>20 25 30 <br>10 <br>Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met <br>35 40 45 <br>Gly Asp Ile Asn Pro Tyr Asn Asp Asp Thr Thr Tyr Asn His Lys Phe <br>15 <br>50 55 60 <br>Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr <br>65 70 75 80 <br>20 <br>Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Va l Tyr Tyr Cys <br>85 90 95 <br>25 <br>Ala Arg Glu Thr Ala Val Ile Thr Thr Asn Ala Met Asp Tyr Trp Gly <br>100 10 5 110 <br>30 Gln Gly Thr Tbr Val Tbr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser <br>35 <br>40 <br>45 <br>50 <br>55 <br>165 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>115 120 125 <br>Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala <br>130 135 140 <br>Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val <br>145 150 155 160 <br>Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala <br>165 170 175 <br>Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Va l <br>180 185 190 <br>Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His <br>195 200 205 <br>Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys Cys <br>210 215 220 <br>Val Glu Cys Pro Pro Cys Pro Al a Pro Pro Val Ala Gly Pro Ser Va l <br>225 230 235 24 0 <br>Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr <br>245 250 255 <br>Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu <br>260 265 270 <br>Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys <br>275 280 285 <br>Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser <br>290 295 300 <br>Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys <br>305 310 315 320 <br>Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile <br>325 330 335 <br>Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro <br>340 345 350 <br>Pro Ser Arg Glu G1u Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu <br>166 <br>r 5 <br>10 <br>15 <br>20 <br>EP 2 569 010 81 <br>355 360 365 <br>Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn <br>370 375 380 <br>Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser <br>385 390 395 400 <br>Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg <br>405 410 415 <br>Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu <br>420 425 430 <br>His Asn His Tyr Thr Gl n Lys Ser Leu Ser Leu Ser Pro Gly Lys <br>435 440 445 <br><210> 187 <br>25 <211> 12 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>30 <223> Ab-17 and Ab-18 LCDR1 <br><400> 187 <br>35 <br>Ser Val Ser Ser Ser I l e Ser Ser Ser Asn Leu His <br>l 5 10 <br><210> 188 <br><211 > 7 <br>40 <212> PRT <br>45 <br>50 <br><213> Artificial Sequence <br><220> <br><223> Ab-17 and Ab-18 LCDR2 <br><400> 188 <br><210> 189 <br><211 > 8 <br><212> PRT <br>55 <213> Artificial Sequence <br><220> <br><223> LCDR3 <br>Gl y Thr Ser Asn Leu Al a Ser <br>l 5 <br>167 5 <br><400> 189 <br><210> 190 <br><211> 5 <br><212> PRT <br>10 <213> Artificial Sequence <br><220> <br><223> Ab-17 and Ab-18 HCDR1 <br>15 <400> 190 <br>20 <br>25 <br>30 <br><210> 191 <br><211> 17 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-17 and Ab-18 HCDR2 <br><400> 191 <br>EP 2 569 010 81 <br>Gln Gln Trp Thr Thr Thr Tyr Thr <br>l 5 <br>Asp Tyr Tyr Ile Hi s <br>l 5 <br>Arg Ile Asp Pro Asp Asn Gly Glu Ser Thr Tyr Val Pro Lys Phe Gln <br>35 <br>l 5 10 15 <br>Gly <br><210> 192 <br><211> 13 <br>40 <212> PRT <br>45 <br>50 <br><213> Artificial Sequence <br><220> <br><223> Synthetic peptide <br><400> 192 <br><210> 193 <br><211> 390 <br><212> DNA <br>Gl u Gly Le u Asp Tyr Gly Asp Tyr Tyr Ala Val Asp Tyr <br>l 5 10 <br>55 <213> Mus musculus <br><400> 193 <br>168 5 <br>10 <br>15 <br>EP 2 569 010 81 <br>atggattttc aggtgcagat tttcagcttc atgctaatca gtgtcacagt catattgtcc 60 <br>agtggagaaa ttgtgctcac ccagtctcca gcactcatgg ctgcatctcc aggggagaag 120 <br>gtcaccatca cctgcagtgt cagc t cgagt ataagttcca gcaacttaca ctggtcccag 180 <br>cagaagtcag gaacctcccc caaactctgg atttatggca catccaacct tgcttctgga 240 <br>gtccc t gttc gcttcagtgg cagtggatct gggacctctt attctctcac aatcagcagc 300 <br>atggaggctg aagatgctgc cacttattac tgtcaacagt ggactactac g t atacgt t c 36 0 <br>ggatcgggga ccaagctgga gctgaaacgt <br><210> 194 <br><21 1> 130 <br><212> PRT <br>390 <br>20 <2 13> Mus muscu lus <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br><400> 194 <br>Met Asp Phe Gln Val Gln Ile Phe Ser Phe Met Leu Ile Ser Val Thr <br>l 5 10 15 <br>Val Ile Leu Ser Ser Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Leu <br>20 25 30 <br>Met Ala Ala Ser Pro Gl y Glu Lys Val Thr Ile Thr Cys Ser Val Ser <br>35 40 45 <br>Ser Ser Ile Ser Ser Ser Asn Leu His Trp Ser Gln Gl n Lys Ser Gly <br>50 55 60 <br>Thr Ser Pro Lys Leu Trp Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly <br>65 70 75 80 <br>Val Pro Val Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu <br>85 90 95 <br>Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln <br>100 105 110 <br>Gl n Trp Thr Thr Thr Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Leu <br>Lys Arg <br>130 <br>115 120 125 <br>169 EP 2 569 010 81 <br><210> 195 <br><211 > 423 <br><21 2> DNA <br><21 3> Mus musculus <br>5 <br><400> 195 <br>atgggatgga actggatcat cttcttcctg atggcagtgg ttacaggggt caattcagag 60 <br>10 <br>gtgcagttgc ggcagtctgg ggcagacctt gtgaagccag gggcctcagt caagttgtcc 120 <br>tgcacagctt ctggcttcaa cattaaagac tactatatac actgggtgaa gcagaggcct 180 <br>15 <br>gaacagggcc tggagtggat tggaaggatt gatcctgata atggtgaaag tacatatgtc 240 <br>ccgaagttcc agggcaaggc cactataaca gcagacacat catccaacac agcctaccta 300 <br>caactcagaa gcctgacatc tgaggacact gccatctatt attgtgggag agaggggctc 360 <br>20 <br>gactatggtg actactatgc tgtggactac tggggtcaag gaacctcggt cacagtctcg 420 <br>age 423 <br>25 <br><210> 196 <br><211 > 141 <br><212> PRT <br><213> Mus musculus <br>30 <br><400> 196 <br>35 <br>40 <br>45 <br>50 <br>55 <br>170 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>EP 2 569 010 81 <br>Met Gly Trp Asn Trp Ile Ile Phe Phe Leu Met Ala Val Val Thr Gly <br>l 5 10 15 <br>Val Asn Ser Glu Val Gln Leu Arg Gln Ser Gl y Ala Asp Leu Val Lys <br>20 25 30 <br>Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile <br>35 40 45 <br>Lys Asp Tyr Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gl y Leu <br>50 55 60 <br>Glu Trp Ile Gly Arg Ile Asp Pro Asp Asn Gly Glu Ser Thr Tyr Val <br>65 70 75 80 <br>Pro Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn <br>85 90 95 <br>Thr Ala Tyr Leu Gln Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Ile <br>100 105 110 <br>Tyr Tyr Cys Gly Arg Glu Gly Leu Asp Tyr Gly Asp Tyr Tyr Ala Val <br>115 120 125 <br>Asp Tyr Trp Gly Gln Gl y Thr Ser Val Thr Val Ser Ser <br><210> 197 <br><2 11 > 390 <br><212> DNA <br>130 135 140 <br>40 <213> Artificial Sequence <br><220> <br><223> Humanized antibody sequence <br>45 <400> 197 <br>50 <br>55 <br>171 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>atggatatgc <br>cgctgcgata <br>gtgaccatta <br>cagaaaccgg <br>gtgccgagcc <br>ctgcagccgg <br>ggccagggca <br><210> 198 <br><211> 130 <br><212> PRT <br>gcgtgccggc <br>ttcagctgac <br>cctgcagcgt <br>gcaaagcgcc <br>gctttagcgg <br>aagattttgc <br>ccaaactgga <br>EP 2 569 010 81 <br>gcagctgctg ggcctgctgc tgctgtggct gccgggcgcg <br>ccagagcccg agctttctga gcgcgagcgt gggcgatcgc <br>gagcagcagc attagcagca gcaacctgca ttggtatcag <br>gaaactgctg atttatggca ccagcaacct ggcgagcggc <br>cagcggcagc ggcaccgaat ttaccctgac cattagcagc <br>gacctattat tgccagcagt ggaccaccac eta tacet tt <br>aattaaacgt <br><213> Artificial Sequence <br><220> <br><223> Humanized antibody sequence <br><400> 198 <br>Met Asp Met Arg Val Pro Ala Gl n Leu Leu Gly Leu Leu Leu Leu Trp <br>l 5 10 15 <br>Leu Pro Gly Ala Arg Cys Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe <br>20 25 30 <br>Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Ser Val Ser <br>35 40 45 <br>Ser Ser Ile Ser Ser Ser Asn Leu His Trp Tyr Gln Gln Lys Pro Gly <br>50 55 60 <br>Lys Ala Pro Lys Leu Leu Ile Tyr , Gly Thr Ser Asn Leu Ala Ser Gly <br>65 70 75 80 <br>Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu <br>85 90 95 <br>Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln <br>100 105 110 <br>Gln Trp Thr Thr Thr Tyr Thr Ph e Gly Gln Gly Thr Lys Leu Glu Ile <br>172 <br>( <br>60 <br>120 <br>180 <br>240 <br>300 <br>360 <br>390 EP 2 569 010 B1 <br>115 120 125 <br>5 <br>Lys Arg <br>13 0 <br><210> 199 <br><211> 423 <br>10 <br><212> DNA <br><213> Artificial Sequence <br><220> <br><223> Humanized antibody sequence <br>15 <br><400> 199 <br>atggattgga cctggagcat tctgtttctg gtggcggcgc cgac cggcgc gcatagcgaa 60 <br>20 <br>gtgcagctgg tgcagagcgg cgcggaagtg aaaaaaccgg gcgcgagcgt gaaagtgagc 120 <br>tgcaaagcga gcggctttaa cattaaagat tattatattc attgggtgcg ccaggcgccg 180 <br>25 <br>ggccagggcc tggaatggat gggccgcatt gatccggata a cggcgaaag cacctatgtg 240 <br>ccgaaatttc agggc cgcgt gaccatgacc accgatacca gcaccagcac cgcgtat atg 3 00 <br>gaactgcgca gcctgcgcag cgat gatacc gcggtgtatt attgcgcgcg cgaaggcctg 360 <br>30 <br>gattatggcg attattatgc ggtggattat tggggccagg gcaccctggt gaccgtctcg 420 <br>age 423 <br>35 <210> 200 <br><211> 141 <br><212> PRT <br><213> Artificial Sequence <br>40 <br><220> <br><223> Humanized antibody sequence <br><400> 200 <br>45 <br>50 <br>55 <br>173 EP 2 569 010 81 <br>Met Asp Trp Thr Trp Ser Ile Leu Phe Leu Val Ala Ala Pro Thr Gly <br>l 5 10 15 <br>5 <br>Al a His Ser Glu Val Gl n Leu Va l Gln Ser Gl y Ala Glu Val Lys Lys <br>20 25 30 <br>10 <br>Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile <br>35 40 45 <br>Lys Asp Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu <br>15 <br>50 55 60 <br>Glu Trp Met Gly Arg I l e Asp Pro Asp Asn Gly Glu Ser Thr Tyr Val <br>20 <br>65 70 75 80 <br>Pro Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser <br>25 <br>85 90 95 <br>Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val <br>100 105 110 <br>30 <br>Tyr Tyr Cys Ala Arg Glu Gly Leu Asp Tyr Gly Asp Tyr Tyr Ala Val <br>115 120 125 <br>35 <br>Asp Tyr Trp Gly Gln Gl y Thr Leu Val Thr Val Ser Ser <br>130 135 140 <br><210> 201 <br>40 <211> 11 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>45 <223> Ab-19, Ab-20 and Ab-23 LCDR1 <br><400> 201 <br>50 <br>Arg Ala Ser Gln Asp Ile Ser Ser Tyr Leu Asn <br><210> 202 <br><211> 7 <br>55 <212> PRT <br>l 5 10 <br><213> Artificial Sequence <br><220> <br>174 EP 2 569 010 81 <br><223> Ab-19, Ab-20 and Ab-23 LCDR2 <br><400> 202 <br>5 <br>Ser Thr Ser Arg Leu Asn Ser <br><210> 203 <br>10 <211> 8 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>l <br>15 <223> Ab-19, Ab-20 and Ab-23 LCDR3 <br><400> 203 <br>5 <br>20 <br>Gln Gln Asp Ile Lys His Pro Thr <br>l 5 <br><210> 204 <br><211> 5 <br>25 <212> PRT <br>30 <br>35 <br><213> Artificial Sequence <br><220> <br><223> Ab-19, Ab-20 and Ab-23 HCDR1 <br><400> 204 <br><210> 205 <br><211>17 <br><212> PRT <br>40 <213> Artificial Sequence <br><220> <br><223> Ab-19, Ab-20 and Ab-23 HCDR2 <br>45 <400> 205 <br>Asp Tyr Il e Met His <br>l 5 <br>Tyr Ile Asn Pro Ty r Asn Asp Asp Thr Glu Tyr As n Glu Lys Phe Lys <br>l 5 10 15 <br>so <br>Gly <br><210> 206 <br>55 <211> 11 <br><212> PRT <br><213> Artificial Sequence <br>175 EP 2 569 010 81 <br><220> <br><223> Ab-19, Ab-20 and Ab-23 HCDR3 <br><400> 206 <br>5 <br>Ser Ile Ty r Tyr Tyr Asp Ala Pro Phe Ala Tyr <br>l 5 10 <br>10 <210> 207 <br><211> 107 <br><212> PRT <br><213> Mus musculus <br>15 <400> 207 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>Asp Ile Gln Met Th r Gl n Thr Thr Ser Ser Le u Ser Al a Ser Leu Gly <br>l 5 10 15 <br>Asp Arg Val Asn I l e Ser Cys Ar g Ala Ser Gln Asp I le Ser Ser Tyr <br>20 25 30 <br>Leu Asn Trp Tyr Gln Gln Lys Pr o As p Gly Thr Val Lys Leu Leu I l e <br>35 40 45 <br>Tyr Ser Thr Ser Arg Leu Asn Ser Gly Va l Pro Ser Arg Phe Ser Gly <br>50 55 60 <br>Ser Gly Ser Gl y Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Ala Gl n <br>65 70 75 80 <br>Glu Asp I le Ala Th r Tyr Phe Cys Gln Gln Asp Ile Lys His Pro Thr <br>85 90 95 <br>Phe Gl y Gl y Gly Thr Ly s Leu Glu Leu Lys Arg <br><210> 208 <br><211> 120 <br><212> PRT <br>100 105 <br>50 <213> Mus musculus <br><400> 208 <br>55 <br>176 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>EP 2 569 010 81 <br>Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala <br>l 5 10 15 <br>Ser Val Lys Met Ser Cys Lys Ala Ser Gl y Phe Thr Phe Thr Asp Tyr <br>20 25 30 <br>Ile Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile <br>35 40 45 <br>Gly Tyr I l e Asn Pro Tyr Asn Asp Asp Thr Glu Tyr Asn Glu Lys Phe <br>50 55 6 0 <br>Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr <br>65 70 75 80 <br>Met Asp Leu Ser Ser Leu Thr Ser Glu Gly Ser Ala Val Tyr Tyr Cys <br>85 90 95 <br>Ala Arg Ser Ile Tyr Tyr Tyr Asp Ala Pro Phe Ala Tyr Trp Gly Gl n <br>100 105 110 <br>Gly Thr Leu Val Thr Val Ser Ser <br><210> 209 <br><211> 381 <br>115 120 <br>35 <212> DNA <br><213> Mus musculus <br><400> 209 <br>40 <br>atgatgtcct ctgctcagtt ccttggtctc ctgttgctct gttttcaagg taccagatgt <br>gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcaac <br>45 <br>atcagctgca gggcaagtca ggacattagc agttatttaa actggtatca gcagaaacca <br>gatggaactg ttaaactcct gatctactcc acatcaagat taaactcagg agtcccatca <br>aggttcagtg gcagtgggtc tgggacagat tattctctca ctattagcaa cctggcacaa <br>50 <br>gaagatattg ccacttactt ttgccaacag gatattaagc atccgacgtt cggtggaggc <br>accaagttgg agctgaaacg t <br>55 <br><210> 210 <br><211> 127 <br><2 12> PRT <br><213> Mus musculus <br>177 <br>60 <br>120 <br>180 <br>240 <br>300 <br>360 <br>381 EP 2 569 010 81 <br><400> 210 <br>Met Met Ser Ser Ala Gl n Ph e Leu Gly Leu Leu Leu Leu Cys Phe Gl n <br>l 5 10 15 <br>5 <br>Gly Thr Arg Cys Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser <br>20 25 30 <br>10 <br>Ala Ser Leu Gly Asp Arg Val Asn Ile Ser Cys Arg Ala Ser Gln Asp <br>35 40 45 <br>15 <br>I le Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val <br>50 55 60 <br>20 <br>Lys Leu Leu Ile Tyr Ser Thr Ser Arg Leu Asn Ser Gly Val Pro Ser <br>65 70 75 80 <br>Arg Phe Ser Gly Ser Gl y Ser Gl y Thr Asp Tyr Ser Leu Thr Ile Ser <br>25 <br>85 90 95 <br>Asn Leu Ala Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Asp Ile <br>100 105 110 <br>30 <br>Lys His Pro Thr Phe Gl y Gly Gl y Thr Lys Leu Glu Leu Lys Arg <br>115 120 125 <br>35 <210> 211 <br><211> 417 <br><212> DNA <br><21 3> Mus musculus <br>40 <400> 211 <br>atggaatgga tctggatatt tctcttcctc ctgtcaggaa ctgcaggtgt ccactctgag <br>45 <br>gtccagctgc agcagtctgg acctgagctg gtaaagcctg gggcttcagt gaagatgtcc <br>tgcaaggctt ctgggttcac attcactgac tacattatgc actgggtgaa gcagaagcct <br>gggcagggcc ttgagtggat tggatatatt aatccttaca atgatgatac tgaatacaat <br>50 <br>gagaagttca aaggcaaggc cacactgact tcagacaaat cctccagcac agcctacatg <br>ga tet cagea gtctgacctc tgagggctct gcggtctatt actgtgcaag atcgatttat <br>55 <br>tactacgatg ccccgtttgc ttactggggc caagggactc tggtcacagt ctcgagc <br><210> 212 <br><211 > 139 <br>178 <br>60 <br>120 <br>180 <br>240 <br>300 <br>360 <br>417 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>EP 2 569 010 81 <br><212> PRT <br><213> Mus musculus <br><400> 212 <br>Met Glu Trp Ile Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly <br>l 5 10 15 <br>Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys <br>20 25 30 <br>Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Phe Thr Phe <br>35 40 45 <br>Thr Asp Tyr Ile Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu <br>50 55 60 <br>Glu Trp Ile Gly Tyr Ile Asn Pro Tyr Asn Asp Asp Thr Glu Tyr Asn <br>65 70 75 80 <br>Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser <br>85 90 95 <br>Thr Ala Tyr Met Asp Leu Ser Ser Leu Thr Ser Glu Gly Ser Ala Val <br>100 105 110 <br>Tyr Tyr Cys Ala Arg Ser Ile Tyr Tyr Tyr Asp Ala Pro Phe Ala Tyr <br>115 120 125 <br>Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser <br><210> 213 <br><211> 381 <br><212> DNA <br>130 135 <br>45 <213> Artificial Sequence <br><220> <br><223> Humanized antibody sequence <br>50 <400> 213 <br>55 <br>179 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>atgatgtcct <br>gatatccaga <br>atcacttgcc <br>gggaaagccc <br>cgcttcagtg <br>gaagattttg <br>accaaggtgg <br><210> 214 <br><211> 127 <br><212> PRT <br>ctgctcagtt <br>tgacccagtc <br>gcgcaagtca <br>ctaagctcct <br>gcagtggctc <br>caacttacta <br>agatcaaacg <br>EP 2 569 010 B1 <br>ccttggtctc ctgttgctct gttttcaagg taccagatgt <br>tccatcctcc ctgtctgcat ctgtaggtga ccgtgtcacc <br>ggatattagc agctatttaa attggtatca gcagaaacca <br>gatctattct acttcccgtt tgaatagtgg ggtcccatca <br>tgggacagat ttcactctca ccatcagcag tctgcaacct <br>ctgtcaacag gatattaaac accctacgtt cggtcaaggc <br>t <br><213> Artificial Sequence <br><220> <br><223> Humanized antibody sequence <br><400> 214 <br>Met Met Ser Ser Ala Gln Phe Leu Gly Leu Leu Leu Leu Cys Phe Gln <br>l 5 10 15 <br>Gly Thr Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser <br>20 25 30 <br>Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp <br>35 40 45 <br>Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro <br>50 55 60 <br>Lys Leu Leu Ile Tyr Ser Thr Ser Arg Leu Asn Ser Gly Val Pro Ser <br>65 70 75 80 <br>Arg Phe Ser Gl y Ser Gly Ser Gl y Thr Asp Phe Thr Leu Thr Ile Ser <br>85 90 95 <br>Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Asp Ile <br>100 105 110 <br>Lys His Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg <br>115 120 125 <br>180 <br>.. <br>60 <br>120 <br>180 <br>240 <br>300 <br>360 <br>381 5 <br>10 <br>15 <br>20 <br><210> 215 <br><211> 417 <br><212> DNA <br><213> Mus musculus <br><400> 215 <br>atggaatgga <br>gtgcagctgg <br>tgcaaggctt <br>ggtcaagggc <br>gagaagttca <br>gagctgagca <br>tactacgatg <br><210> 216 <br><211> 139 <br>tctggatatt <br>tgcagtctgg <br>ctggttttac <br>ttgagtggat <br>agggccgtgt <br>gcctgcgctc <br>ccccgtttgc <br>EP 2 569 010 81 <br>tctcttcctc ctgtcaggaa ctgcaggtgt ccactctgag <br>ggctgaggtg aagaagcctg ggtcctcggt gaaggtctcc <br>cttcaccgac tatattatgc actgggtgcg tcaggcccct <br>gggctatatc aacccttata atgatgacac cgaatacaac <br>cacgattacc gcggacaaat ccacgagcac agcctacatg <br>tgaggacacg gccgtgtatt actgtgcgcg ttcgatttat <br>ttactggggc caagggactc tggtcacagt ctcgagc <br>25 <212> PRT <br><213> Artificial Sequence <br><220> <br><223> Humanized antibody sequence <br>30 <br><400> 216 <br>Met Glu Trp Ile Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly <br>35 <br>l 5 10 15 <br>Val His Ser Glu Va l Gln Leu Va l Gln Ser Gl y Ala Glu Val Lys Lys <br>20 25 30 <br>40 <br>Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe <br>35 40 45 <br>45 <br>Thr Asp Tyr Ile Met His Trp Val Arg Gln Al a Pro Gly Gln Gly Leu <br>50 55 60 <br>50 <br>Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn Asp Asp Thr Glu Tyr Asn <br>65 70 75 80 <br>Glu Lys Phe Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser <br>55 85 90 95 <br>181 <br>60 <br>120 <br>180 <br>240 <br>300 <br>360 <br>417 5 <br>10 <br>EP 2 569 010 81 <br>Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val <br>100 105 110 <br>Tyr Tyr Cys Ala Arg Ser Ile Tyr Tyr Tyr Asp Ala Pro Phe Al a Tyr <br>11 5 120 125 <br>Trp Gly Gln Gly Th r Leu Val Thr Va l Ser Ser <br><210> 217 <br><211> 318 <br>130 135 <br>15 <212> DNA <br>20 <br>25 <br>30 <br><213> Mus musculus <br><400> 217 <br>gacatccaga <br>atcacttgcc <br>gggaaagccc <br>cgcttcagtg <br>gaagat tttg <br>accaaggtgg <br><210> 218 <br><211> 106 <br>tgacccagtc <br>g cgcaagtca <br>ctaagctcct <br>g cagtggctc <br>caacttacta <br>agatcaaa <br>35 <212> PRT <br><213> Mus musculus <br><400> 218 <br>40 <br>45 <br>50 <br>55 <br>tccatcctcc ctgtctgcat ctgtaggtga ccgtgtcacc <br>ggat attagc agctatttaa a t tggtatca gcagaaacca <br>gatctattct acttcccgtt tgaatagtgg ggtcccatca <br>tgggacagat ttcactctca c c atcagcag tctgcaacct <br>ctgtcaacag gatattaaac accctacgt t cggtcaaggc <br>182 <br>60 <br>120 <br>180 <br>240 <br>300 <br>318 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>Asp Ile Gln Met Thr Gl n Ser Pro Ser Ser Leu Ser Ala Ser Val Gly <br>l 5 10 15 <br>Asp Arg Va l Thr Ile Thr Cys Arg Ala Ser Gl n Asp Ile Ser Ser Tyr <br>20 25 30 <br>Leu Asn Trp Tyr Gln Gl n Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile <br>35 40 45 <br>Tyr Ser Thr Ser Arg Leu Asn Ser Gly Va l Pro Ser Arg Phe Ser Gl y <br>50 55 60 <br>Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Il e Ser Ser Leu Gl n Pr o <br>65 70 75 80 <br>Gl u Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Asp Ile Lys His Pro Thr <br>85 90 <br>Phe Gly Gln Gly Thr Lys Val Gl u I l e Lys <br>100 105 <br><21 0> 219 <br><2 11 > 360 <br><212> DNA <br><213> Mus musculus <br><400> 219 <br>gaggtgcagc tggtgcagtc <br>tcctgcaagg cttctggttt <br>cctggtcaag ggcttgagtg <br>aacgagaagt tcaagggccg <br>atggagctga gcagcctgcg <br>tattact acg atgccccgtt <br><21 0> 220 <br><2 11 > 120 <br><212> PRT <br><213> Mus musculus <br><400> 220 <br>tggggctgag gtgaagaagc <br>tacet t cace gactatatta <br>gatgggctat atcaaccctt <br>tgtcacgatt accgcggaca <br>ctct gaggac acggccgtgt <br>tgcttactgg ggccaaggga <br>183 <br>c t gggtcctc <br>tgcactgggt <br>ataatgatga <br>aatccacgag <br>att actgtgc <br>ctct ggtcac <br>95 <br>ggtgaaggtc <br>gcgtcaggcc <br>caccgaatac <br>cacagcctac <br>gcgttcgatt <br>cgtctctagt <br>60 <br>120 <br>180 <br>240 <br>300 <br>360 EP 2 569 010 81 <br>Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser <br>l 5 10 15 <br>5 <br>Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Asp Tyr <br>20 25 30 <br>10 <br>Ile Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met <br>35 40 45 <br>Gly Tyr Ile Asn Pro Tyr Asn Asp Asp Thr Glu Tyr Asn Glu Lys Phe <br>15 <br>50 55 60 <br>Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr <br>65 70 75 80 <br>20 <br>Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys <br>85 90 95 <br>25 <br>Ala Arg Ser Il e Tyr Tyr Tyr Asp Ala Pro Phe Ala Tyr Trp Gly Gln <br>100 105 110 <br>30 Gly Thr Leu Val Thr Val Ser Ser <br>115 120 <br>35 <210> 221 <br><211> 639 <br><212> DNA <br><213> Mus musculus <br>40 <400> 221 <br>45 <br>50 <br>55 <br>184 <br>• ... <br>EP 2 569 010 B1 <br>gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggtga ccgtgtcacc 60 <br>atcacttgcc gcgcaagtca ggatattagc agctatttaa attggtatca gcagaaacca 120 <br>5 <br>gggaaagccc ctaagctcct gatctattct acttcccgtt tgaatagtgg ggtcccatca 180 <br>cgcttcagtg gcagtggctc tgggacagat ttcactctca ccatcagcag tctgcaacct 240 <br>10 <br>gaagattttg caacttacta ctgtcaacag gatattaaac accctacgtt cggtcaaggc 300 <br>accaaggtgg agatcaaacg tacggtggct gcaccatctg tcttcatctt cccgccatct 360 <br>gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc 420 <br>15 <br>agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag 480 <br>agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg 540 <br>20 <br>agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg 600 <br>agctcgcccg tcacaaagag cttcaacagg ggagagtgt 639 <br><210> 222 <br>25 <br><211> 213 <br><212> PRT <br><213> Mus musculus <br><400> 222 <br>30 <br>As p Ile Gln Met T hr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly <br>l 5 lO 15 <br>35 <br>Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp I l e Ser Ser Tyr <br>20 25 30 <br>40 <br>Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile <br>35 40 45 <br>Tyr Ser Thr Ser Arg Leu Asn Ser Gly Val Pro Ser Arg Phe Ser Gly <br>45 <br>50 55 60 <br>Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro <br>65 70 75 80 <br>50 <br>Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Asp Ile Lys His Pro Thr <br>55 <br>185 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br>85 90 95 <br>Phe Gly Gl n Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro <br>100 105 110 <br>Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr <br>115 120 125 <br>Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys <br>130 135 140 <br>Val Gln Trp Lys Va l Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu <br>145 150 155 160 <br>Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser <br>165 170 175 <br>Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala <br>180 185 190 <br>Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe <br>195 200 205 <br>Asn Arg Gly Glu Cys <br>210 <br><210> 223 <br><211> 1338 <br><212> DNA <br><213> Mus musculus <br><400> 223 <br>186 EP 2 569 010 81 <br>gaggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60 <br>tcctgcaagg cttctggttt taccttcacc gactatatta tgcactgggt gcgtcaggcc 120 <br>5 <br>cctggtcaag ggcttgagtg gatgggctat atcaaccctt ataatgatga caccgaatac 180 <br>aacgagaagt tcaagggccg tgtcacgatt accgcggaca aat ccacgag cacagcctac 240 <br>10 <br>atggagctga gcagcctgcg ctctgaggac acggccgtgt attactgtgc gcgttcgatt 300 <br>tattactacg atgccccgtt tgcttactgg ggccaaggga ctctggtcac cgtctctagt 360 <br>gcctccacca agggcccatc ggtcttcccc ctggcgccct gct ccaggag cacctccgag 420 <br>15 <br>agcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 480 <br>tggaactcag gcgctct gac cagcggcgtg cacaccttcc cagctgtcct acagtcctca 540 <br>20 <br>ggactctact ccctcagcag cgtggtgacc gtgccctcca gcaacttcgg cacccagacc 600 <br>tacacctgca acgtagatca caagcccagc aacaccaagg tggacaagac agttgagcgc 660 <br>aaatgttgtg tcgagtgccc accgtgccca gcaccacctg tggcaggacc gtcagtcttc 720 <br>25 <br>ctcttccccc caaaacccaa ggacaccctc atgatctccc ggacccctga ggt cacgtgc 780 <br>gtggtggtgg acgtgagcca cgaagacccc gaggtccagt tcaactggta cgtggacggc 840 <br>30 <br>gtggaggtgc ataatgccaa gacaaagcca cgggaggagc agttcaacag cacgttccgt 900 <br>gtggtcagcg tcctcaccgt tgtgcaccag gactggctga acggcaagga gtacaagtgc 960 <br>35 <br>aaggtctcca acaaaggcct cccagccccc atcgagaaaa ccatctccaa aaccaaaggg 1020 <br>cagccccgag aaccacaggt gtacaccctg cccccatccc gggaggagat gaccaagaac 1080 <br>caggtcagcc tgacctgcct ggtcaaaggc ttctacccca gcgacatcgc cgtggagtgg 1140 <br>40 <br>gagagcaatg ggcagccgga gaacaactac aagaccacac ctcccatgct ggactccgac 1200 <br>ggctccttct tcctctacag caagctcacc gtggacaaga gcaggtggca gcaggggaac 1260 <br>45 <br>gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacgca gaagagcctc 1320 <br>tccctgtctc cgggtaaa 1338 <br><210> 224 <br>50 <211> 446 <br><212> PRT <br><213> Mus musculus <br><400> 224 <br>55 <br>187 EP 2 569 010 B1 <br>Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser <br>l 5 10 15 <br>5 <br>Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Asp Tyr <br>20 25 30 <br>10 <br>Ile Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met <br>35 40 45 <br>Gly Tyr Ile Asn Pro Tyr Asn Asp Asp Thr Glu Tyr Asn Glu Lys Phe <br>15 <br>50 55 60 <br>Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr <br>65 70 75 80 <br>20 <br>Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys <br>85 90 95 <br>25 <br>Ala Arg Ser Ile Tyr Tyr Tyr Asp Ala Pro Phe Ala Tyr Trp Gly Gln <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>188 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>100 105 110 <br>Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Va l <br>11 5 120 125 <br>Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala <br>130 135 140 <br>Leu Gly Cys Leu Va l Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser <br>145 150 155 160 <br>Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Va l <br>165 170 175 <br>Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro <br>180 185 190 <br>Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His Lys <br>19 5 200 205 <br>Pro Ser Asn Thr Lys Val Asp Lys Thr Va l Gl u Arg Lys Cys Cys Va l <br>210 215 220 <br>Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe <br>225 230 235 240 <br>Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro <br>245 250 255 <br>Glu Val Thr Cys Va l Val Val Asp Val Ser His Glu Asp Pro Glu Va l <br>260 265 270 <br>Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr <br>275 280 285 <br>Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val <br>290 295 300 <br>Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys <br>305 310 315 320 <br>Lys Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser <br>325 330 335 <br>Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro <br>189 5 <br>10 <br>15 <br>20 <br>25 <br>EP 2 569 010 81 <br>340 345 350 <br>Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Th r Cys Leu Val <br>355 36 0 365 <br>Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly <br>370 375 380 <br>Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp <br>385 390 395 400 <br>Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Tr p <br>405 410 415 <br>Gln Gln Gly Asn Val Phe Ser Cys Ser Va l Met His Glu Ala Leu His <br>420 425 430 <br>Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys <br><210> 225 <br><211> 11 <br>435 440 445 <br>30 <212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-21 and Ab-22 LCDR1 <br>35 <br><400> 225 <br>Lys Ala Ser Gln Asp Val Phe Thr Ala Va l Ala <br>40 <br>l 5 10 <br><210> 226 <br><211>7 <br><212> PRT <br>45 <213> Artificial Sequence <br><220> <br><223> Ab-21 and Ab-22 LCDR2 <br>50 <400> 226 <br>55 <br><210> 227 <br><211 > 9 <br><212> PRT <br>Trp Ala Ser Thr Arg Hi s Thr <br>l 5 <br>190 5 <br>10 <br>EP 2 569 010 81 <br><213> Artificial Sequence <br><220> <br><223> Ab-21 and Ab-22 LCDR3 <br><400> 227 <br><210> 228 <br><211 > 5 <br><212> PRT <br>Gln Gln Tyr Ser Ser Tyr Pro Leu Thr <br>l 5 <br>15 <213> Artificial Sequence <br><220> <br><223> Ab-21 and Ab-22 HCDR1 <br>20 <400> 228 <br>25 <br>30 <br>35 <br>40 <br><210> 229 <br><211>17 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> Ab-21 and Ab-22 HCDR2 <br><400> 229 <br>Asp Tyr Tyr Met His <br>l 5 <br>Arg Ile Asp Pro Glu Asn Gly Asp Ile Ile Tyr Asp Pro Lys Phe Gln <br>l 5 10 15 <br>Gly <br><210> 230 <br><211 > 10 <br>45 <212> PRT <br>50 <br>55 <br><213> Artificial Sequence <br><220> <br><223> Ab-21 and Ab-22 HCDR3 <br><400> 230 <br><210> 231 <br><211 > 381 <br>Asp Ala Gl y Asp Pro Ala Trp Phe Thr Tyr <br>l 5 10 <br>191 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 81 <br><212> DNA <br><213> Mus musculus <br><400> 231 <br>atgaagtcac <br>gacattgtga <br>atcacctgca <br>ggacaatctc <br>cgcttcacag <br>gaagacttgg <br>gggaccaagt <br><210> 232 <br><211> 128 <br><212> PRT <br>agacccaggt ctttgtatac <br>tgacccagtc tcacaaattc <br>aggccagtca ggatgtcttt <br>ctaaactact gatttactgg <br>gcagtggatc tgggacagat <br>cagattattt ctgtcaacaa <br>tggagctgaa a <br>atgttgctgt ggttgtctgg tgttgaagga <br>atgtccacgt cagtaggaga cagggtcacc <br>actgctgtag cctggtatca acagaaacca <br>gcatccaccc ggcacactgg agtccctgat <br>ttcactctca ccattagcaa tgtgcagtct <br>tatagcagct atcctctcac gttcggtgct <br><213> Mus musculus <br><400> 232 <br>Met Lys Ser Gln Thr Gln Val Phe Val Tyr Met Leu Leu Trp Leu Ser <br>l 5 10 15 <br>Gly Val Glu Gly Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser <br>20 25 30 <br>Thr Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp <br>35 40 45 <br>Val Phe Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro <br>50 55 60 <br>Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp <br>65 70 75 80 <br>Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser <br>85 90 95 <br>Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser <br>100 105 110 <br>Ser Tyr Pro Leu Thr Phe Gly Al a Gly Thr Lys Leu Glu Leu Lys Arg <br>115 120 125 <br>192 <br>. . <br>60 <br>120 <br>180 <br>240 <br>300 <br>360 <br>381 .. <br>EP 2 569 010 81 <br><210> 233 <br><211 > 41 1 <br><212> DNA <br><213> Mus musculus <br>5 <br><400> 233 <br>atgggat gga actggatcat cttcttcctg atggcagtgg ttacaggggt caattcagag 60 <br>10 <br>gttcagctgc agcagtctgg ggct gagctt gtgaggccag gggccttagt caagttgtcc 120 <br>tgcaaagctt ctggcttcaa tattaaagac tactatatgc actgggtgaa gcagaggcct 180 <br>15 <br>gaacagggcc tggagtggat tggaaggatt gatcctgaga atggtgatat tatatatgac 240 <br>ccgaagttcc agggcaaggc cagtataaca acagacacat cctccaacac agcctacctg 300 <br>cagctcagca gcctgacgtc tgaggacact gccgtctatt actgtgctta cgatgctggt 360 <br>20 <br>gaccccgcct ggtttactta ctggggccaa gggactctgg tcaccgtctc g 411 <br><210> 234 <br><2 11 > 138 <br>25 <br><212> PRT <br><213> Mus musculus <br><400> 234 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>193 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>EP 2 569 010 81 <br>Met Gly Trp Asn Trp Ile Ile Phe Phe Leu Met Ala Val Val Thr Gly <br>l 5 10 15 <br>Val Asn Ser Glu Va l Gln Leu Gln Gln Ser Gly Ala Gl u Leu Va l Ar g <br>20 25 30 <br>Pro Gly Ala Leu Val Lys Leu Ser Cys Lys Ala Ser Gly Phe Asn Ile <br>35 40 45 <br>Lys Asp Tyr Tyr Met His Trp Va l Lys Gln Arg Pro Glu Gln Gly Leu <br>50 55 60 <br>Glu Trp Ile Gly Arg Ile Asp Pro Glu Asn Gly Asp Ile Ile Tyr Asp <br>65 70 75 80 <br>Pro Lys Phe Gln Gly Lys Ala Ser Ile Thr Thr Asp Thr Ser Ser Asn <br>85 90 95 <br>Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Va l <br>100 105 110 <br>Tyr Tyr Cys Ala Tyr Asp Ala Gly Asp Pro Ala Trp Phe Thr Tyr Trp <br>115 12 0 125 <br>Gly Gln Gly Thr Leu Val Thr Va l Ser Ser <br><210> 235 <br><211>324 <br><212> DNA <br>130 135 <br>40 <213> Mus musculus <br><400> 235 <br>45 <br>gatatccaga tgacccagag cccgagcagc ctgagcgcga gcgtgggcga tcgcgtgacc <br>attacctgca aagcgagcca ggat gtgttt accgcggtgg cgtggtatca gcagaaaccg <br>ggcaaagcgc cgaaactgct gatttattgg gcgagcaccc gccataccgg cgtgccgagt <br>50 <br>cgctttagcg gcagcggcag cggcaccgat tttaccctga ccattagcag cctgcagccg <br>gaagattttg cgacctatta ttgccagcag tatagcagct atccgctgac ctttggcggc <br>55 <br>ggcaccaaag tggaaattaa acgt <br><210> 236 <br><211 > 108 <br>194 <br>60 <br>120 <br>180 <br>240 <br>300 <br>324 EP 2 569 010 81 <br><212> PRT <br><213> Mus musculus <br><400> 236 <br>5 <br>Asp Ile Gl n Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly <br>l 5 10 15 <br>10 <br>Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Phe Thr Ala <br>20 25 30 <br>15 <br>Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile <br>35 40 45 <br>Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Ser Arg Phe Ser Gly <br>20 <br>50 55 60 <br>Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro <br>65 70 75 80 <br>25 <br>Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Ser Tyr Pro Leu <br>85 90 95 <br>30 <br>Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg <br>100 105 <br><2 10> 237 <br>35 <211> 357 <br><212> DNA <br><213> Mus musculus <br><400> 237 <br>40 <br>gaagtgcagc tggtgcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 <br>agctgcaaag cgagcggctt taacattaaa gattattata tgcattgggt gcgccaggcg 120 <br>45 <br>ccgggccagg gcctggaatg gatcggccgc attgatccgg aaaacggcga t attatttat 180 <br>gatccgaaat ttcagggccg cgtgaccatg accaccgata ccagcaccag caccgcgtat 240 <br>50 <br>atggaactgc gcagcctgcg cagcgatgat accgcggtgt attattgcgc gtatgatgcg 300 <br>ggcgatccgg cgtggtttac ctattggggc cagggcaccc tggtgaccgt ctcgagc 357 <br>55 <br><210> 238 <br><211> 119 <br><212> PRT <br><213> Mus musculus <br>195 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>EP 2 569 010 81 <br><400> 238 <br>Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala <br>l 5 10 15 <br>Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr <br>20 25 30 <br>Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile <br>35 40 45 <br>Gly Arg Ile Asp Pro Glu Asn Gly Asp Ile Ile Tyr Asp Pro Lys Phe <br>50 55 60 <br>Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr <br>65 70 75 80 <br>Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys <br>85 90 95 <br>Ala Tyr Asp Ala Gly Asp Pro Ala Trp Phe Thr Tyr Trp Gly Gln Gly <br>100 105 110 <br>Thr Leu Val Thr Va l Ser Ser <br>115 <br>35 <210> 239 <br><211> 15 <br><212> PRT <br><213> Artificial Sequence <br>40 <220> <br><223> Synthetic peptide <br><400> 239 <br>45 <br>Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Thr Ser Tyr Met Asn <br>50 l 5 lO 15 <br><210> 240 <br><211> 7 <br>55 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>196 <223> Synthetic peptide <br><400> 240 <br>5 <br><210> 241 <br>10 <211>9 <br><212> PRT <br><213> Artificial Sequence <br><220> <br>15 <223> Synthetic peptide <br>20 <br><400> 241 <br><210> 242 <br><211> 5 <br>25 <212> PRT <br>30 <br>35 <br><213> Artificial Sequence <br><220> <br><223> Synthetic peptide <br><400> 242 <br><210> 243 <br><211> 17 <br><212> PRT <br>40 <213> Artificial Sequence <br><220> <br><223> Synthetic peptide <br>45 <400> 243 <br>EP 2 569 010 81 <br>Ala Al a Ser Asn Le u Glu Ser <br>l 5 <br>Gln Gl n Ser Asn Gl u Asp Pro Phe Thr <br>l 5 <br>Thr Tyr Trp Met Asn <br>l 5 <br>Met Ile Hi s Pro Ser Ala Ser Gl u Ile Arg Leu Asp Gln Ly s Phe Lys <br>l 5 10 15 <br>50 <br>As p <br><210> 244 <br>55 <211>9 <br><212> PRT <br><213> Artificial Sequence <br>197 EP 2 569 010 81 <br><220> <br><223> Synthetic peptide <br><400> 244 <br>5 <br>Ser Gly Glu Trp Gl y Ser Met Asp Tyr <br>l 5 <br>10 <210> 245 <br><211> 657 <br><212> DNA <br><213> Mus musculus <br>15 <400> 245 <br>gacattgtgt tgacccagtc tccagcttct ttggctgtgt ctctagggca gagggccacc <br>20 <br>atcgcctgca aggccagcca aagtgttgat tatgatggta ctagttatat gaattggtac <br>caacagaaac caggacagcc acccaaactc ctcatctatg ctgcatccaa tctagaatct <br>gagatcccag ccaggtttag tggcactggg tctgggacag acttcaccct caacatccat <br>25 <br>cct gtggagg aggaggatat cacaacctat tact gtcagc aaagtaatga ggatccgttc <br>acgttcggag gggggaccaa g t tggaaata aaacgggctg a t gctgcacc aactgtatcc <br>30 <br>atcttcccac catccagtga gcagttaaca tctggaggtg cct cagtcgt gtgcttcttg <br>aacaacttct accccaaaga catcaatgtc aagtggaaga ttgatggcag tgaacgacaa <br>aatggcgtcc tgaacagttg gact gatcag gacagcaaag acagcaccta cagcatgagc <br>35 <br>agcaccctca cgttgaccaa ggacgagtat gaacgacata acagctatac ctgtgaggcc <br>actcacaaga catcaacttc acccattgtc aagagcttca ac aggaatga gtgt tag <br>40 <br><210> 246 <br><211> 218 <br><212> PRT <br><213> Mus musculus <br>45 <br><400> 246 <br>Asp Ile Va l Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gl y <br>l 5 10 15 <br>50 <br>Gln Arg Ala Tbr Ile Ala Cy s Ly s Ala Ser Gl n Ser Val Asp Tyr Asp <br>20 25 30 <br>55 <br>Gly Thr Ser Tyr Met Asn Trp Ty r Gln Gln Lys Pro Gly Gln Pr o Pr o <br>198 <br>, <br>60 <br>120 <br>180 <br>2 40 <br>300 <br>360 <br>420 <br>480 <br>540 <br>600 <br>657 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>EP 2 569 010 81 <br>35 40 45 <br>Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Glu Ile Pro Ala <br>50 55 60 <br>Arg Phe Ser Gly Thr Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His <br>65 70 75 80 <br>Pro Val Glu Glu Glu Asp Ile Thr Thr Tyr Tyr Cys Gln Gln Ser Asn <br>85 90 95 <br>Glu Asp Pro Phe Thr Phe Gly Gl y Gly Thr Lys Leu Glu Ile Lys Arg <br>100 105 110 <br>Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln <br>115 120 125 <br>Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr <br>130 135 140 <br>Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln <br>145 150 155 160 <br>Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr <br>165 170 175 <br>Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg <br>180 185 190 <br>His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro <br>195 200 205 <br>Ile Val Lys Ser Phe Asn Arg Asn Glu Cys <br><21 0> 247 <br><211> 442 <br>210 215 <br>50 <212> PRT <br><213> Mus musculus <br><400> 247 <br>55 <br>199 EP 2 569 010 B1 <br>Gln Val Gln Leu Gln Gln Pro Gly Thr Glu Leu Val Arg Pro Gly Thr <br>l 5 10 15 <br>5 <br>Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Thr Tyr <br>20 25 30 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>200 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>45 <br>50 <br>55 <br>EP 2 569 010 B1 <br>Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile <br>35 40 45 <br>Gly Met Ile His Pro Ser Ala Ser Glu Ile Arg Leu Asp Gln Lys Phe <br>50 55 60 <br>Lys Asp Lys Ala Thr Leu Thr Leu Asp Lys Ser Ser Ser Thr Ala Tyr <br>65 70 75 80 <br>Met His Leu Ser Gly Pro Thr Ser Val Asp Ser Ala Val Tyr Tyr Cys <br>85 90 95 <br>Ala Arg Ser Gl y Gl u Tr p Gly Ser Met Asp Ty r Trp Gly Gl n Gl y Thr <br>100 105 110 <br>Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro <br>115 120 125 <br>Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gl y <br>130 135 140 <br>Cys Leu Va l Lys Gly Tyr Phe Pro Glu Pro Va l Thr Val Thr Trp Asn <br>145 150 155 160 <br>Ser Gly Ser Leu Ser Ser Gly Val Hi s Thr Phe Pro Ala Val Leu Gln <br>165 170 175 <br>Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Th r Val Pro Ser Ser Thr <br>180 185 190 <br>Trp Pro Ser Glu Thr Val Thr Cys Asn Val Al a His Pro Ala Ser Ser <br>195 200 205 <br>Thr Lys Val Asp Lys Lys Ile Va l Pro Arg Asp Cys Gly Cys Lys Pro <br>210 215 220 <br>Cys I le Cys Thr Val Pro Glu Va l Ser Ser Val Phe Ile Phe Pro Pro <br>225 230 235 240 <br>Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys <br>245 250 255 <br>Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp <br>260 265 270 <br>201 5 <br>10 <br>15 <br>20 <br>25 <br>30 <br>35 <br>40 <br>EP 2 569 010 B1 <br>Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro Arg Glu <br>275 280 285 <br>Glu Gln Ph e Asn Ser Thr Phe Arg Ser Va l Ser Glu Leu Pro Ile Met <br>290 295 300 <br>His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn Ser <br>305 310 315 320 <br>Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr I le Ser Lys Thr Lys Gly <br>325 330 335 <br>Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln <br>340 345 350 <br>Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe <br>355 360 365 <br>Pro Glu Asp I le Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Gl u <br>370 375 380 <br>Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe <br>385 390 395 400 <br>Ile Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly Asn <br>405 410 415 <br>Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn His His Thr <br>420 425 430 <br>Glu Lys Ser Leu Ser His Ser Pro Gly Lys <br>435 440 <br>45 <210> 248 <br><211 > 1329 <br><212> DNA <br><21 3> Mus musculus <br>50 <400> 248 <br>55 <br>202 'l <br>EP 2 569 010 B1 <br>caggtccaac tacagcagcc tgggactgag ctggtgaggc ctggaacttc agtgaagttg 60 <br>tcctgtaagg cttctggcta catcttcacc acctactgga tgaactgggt gaaacagagg 120 <br>5 <br>cctggacaag gccttgagtg gat t ggcatg attcatcctt ccgcaagtga aattaggttg 180 <br>gatcagaaat tcaaggacaa ggccacattg actcttgaca aatcctccag cacagcctat 240 <br>10 <br>atgcacctca gcggcccgac atctgtggat tctgcggtct attactgtgc aagatcaggg 300 <br>gaatgggggt ctatggacta ctggggtcaa ggaacctcag tcaccgtctc ctcagccaaa 360 <br>acgacacccc catctgtcta tccactggcc cctggatctg ctgcccaaac taactccatg 420 <br>15 <br>gtgaccctgg gatgcctggt caagggctat ttccctgagc cagtgacagt gacctggaac 480 <br>tctggatccc tgtccagcgg tgtgcacacc ttcccagctg tcctgcagtc tgacctctac 540 <br>20 <br>actctgagca gctcagtgac tgtcccctcc agcacctggc ccagcgagac cgtcacctgc 600 <br>aacgttgccc acccggccag cagcaccaag gtggacaaga aaattgtgcc cagggattgt 660 <br>25 <br>ggttgtaagc cttgcatatg tacagtccca gaagtatcat ctgtcttcat cttcccccca 720 <br>aagcccaagg atgtgctcac cat t actctg actcctaagg tcacgtgtgt tgtggtagac 780 <br>atcagcaagg atgatcccga ggtccagttc agctggtttg tagatgatgt ggaggtgcac 840 <br>30 <br>acagctcaga cgcaaccccg ggaggagcag ttcaacagca ctttccgctc agtcagtgaa 900 <br>cttcccatca tgcaccagga ctggctcaat ggcaaggagt tcaaatgcag ggtcaacagt 960 <br>35 <br>gcagctttcc ctgcccccat cgagaaaacc atctccaaaa ccaaaggcag accgaaggct 1020 <br>ccacaggtgt acaccattcc acctcccaag gagcagatgg ccaaggataa agtcagtctg 1080 <br>acctgcatga taacagactt cttccctgaa gacattactg tggagtggca gtggaatggg 1140 <br>40 <br>cagccagcgg agaactacaa gaacactcag cccatcatgg acacagatgg ctcttacttc 1200 <br>atctacagca agctcaatgt gcagaagagc aactgggagg caggaaatac tttcacctgc 1260 <br>45 tctgtgttac atgagggcct gcacaaccac catactgaga agagcctctc ccactctcct 1320 <br>ggtaaat ga 1329 <br>50 <br>Claims <br>1. A steri le liquid formulation that has an absolute viscosity of 1 O cP or less comprising: (a) an anti-sclerostin im mu-<br>noglobulin at a concentration of at least 70 mg/ml; and (b) calcium acetate at a concentration ranging from 1 mM <br>to 20 mM, where in the anti-sclerostin immunoglobulin comprises amino acid sequences of SEQ ID NO: 86 and SEQ <br>55 <br>ID NO: 84. <br>2. The formulation of claim 1, wherein the formulation comprises a total concentration of acetate between 1 O mM and <br>90 mM. <br>203
Claims (23)
1. Sterilna tečna formulacija koja ima apsolutnu viskoznost od 1 O cP ili manje obuhvata: (a) antisklerostin imunoglobulin pri koncentraciji od barem 70 mg/ml; i (b) kalcijum acetat u koncentraciji koja se kreće u opsegu od 1 mM do 20 mM, pri čemu anti-sklerostin imunoglobulin obuhvata sekvence amino kiseline sa SEK ID BR: 86 i SEK ID BR: 84.
2. Formulacija iz patentnog zahtjeva 1, pri čemu ova formulacija obuhvata ukupnu koncentraciju acetata između 1 O mM i 90 mM.
3. Formulacija iz patentnog zahtjeva 1 ili patentnog zahteva 2 pri čemu ova formulacija obuhvata ukupnu koncentraciju acetata između 30 mM i 90 mM ili između 30 mM i 75 mM.
4. Formulacija iz patentnog zahtjeva 2 ili patentnog zahteva 3 pri čemu je koncentracija soli kalcij uma barem 5 mM i ne veća od 15 mM, i ova koncentracija acetata je barem 50 mM.
5. Formulacija iz bilo kog od patentnih zahtjeva 1-4 pri čemu je imunoglobulin u koncentraciji od 70 mg/ml do 200 mg/ml.
6. Formulacija iz bilo kog od patentnih zahtjeva 1-5, čija je ukupna osmolarnost manja od 350 mOsm/L.
7. Formulacija iz bilo kog od patentnih zahtjeva 1-5, pri čemu je imunoglobulin prisutan u koncentraciji od 120 mg/ml.
8. Formulacija iz patentnog zahtjeva 7, pri čemu je imunoglobulin prisutan u koncentraciji od 140 mg/ml.
9. Formulacija iz bilo kog od patentnih zahtjeva 1-5, pri čemu je imunoglobulin prisutan u koncentraciji od 90 mg/ml.
10. Formulacija iz bilo kog od patentnih zahteva 1-5, pri čemu apsolutna viskoznost ove formulacije jeste 8 cP ili manja.
11.Formulacija iz patentnog zahteva 1 O, pri čemu apsolutna viskoznost ove formulacije jeste 6 cP ili manja.
12. Formulacija iz bilo kog od patentnih zahtjeva 1-11 , pri čemu ova formulacija još obuhvata poliol u količ i ni u opsegu od 4% w/v do 6% w/v.
13.Formulacija iz patentnog zahtjeva 12, pri čemu je poliol saharoza.
14.Formulacija iz bilo kog od patentnih zahtjeva 1-13, pri čemu ova formulacija ima pH u opsegu od 4,5 do 6.
15.Formulacija iz patentnog zahtjeva 14, pri čemu ova formulacija ima pH u opsegu od 5 do 5,5.
16.Postupak za smanjenje viskoznosti formulacije proteina, ovaj postupak obuhvata dodavanje kalcijum acetata pri koncentraciji između 1 mM i 20 mM, na anti-sklerostin imunoglobulin formulaciju, pri čemu ova formulacija obuhvata imunoglobulin u koncentraciji od 70 mg/ml do 200 mg/ml, pri čemu ovaj anti-sklerostin imunoglobulin obuhvata sekvence amino kisel ine SEK ID BR: 86 i SEK ID BR: 84, i pri čemu viskoznost ove formulacije sa kalcijum acetatom jeste smanjena u poređenju sa viskoznošću formulacije antitela bez kalcijum acetata.
17.Formulacija iz bilo kog od patentnih zahtjeva 1-15, pri čemu ovaj imunoglobulin ima teške lance SEK ID BR:. 90 i lake lance SEK ID BR:88.
18.Formulacija iz patentnog zahtjeva 17, još obuhvata surfaktant.
19.Formulacija iz patentnog zahtjeva 18, pri čemu ova koncentracija surfaktanta jeste od 0,004% w/v do 0,2% w/v.
20.Formulacija iz bilo kog od patentnih zahtjeva 1-15 i 17, pri čemu kalcijum acetat smanjuje apsolutnu viskoznost iz formulacije za barem 10% u poređenju sa viskoznošću formulacije antitela bez kalcijum acetata.
21.Formulacija iz patentnog zahteva 19, pri čemu je surfaktant polisorbat 20.
22.Formulacija iz jednog od patentnih zahtjeva 1-15 i 17-21 za upotrebu u postupku za poboljšanje ishoda ortopedskog postupka, stomatološkog postupka, ugradnje implanta, zamene zgloba, presađivanje kosti, kozmetičkoj hirurgiji kosti ili popravku kosti, ili za upotrebu u postupku za lečenje osteoporoze ili osteopenije.
23. Formulacija za upotrebu u ovom postupku iz patentnog zahtjeva 22, pri čemu je popravak kosti zaceljenje preloma, neujednačeno zaceljenje kosti, odloženo potpuno zaceljenje kosti ili rekonstrukcija lica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33498610P | 2010-05-14 | 2010-05-14 | |
| EP11720278.8A EP2569010B1 (en) | 2010-05-14 | 2011-05-11 | High concentration antibody formulations |
| PCT/US2011/036062 WO2011143307A1 (en) | 2010-05-14 | 2011-05-11 | High concentration antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02819B true ME02819B (me) | 2018-01-20 |
Family
ID=44146975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-147A ME02819B (me) | 2010-05-14 | 2011-05-11 | Formulacije sa visokom koncentracijom antitijela |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9352043B2 (me) |
| EP (4) | EP3195880B1 (me) |
| JP (6) | JP5889877B2 (me) |
| KR (3) | KR101861867B1 (me) |
| CN (1) | CN102946903B (me) |
| AU (1) | AU2011250920B2 (me) |
| BR (1) | BR112012028920B1 (me) |
| CA (1) | CA2798888C (me) |
| CL (1) | CL2012003172A1 (me) |
| CO (1) | CO6640258A2 (me) |
| CY (2) | CY1119069T1 (me) |
| DK (3) | DK3620175T3 (me) |
| EA (3) | EA027039B1 (me) |
| ES (3) | ES2773031T3 (me) |
| FI (1) | FI3620175T3 (me) |
| HN (1) | HN2012002446A (me) |
| HR (3) | HRP20250025T1 (me) |
| HU (3) | HUE069682T2 (me) |
| IL (3) | IL264636B (me) |
| LT (3) | LT2569010T (me) |
| ME (1) | ME02819B (me) |
| MX (1) | MX2012013268A (me) |
| PL (3) | PL3195880T3 (me) |
| PT (3) | PT2569010T (me) |
| RS (3) | RS56210B1 (me) |
| SG (3) | SG10201701869YA (me) |
| SI (3) | SI2569010T1 (me) |
| SM (3) | SMT202000095T1 (me) |
| TW (4) | TWI617570B (me) |
| WO (1) | WO2011143307A1 (me) |
| ZA (1) | ZA201208543B (me) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040002451A1 (en) * | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| BRPI0809435A2 (pt) | 2007-03-27 | 2014-09-09 | Sea Lane Biotechnologies, Llc | Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos |
| CN102482345A (zh) | 2009-05-13 | 2012-05-30 | 航道生物技术有限责任公司 | 针对流感病毒的中和分子 |
| SMT202000095T1 (it) * | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| WO2013016714A1 (en) | 2011-07-28 | 2013-01-31 | Sea Lane Biotechnologies | Sur-binding proteins against erbb3 |
| EP3446707A1 (en) | 2011-12-22 | 2019-02-27 | i2 Pharmaceuticals, Inc. | Surrogate binding proteins |
| SG11201403718YA (en) * | 2011-12-28 | 2014-07-30 | Amgen Inc | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
| PE20150190A1 (es) * | 2012-06-21 | 2015-02-13 | Ucb Pharma Sa | Formulacion farmaceutica |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| US9527922B2 (en) | 2014-12-31 | 2016-12-27 | Development Center For Biotechnology | Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy |
| WO2016108894A1 (en) * | 2014-12-31 | 2016-07-07 | Develpment Center For Biotechnology | Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy |
| TW201726111A (zh) * | 2015-09-30 | 2017-08-01 | 持田製藥股份有限公司 | 含高濃度抗體之液體製劑 |
| GB201604124D0 (en) * | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| SG11201901081XA (en) * | 2016-08-17 | 2019-03-28 | Boehringer Ingelheim Int | Process for the preparation of highly concentrated liquid formulations containing biomolecules |
| WO2018115879A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| EP3562506A4 (en) | 2016-12-29 | 2021-01-06 | University of Miami | METHOD TO MODULATE INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG |
| CA3063324A1 (en) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| WO2018213151A1 (en) * | 2017-05-18 | 2018-11-22 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation comprising incretin-insulin conjugates |
| KR20200034748A (ko) * | 2017-07-27 | 2020-03-31 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Sost 항체 약학적 조성물 및 그의 용도 |
| GB201719447D0 (en) * | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| JP6544669B1 (ja) | 2018-03-16 | 2019-07-17 | ディヴェロップメント センター フォー バイオテクノロジー | アルファエノラーゼに特異的な抗体及びその使用 |
| EP3774879B1 (en) * | 2018-03-30 | 2026-01-28 | Amgen Inc. | C-terminal antibody variants |
| WO2020010273A1 (en) * | 2018-07-03 | 2020-01-09 | University Of Miami | Compositions and methods for treating inflammasome related diseases or conditions |
| MA53333A (fr) * | 2018-07-31 | 2021-11-03 | Amgen Inc | Formulations pharmaceutiques d'anticorps masqués |
| MX2021001554A (es) * | 2018-08-10 | 2021-04-13 | Amgen Inc | Metodo de preparacion de una formulacion farmaceutica de anticuerpos. |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| EP4103235A1 (en) * | 2020-02-13 | 2022-12-21 | Amgen Inc. | Formulations of human anti-tslp antibodies and methods of treating inflammatory disease |
| CN114703067B (zh) * | 2022-04-06 | 2023-09-05 | 上海光玥生物科技有限公司 | 一种光合微生物及其用途和质粒 |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4427115A (en) | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
| JPS5889877A (ja) | 1981-11-21 | 1983-05-28 | Nippon Telegr & Teleph Corp <Ntt> | 超伝導回路装置 |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| DE3417525C1 (de) | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗hiv改変抗体および改変抗体の調製方法 |
| US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
| WO1992006693A1 (en) | 1990-10-22 | 1992-04-30 | Fox Chase Cancer Center | Dna construct for providing rna therapy |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| EP0628639B1 (en) | 1991-04-25 | 1999-06-23 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| EP0708659A4 (en) | 1993-06-07 | 2000-08-23 | Genentech Inc | HIV ENVELOPE POLYPEPTIDES |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| AU702163B2 (en) | 1994-04-29 | 1999-02-18 | Creative Biomolecules, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
| DE4427221A1 (de) | 1994-08-01 | 1996-02-08 | Gsf Forschungszentrum Umwelt | Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie |
| US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
| US6057421A (en) | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| DK0912738T3 (da) | 1996-05-22 | 2008-11-17 | Viventia Biotech Inc | Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
| US6117911A (en) | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| EP1367124A1 (en) | 1997-08-01 | 2003-12-03 | Genset | 5' ests for secreted proteins expressed in muscle and other mesodermal tissues |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US6544485B1 (en) | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
| DE69933044T3 (de) | 1998-11-27 | 2016-11-24 | Ucb Pharma, S.A. | Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| CN1345334A (zh) | 1999-01-29 | 2002-04-17 | 伊姆克罗尼系统公司 | 对kdr特异的抗体及其应用 |
| CA2371434A1 (en) | 1999-06-09 | 2000-12-14 | Genentech, Inc. | Compositions and methods for the treatment of tumor |
| US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
| JP4141095B2 (ja) | 1999-10-29 | 2008-08-27 | 三洋電機株式会社 | 半導体装置とその製造方法 |
| JP2003525611A (ja) | 2000-03-02 | 2003-09-02 | アムジェン インコーポレーテッド | コルディン様−2分子およびその使用 |
| MXPA02011808A (es) | 2000-06-01 | 2003-04-10 | Amgen Inc | Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos. |
| AU2001272482A1 (en) | 2000-06-19 | 2002-01-02 | F.Hoffmann-La Roche Ag | Osteolevin gene polymorphisms |
| CA2632702A1 (en) | 2000-09-01 | 2002-03-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2374027A1 (en) | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
| DE10145772A1 (de) | 2001-09-17 | 2003-04-10 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
| NZ533051A (en) | 2001-12-06 | 2006-10-27 | Biocontrol Systems Inc | Sample collection and testing system |
| US20030186915A1 (en) | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
| US7332276B2 (en) | 2002-03-01 | 2008-02-19 | Celltech R&D, Inc. | Methods to increase or decrease bone density |
| US7799523B2 (en) | 2002-04-03 | 2010-09-21 | Celltech R & D, Inc. | Association of polymorphisms in the SOST gene region with bone mineral density |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| US20040023356A1 (en) | 2002-06-14 | 2004-02-05 | Robb Krumlauf | Wise/Sost nucleic acid sequences and amino acid sequences |
| WO2004001007A2 (en) | 2002-06-21 | 2003-12-31 | Idec Pharmaceuticals Corporation | Buffered formulations for concentrating antibodies and methods of use thereof |
| AU2003291689A1 (en) | 2002-10-31 | 2004-05-25 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
| AU2003304107B2 (en) | 2002-11-01 | 2008-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
| US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| US20040141875A1 (en) | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
| NZ542587A (en) | 2003-03-14 | 2008-05-30 | Celltech R & D Inc | Complex comprising a TGF-beta binding protein and a BMP antagonist protein in specific association used to modulate bone mineralization |
| US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| EP1636270B1 (en) | 2003-06-16 | 2016-07-20 | UCB Pharma S.A. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US20050267233A1 (en) | 2004-05-25 | 2005-12-01 | Joshi Ashok V | Anti-microbial handle system |
| MX2007001221A (es) | 2004-08-04 | 2007-03-23 | Amgen Inc | Anticuerpos para proteina dickkopf-1 (dkk-1). |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| BRPI0620316A2 (pt) | 2005-12-21 | 2011-11-08 | Wyeth Corp | formulações de proteìnas com viscosidades reduzida e seus usos |
| US8541177B2 (en) | 2006-01-13 | 2013-09-24 | A Chan Holding B.V. | Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction |
| WO2008133722A2 (en) | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
| US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| WO2009131553A2 (en) | 2006-12-29 | 2009-10-29 | Osteogenex Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| EP2114435A1 (en) | 2007-02-02 | 2009-11-11 | Novartis AG | Modulators of sclerostin binding partners for treating bone-related disorders |
| NZ578870A (en) | 2007-03-20 | 2012-01-12 | Lilly Co Eli | Anti-sclerostin antibodies |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素(sclerostin)抗體組合物及使用方法 |
| KR20100091170A (ko) | 2007-11-02 | 2010-08-18 | 노파르티스 아게 | 저밀도-지단백질 수용체-관련 단백질 6 (lrp6)을 조정하기 위한 분자 및 방법 |
| US20110044978A1 (en) | 2007-12-14 | 2011-02-24 | Amgen Inc. | Method for treating bone fracture |
| WO2009141433A1 (en) * | 2008-05-23 | 2009-11-26 | Novo Nordisk Health Care Ag | Low viscosity compositions comprising a pegylated gla-domain containing protein |
| PE20100092A1 (es) | 2008-06-03 | 2010-03-12 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
| WO2010100200A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Lyophilised antibody formulation |
| WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
| WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
| WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
| SMT202000095T1 (it) * | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| JP6066912B2 (ja) | 2010-10-27 | 2017-01-25 | アムジエン・インコーポレーテツド | Dkk1抗体およびその使用方法 |
| PH12016502073B1 (en) * | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
-
2011
- 2011-05-10 SM SM20200095T patent/SMT202000095T1/it unknown
- 2011-05-11 AU AU2011250920A patent/AU2011250920B2/en active Active
- 2011-05-11 DK DK19202835.5T patent/DK3620175T3/da active
- 2011-05-11 ES ES17158990T patent/ES2773031T3/es active Active
- 2011-05-11 BR BR112012028920-9A patent/BR112012028920B1/pt active IP Right Grant
- 2011-05-11 CN CN201180023921.4A patent/CN102946903B/zh active Active
- 2011-05-11 HR HRP20250025TT patent/HRP20250025T1/hr unknown
- 2011-05-11 DK DK17158990.6T patent/DK3195880T3/da active
- 2011-05-11 PL PL17158990T patent/PL3195880T3/pl unknown
- 2011-05-11 WO PCT/US2011/036062 patent/WO2011143307A1/en not_active Ceased
- 2011-05-11 PT PT117202788T patent/PT2569010T/pt unknown
- 2011-05-11 HU HUE19202835A patent/HUE069682T2/hu unknown
- 2011-05-11 LT LTEP11720278.8T patent/LT2569010T/lt unknown
- 2011-05-11 ES ES11720278.8T patent/ES2626033T3/es active Active
- 2011-05-11 EP EP17158990.6A patent/EP3195880B1/en active Active
- 2011-05-11 RS RS20170674A patent/RS56210B1/sr unknown
- 2011-05-11 PT PT171589906T patent/PT3195880T/pt unknown
- 2011-05-11 KR KR1020127032558A patent/KR101861867B1/ko active Active
- 2011-05-11 US US13/702,658 patent/US9352043B2/en active Active
- 2011-05-11 ME MEP-2017-147A patent/ME02819B/me unknown
- 2011-05-11 EP EP24198927.6A patent/EP4483901A3/en active Pending
- 2011-05-11 SM SM20170252T patent/SMT201700252T1/it unknown
- 2011-05-11 IL IL264636A patent/IL264636B/en unknown
- 2011-05-11 PL PL11720278T patent/PL2569010T3/pl unknown
- 2011-05-11 EA EA201291226A patent/EA027039B1/ru not_active IP Right Cessation
- 2011-05-11 SI SI201131181T patent/SI2569010T1/sl unknown
- 2011-05-11 HU HUE11720278A patent/HUE033315T2/en unknown
- 2011-05-11 SG SG10201701869YA patent/SG10201701869YA/en unknown
- 2011-05-11 SI SI201132124T patent/SI3620175T1/sl unknown
- 2011-05-11 EA EA202092884A patent/EA202092884A1/ru unknown
- 2011-05-11 EP EP11720278.8A patent/EP2569010B1/en active Active
- 2011-05-11 EA EA201692242A patent/EA037392B1/ru not_active IP Right Cessation
- 2011-05-11 KR KR1020187014175A patent/KR102026038B1/ko active Active
- 2011-05-11 MX MX2012013268A patent/MX2012013268A/es active IP Right Grant
- 2011-05-11 ES ES19202835T patent/ES3008262T3/es active Active
- 2011-05-11 SG SG10201912670XA patent/SG10201912670XA/en unknown
- 2011-05-11 FI FIEP19202835.5T patent/FI3620175T3/fi active
- 2011-05-11 SI SI201131842T patent/SI3195880T1/sl unknown
- 2011-05-11 SM SM20250009T patent/SMT202500009T1/it unknown
- 2011-05-11 RS RS20241450A patent/RS66360B1/sr unknown
- 2011-05-11 IL IL295275A patent/IL295275B2/en unknown
- 2011-05-11 JP JP2013510274A patent/JP5889877B2/ja active Active
- 2011-05-11 DK DK11720278.8T patent/DK2569010T3/en active
- 2011-05-11 CA CA2798888A patent/CA2798888C/en active Active
- 2011-05-11 KR KR1020197027464A patent/KR102220879B1/ko active Active
- 2011-05-11 EP EP19202835.5A patent/EP3620175B1/en active Active
- 2011-05-11 LT LTEP19202835.5T patent/LT3620175T/lt unknown
- 2011-05-11 RS RS20200217A patent/RS59993B1/sr unknown
- 2011-05-11 HU HUE17158990A patent/HUE047492T2/hu unknown
- 2011-05-11 PL PL19202835.5T patent/PL3620175T3/pl unknown
- 2011-05-11 SG SG2012082202A patent/SG185465A1/en unknown
- 2011-05-11 LT LTEP17158990.6T patent/LT3195880T/lt unknown
- 2011-05-11 PT PT192028355T patent/PT3620175T/pt unknown
- 2011-05-11 HR HRP20170983TT patent/HRP20170983T1/hr unknown
- 2011-05-13 TW TW100116950A patent/TWI617570B/zh active
- 2011-05-13 TW TW105120111A patent/TWI689517B/zh active
- 2011-05-13 TW TW111107371A patent/TWI871502B/zh active
- 2011-05-13 TW TW108135531A patent/TWI759634B/zh active
-
2012
- 2012-11-12 CL CL2012003172A patent/CL2012003172A1/es unknown
- 2012-11-13 HN HN2012002446A patent/HN2012002446A/es unknown
- 2012-11-13 ZA ZA2012/08543A patent/ZA201208543B/en unknown
- 2012-11-13 IL IL223014A patent/IL223014B/en active IP Right Grant
- 2012-12-03 CO CO12218641A patent/CO6640258A2/es unknown
-
2016
- 2016-02-17 JP JP2016027699A patent/JP6174176B2/ja active Active
- 2016-05-02 US US15/144,256 patent/US10064946B2/en active Active
-
2017
- 2017-05-25 CY CY20171100542T patent/CY1119069T1/el unknown
- 2017-07-05 JP JP2017131572A patent/JP6416336B2/ja active Active
-
2018
- 2018-07-26 US US16/045,928 patent/US11040102B2/en active Active
- 2018-10-03 JP JP2018187831A patent/JP7267707B2/ja active Active
-
2020
- 2020-02-17 CY CY20201100145T patent/CY1122669T1/el unknown
- 2020-02-18 HR HRP20200268TT patent/HRP20200268T1/hr unknown
-
2021
- 2021-05-21 US US17/326,725 patent/US12178873B2/en active Active
- 2021-09-13 JP JP2021148735A patent/JP2022000436A/ja not_active Withdrawn
-
2023
- 2023-09-29 JP JP2023169763A patent/JP7675774B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7675774B2 (ja) | 高濃度抗体製剤 | |
| KR101450888B1 (ko) | 스클레로스틴 결합제 | |
| US8715663B2 (en) | Epitopes | |
| KR102033669B1 (ko) | 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법 | |
| CN101896201A (zh) | 使用抗硬骨素抗体治疗骨折的方法 | |
| AU2013285488B2 (en) | Treatment for bone diseases | |
| KR20190037261A (ko) | 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법 | |
| HK1150783A (en) | Method for treating bone fracture with anti-sclerostin antibodies | |
| HK1198444B (en) | Sclerostin binding agents | |
| HK1192260A (en) | Sclerostin binding agents | |
| HK1192260B (zh) | Sclerostin结合剂 |